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Abstract 
Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder 
which results in the global formation of hamartomas, along with epilepsy, autism and 
learning difficulties. TSC is caused by mutations in TSC1 and/or TSC2 genes, which 
are involved in regulating the mTOR pathway, an essential pathway involved in cell 
cycling, proliferation, survival and growth.  
For non-surgically viable tumours, the use of mTOR inhibitors such as 
rapamycin (and rapalogs) have been shown to reduce tumour size and incidence of 
seizures and to improve intellectual and social development. However, these 
tumours will grow back rapidly when treatment ceases  
Research has shown that mTOR-hyperactive cells have increased basal 
levels of endoplasmic reticulum (ER) stress compared to wildtype cells which could 
be seen as a potential drug target. Several combinations containing nelfinavir, a 
known ER stress enhancer, have been shown to selectively target Tsc2-/- mouse 
embryonic fibroblasts (MEFs) and mTOR-hyperactive sporadic cancer cells while 
being well tolerated by wildtype cells.  
In this thesis, the key findings were the identification of three nelfinavir-based 
combinations (mefloquine, Bortezomib and cepharanthine). Results showed that 
optimised combinations caused selective cytotoxicity in Tsc2-/- MEFs and mTOR-
hyperactive sporadic cancer cells while being tolerated by wildtype control cells 
(measured by DRAQ7 staining). All combinations caused cytotoxicity in a 3D 
environment (using tumour spheroids). The mechanism of action for each 
combination was investigated via several method including western blot analysis, 
rescue assays and RNA sequencing. Results show that mefloquine/nelfinavir and 
cepharanthine/nelfinavir combinations caused cell death via combined energy 
stress (cell death was rescued by the addition of methyl pyruvate) and potentially 
prolonged ER stress while the Bortezomib/nelfinavir combination caused cell death 
via prolonged ER stress and proteasome inhibition. This work highlights critical 
vulnerabilities in cancer cells with hyperactive mTORC1 activity that lack flexibility 
in homeostatic pathways. 
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Chapter 1: General Introduction 
 
1.1 Tuberous Sclerosis Complex (TSC) 
 
1.1.1 History and General Introduction 
 
1.1.1.1 General Introduction 
Tuberous Sclerosis Complex (TSC) (previously known as Bournville-Pringle 
disease (Verma and Radhakrishnan 2011)) is an autosomal dominant 
neurocutaneous (second most common behind neurofibromatosis (K et al. 2015) 
and progressive syndrome (Nathan et al. 2016; Rosset et al. 2017), which is 
characterized by the presence of benign tumours (called hamartomas) in multiple 
organ systems including the brain, lungs, heart, the kidneys and skin (Dodd and 
Dunlop 2016; Peron et al. 2016). TSC is also associated with various neurological 
and psychiatric symptoms, such as epilepsy (70–90% of TSC cases), autism 
spectrum disorder (ASD; 20–50%), attention-deficit/hyperactivity disorder (ADHD; 
30–50 %), intellectual disability (ID; 50%), depression and anxiety disorders (30–
60%) (Both et al. 2018). The underlying pathomolecular mechanism of tumour 
growth that is also linked to neurological conditions involves hyperactivation of the 
mechanistic target of rapamycin (mTOR) pathway, caused by heterozygous loss of 
function mutations of TSC1 or TSC2 (Kwiatkowski et al. 2010).  
TSC is a rare condition that was previously underdiagnosed until the 1980s 
as cases were originally reported in 1 in 100,000-200,000 live births (Northrup and 
Krueger 2013). However, with increased understanding of the disease, the number 
of cases reported with TSC is now 1 in 6000-9,000 live births with at least 2 million 
people affected worldwide by the disease with 8,000 cases in the United Kingdom 
and 40,000 cases in the United States of America. TSC affects all ethnic groups and 
is equally identified in both sexes (Nasuti et al. 2016; Kaneda 2017).   
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1.1.1.2 History of TSC 
The first recorded descriptions of TSC were in the 19th century. The first description 
was done in 1835 by Pierre Francois Olive Rayer in an atlas of skin diseases where 
angiofibromas were described as “végétations vasculaires” around the mouth and 
nose. Further references to the disease were seen in 1850 by Thomas Addsion and 
William Gull who called angiofibromas “vitiligoidea tuberosa” and between 1862-
1864 by Friedrich Daniel von Recklinghausen and Rudolf Virchow who reported a 
child who died with tumours of the heart and several scleroses of the brain. Virchow 
later observed that a child with tuberous sclerosis had a sister who also died of a 
cerebral tumour.  
It wasn’t until 1880 that the first true report of TSC was reported by Désiré-
Magloire Bourneville (from whom the disease got its original name). He observed 
and documented a 15-year-old girl called Marie who had psychomotor retardation, 
epilepsy, a "confluent vascular-papulous eruption of the nose, the cheeks and 
forehead” and a history of seizures since infancy. The post-mortem examination 
disclosed hard, dense tubers in the brain, which Bourneville named “Sclérose 
tubéreuse des circonvolutions cérébrales” and whitish hard masses were found in 
both kidneys (Gómez 1995). 
Throughout the remainder of the 19th and into the 20th Century, important 
discoveries about TSC were made, such as the first diagnostic criteria (1906 by 
Campbell and 1908 by Vogt). Also, it was established that the disease was not only 
genetic (Kirpicznick in 1910) but could also be hereditary (Berg in 1913). The first 
reported cases of lymphangioleiomyomatosis (LAM) - rare, progressive and 
systemic disease that typically results in cystic lung destruction caused by mutations 
in TSC1 and TSC2 and often reported in female TSC patients was also described 
by Lutembacher in 1918 (Gómez 1995). In 1942, Moolten proposed the name 
‘Tuberous Sclerosis Complex’ for the disease and introduced the terms hamartial 
(basic lesion), hamartoma (tumour-like lesion) and hamartoblastoma (truly 
neoplastic) (Moolten 2011). In 1979, Gomez described the first clinical spectrum for 
TSC and developed a diagnostic criteria (Sancak 2005). These diagnostic criteria 
was revised in 1998 (Roach et al. 1998) and revised again to its current version in 
2012 (Northrup and Krueger 2013).  
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1.1.1.3 TSC diagnosis criteria 
In 2012, the International Tuberous Sclerosis Complex Consensus Group updated 
the diagnostic criteria for TSC. The criteria consist of two parts; genetic and clinical. 
The genetic criteria consist of identification of either a TSC1 or TSC2 pathogenic 
mutation (mutation that clearly inactivates the function of the TSC1 or TSC2 
proteins, respectively) in DNA from normal tissue and is sufficient evidence to make 
a definite diagnosis of TSC. However, mutations of either TSC1 or TSC2, whose 
effect on function is less certain do not meet these criteria and are not sufficient 
alone to make a definite diagnosis of TSC. It is also important to note that 10-25% 
of TSC patients have no mutation identified by conventional genetic testing (which 
will be discussed later), and a normal result does not exclude TSC, or have any 
effect on the use of clinical diagnostic criteria to diagnose TSC.  
The second part of the criteria is clinical based as patients must have two 
major TSC features or one major feature and more than two minor TSC features. A 
possible diagnosis can be made if the patient has either a major TSC feature or two 
or more minor TSC features. The major TSC features include: hypomelanotic 
macules (>3, at least 5-mm diameter), angiofibromas (>3) or fibrous cephalic 
plaque, ungual fibromas (>2), shagreen patch, multiple retinal hamartomas, cortical 
dysplasias, subependymal nodules, subependymal giant cell astrocytoma (SEGA), 
cardiac rhabdomyoma, LAM and angiomyolipomas (>2). The minor features of TSC 
are defined as: “confetti” skin lesions, dental enamel pits (>3), intraoral fibromas 
(>2), retinal achromic patch, multiple renal cysts and nonrenal hamartomas. Each 
feature will be explained in detail in later sections of this chapter (Northrup and 
Krueger 2013). 
 
1.1.1.4 Mutations associated with TSC  
As previously mentioned, TSC is caused by loss of function mutations in either 
TSC1 and/or TSC2 (Verma and Radhakrishnan 2011). Disease causing mutations 
can be identified in up to 85% of TSC patients tested with between 500 to 2000 
different mutations reported in both the TSC1 and TSC2 genes, respectively 
(Williams et al. 2007; Kwiatkowski et al. 2015). A third of identifiable mutations can 
be hereditary (K et al. 2015; Lam et al. 2017a), although 60% of TSC cases are 
caused by sporadic mutations (Hoelz et al. 2018). TSC-associated tumours follow 
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the classical Knudson’s two-hit inactivation model, where loss of heterozygosity 
occurs.  
Typically, the first inactivating mutation is germline and TSC patients are born 
heterozygous TSC1+/- or TSC2+/-. Homozygous deletion of either gene is 
embryonically lethal (as shown in Eker rats, a TSC rat model) (Aizawa et al. 2016). 
The second mutational hit is somatic and can be the result of several causes, 
including loss of heterozygosity through large gene deletion or mutation as well as 
promoter methylation (Rosset et al. 2017).  
TSC2 mutations are around four times more common than TSC1 (Lim et al. 
2016; Kaneda 2017). Mutations in TSC1 are usually small insertions or deletions 
causing nonsense and frameshift mutations (Dabora et al. 2001; Franz et al. 2001). 
Many TSC2 mutations contain missense mutations (25-32%) and large deletions or 
rearrangements (12-17%) (Cheadle et al. 2000). In general, patients with TSC2 
mutations are more likely to have a more severe phenotype than TSC1 mutations. 
Patients with TSC2 mutations often present with symptoms at a younger age and 
are more likely to have seizures, cognitive impairment, infantile spasms, autism 
spectrum disorder and have been reported to have a greater risk for renal 
malignancy. Patients with TSC1 variants are less likely to have intellectual disability, 
renal abnormalities, and retinal abnormalities but are more likely to have shagreen 
patches (Domanska-Pakiela et al. 2002; Sancak et al. 2005; Goedbloed et al. 2006; 
Algra et al. 2007; Kothare et al. 2014; Mortaji et al. 2017; Rosset et al. 2017).  
10-15% of TSC patients have mutations that cannot be detected by 
conventional genetic testing and are referred to as no mutation identified (NMI) 
patients. Tyburczy et al. (2015) used next generation sequencing (NGS) to identify 
mutations in 45 out of 53 patients. Mosaicism (small insertions and deletions, larger 
genomic deletions, and nonsense, splice site, and missense mutations) was 
observed in 26 out of 45 of patients, and intronic mutations were also unusually 
common, seen in 18 of these 45 subjects. 82% of these mutations were detected in 
the TSC2 gene and 18% in the TSC1 gene, like the general distribution of mutations. 
Heterozygous non-mosaic mutations in coding exons and consensus splice sites 
were identified in 11% of the remaining samples, which had been previously missed 
with NGS. Mutations in the introns, non-coding regions of the genes, were detected 
in 40% of the NMI samples, 33% of which were mutations that had not been 
previously reported.  
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The incidence and severity of TSC manifestations can vary widely between 
individuals, and even between identical twins. This phenotypic heterogeneity is likely 
due to differences in mutations occurring in TSC1 versus TSC2, and other poorly 
defined factors (Sahin et al. 2016). There are no identifiable risk factors making 
someone susceptible to developing tuberous sclerosis. A parent with TSC has a 
50% chance of passing the disease on to their child, while sporadic TSC patients 
likely have a “second hit” phenomenon (a fundamental concept that sequential 
insults, which are individually innocuous, can lead to overwhelming physiologic 
reactions (Lasanianos et al. 2010)). 
With regards to Tre2-Bub2-Cdc16 (TBC) 1 domain family member 7 
(TBC1D7), mutations in this protein are not associated with TSC. However, 
mutations within TBC1D7 are associated with several diseases including intellectual 
disability, macrocrania, patellar dislocation and coeliac disease (Chrast et al. 2014). 
 
1.1.1.5 TSC - tumour suppressor protein complex  
The two causative genes of TSC form a multiprotein complex. The 130 kDa TSC1 
protein (hamartin) and the 200 kDa protein TSC2 (tuberin) associate with each other 
as a protein complex with another core subunit, TBC1D7 (Asara et al. 2012; Zech 
et al. 2016). TSC1 is responsible for TSC2 stabilisation, preventing ubiquitin-
mediated degradation of TSC2. TSC2 contains a C-terminal GAP domain, which is 
required for its tumour suppressor role. Through this GAP domain, TSC1/TSC2 
negatively controls mTORC1 activity via converting the small G protein, Ras 
homolog enriched in brain (Rheb), to its inactive GDP-bound form (Tee et al. 2005). 
Rheb is a member of the RAS-family of small G proteins that directly binds to and 
activates mTORC1 when Rheb is GTP-bound (Sarbassov et al. 2005; Groenewoud 
and Zwartkruis 2013). Therefore, the tumour suppressor role of TSC1/TSC2 is to 
inactivate mTORC1 through conversion of active  GTP-bound Rheb to an inactive 
GDP-bound state (Groenewoud and Zwartkruis 2013).  
Growth signalling inputs are known to activate mTORC1 through repression 
of TSC2. For instance, AKT in the PI3K signalling pathway can directly 
phosphorylate and inactivate TSC2 at five residues (Ser939, Ser981 Ser1130, Ser1132 
and Thr1462 - all of which exist outside of the GAP domain of TSC2) (Dibble and 
Cantley 2015), which causes an increase of Rheb-GTP and mTORC1 activation. 
There are multiple signalling inputs towards the TSC1/TSC2 complex, such as; 
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through activation of the MAPK pathways (which results in ERK phosphorylates 
TSC2) (Ma et al. 2005), phosphorylation by IκKβ, phosphorylation on Ser644 or by 
WNT pathway inhibition of glycogen synthase kinase 3 (GSK3) beta. GSK3 
phosphorylates TSC2 on Ser1341 and Ser1337, in conjunction with phosphorylation by 
AMPK  activates TSC2 to downregulate mTORC1 signalling (Sulaimanov et al. 
2017; Wataya-Kaneda, 2015). 
 
1.1.2 Clinical management of TSC 
TSC is a complex disease with pathological features of multiple organs that needs 
careful clinical management. The current therapy for TSC uses mTORC1 inhibitors, 
with the idea to restore the pathological defect of hyperactive mTORC1 signalling to 
restore disease state. mTORC1 promotes cell growth and is thought to be the main 
driver of hamartomas (benign tumour growth), but may also contribute to other 
aspects of disease, such as enhanced cell motility and differentiation states. In the 
sections below, different pathological features of TSC will be described with their 
clinical management. Therapy with mTORC1 inhibitors has markedly improved the 
clinical care of TSC patients and will also be summarised below for each organ type. 
Yet there are also aspects of TSC that are not cured with mTORC1 inhibitors, 
revealing that there is a clinical need to find better therapies. 
 
1.1.2.1 Renal manifestations  
Renal angiomyolipomas (AMLs) are a very common manifestation of TSC patients. 
80% of TSC patients develop at least one AML in their lifetime (Ikarashi et al. 2017; 
Warncke et al. 2017). AMLs are benign mesenchymal tumours which are composed 
of various tissue types including adipose tissue, spindle and epithelioid smooth 
muscle cells and abnormal vessels (Champagnac et al. 2016; Ikarashi et al. 2017) 
and occur as multiple and bilateral lesions (Rabenou and Charles 2015) (Figure 
1.1).  
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Figure 1.1 CT scan of Angiomyolipoma (AML). White arrows indictate the locations of AMLs in 
patients kidneys. Image taken from (von Ranke et al. 2015). 
 
Adverse effects of AML include acute injuries such as haemorrhage of a 
lesion (also referred to as Wunderlich syndrome) in which the risk of a bleed 
correlates with the size of the tumours. This is because vasculature of AMLs is 
characterized by thick-walled blood vessels that contain little or no elastin, making 
them prone to rupture. Long term effects of AMLs include progressive loss of normal 
renal parenchyma leading to reduced kidney function and eventually kidney failure. 
AMLs are the second leading cause of morbidity and mortality (behind epilepsy) in 
TSC patients (Sheperd et al. 1991). 
 In terms of AMLs, dysfunctional mTORC1 activity plays an important role in 
tumour development. mTORC1 regulates the nuclear entry of lipin-1, a phosphatidic 
acid phosphatase, which is involved in activating SREBP-1 (sterol regulatory 
element-binding protein-1), a transcription factor which is a master regulator of de 
novo lipogenesis (Laplante and Sabatini 2009; Peterson et al. 2011). Increased de 
novo lipid synthesis is a hallmark of proliferating cancer cells by providing the lipids 
required for membrane synthesis (Laplante and Sabatini 2009) and since mTORC1 
is constitutively active in AMLs, there are increased levels of lipid production (hence 
why AMLs are considered as fatty tumours). 
Hypoxia inducible factors (HIFs) play a role in vascularisation and 
angiogenesis and regulates vascular endothelial growth factor (VEGF) – a 
biomarker involved in angiogenesis. mTORC1 causes an accumulation of HIF1α via 
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direct phosphorylation and activation of signal transducer and activation of 
transcription 3 (STAT3) (Dodd et al. 2015). Hyperactive mTORC1 results in 
overexpression of VEGF and HIF1α which leads to hypervascularisation and is a 
common trait found on tumours, especially TSC-associated tumours such as AMLs 
(Dodd et al. 2015).   
Given the links of mTORC1 hyperactivity to drive tumour growth in AMLs, 
mTORC1 inhibitors have been shown efficacy to shrink tumours. Rapamycin and 
everolimus have both undergone extensive in vitro and in vivo investigation in 
models of TSC. Rapamycin was shown to have antitumour properties as first 
reported in 2002 (Guba et al. 2002). Rapamycin was shown to be able to inhibit 
primary and metastatic tumour growth via antiangiogenesis (decreased vascular 
epithelial growth factor (VEGF) production).  
mTOR inhibitors have been shown to decrease the phosphorylation of 
downstream effectors of mTOR, resulting in decreased DNA synthesis and cellular 
proliferation in TSC patient–derived tumour cell lines, including angiomyolipomas 
(Krymskaya et al. 2002; Lesma et al. 2005). In Tsc1-null and Tsc2-null MEFs, 
rapamycin caused VEGF levels to rapidly decrease in vitro (El-Hashemite et al. 
2003).  
A meta-analysis of 4 clinical trials and 4 case reports showed that in the 
presence of rapamycin and rapalogs (analogues of rapamycin, such as everolimus), 
there was a significant reduction in the size of renal AMLs and SEGAs (Sasongko 
et al. 2015). ‘EXamining everolimus In a Study of Tuberous Sclerosis Complex-2’ 
(EXIST-2) was a randomized, double-blind, placebo-controlled trial in 118 TSC or 
sporadic LAM patients aged >18 years old with at least one AML >3 cm diameter. 
The angiomyolipoma response rate was 42% for everolimus compared to 0% for 
patients treated with a placebo control (Bissler et al. 2015; Budde et al. 2016). In a 
2-year, nonrandomized, open-label trial consisting of 18 patients of AML, with at 
least one AML ≥3 cm diameter, the proportion of patients who achieved ≥50% 
reduction from baseline in the sum of volumes of target lesions increased from 
52.94% at 3 months, to 58.82% and 66.67% at months 6 and 12 (Cai et al. 2018). 
In 8 patients tested, everolimus treatment had a statistically significant effect on AML 
volume reduction that ranged from 10.5-45.3% reduction in four patients with 
everolimus at 2.5 mg daily and 40.7-73.1% in four patients with everolimus at 5.0 
mg daily (Tsai et al. 2017). 
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However, the main problem with using mTORC1 inhibitors is that while the 
use of these drugs can reduce tumour volume and angiogenesis when patients are 
on treatment, tumours regrow cessation of treatment. In other words, these drugs 
are cytostatic rather than being cytotoxic (Sheth et al. 2016). Along with this are 
several known side effects include mTOR inhibitors-related pneumonitis, 
immunosuppression, and high incidences of hyperglycaemia, new-onset diabetes, 
hyperlipidaemia and hypercholesterolemia. 
 The use of mTORC1 inhibitors reduces the need to operate on AML which 
(according to international guidelines) is recommended when AML grows to 30-40 
mm in diameter. Approximately one-quarter of adult TSC patients have experienced 
renal embolization or partial nephrectomy (Krueger et al. 2013; Bissler et al. 2015; 
Curatolo et al. 2016). However, due to the complex nature of TSC-associated AMLs, 
tumours may regrow and require recurring intervention resulting in progressive loss 
of functioning kidney tissue and even end stage renal disease (O’Callaghan et al. 
2004). 
While mTORC1 inhibitors are sufficient to prevent AML growth and reduce 
the need to remove these tumours, TSC patients would be required to take 
mTORC1 treatment for life. This is due to the cytostatic drug activity of mTORC1 
inhibitors. Therefore, there is a clinical need to find an alternative therapy that might 
completely remove the tumour through a cytotoxic activity. 
 
1.1.2.2 Skin 
Between 81-95% of TSC patients will have at least one TSC-associated skin 
condition (Lim et al. 2017). These can be painful, disfiguring, emotionally distressful, 
or prone to bleeding (Nathan et al. 2015). Angiofibromas (reddish-brown papules 
which primarily affect the nasolabial folds, cheeks and chin, bilaterally and 
symmetrically or unilaterally and mosaic (Rodrigues et al. 2012)) are the most 
recognized cutaneous manifestations of TSC (Figure 1.2B). Other forms of TSC-
associated skin conditions include hypopigmented macules (found on nearly all of 
patients and present as white lesions (Rabito and Kaye 2014)) (Figure 1.2A), 
Shagreen patches (fibrotic plaque with irregular margins and raised, greyish-green 
or light brown roughened surfaces (often referred to as “orange-peel’’), generally 
appearing on the trunk (most specifically in the lumbosacral area) and present in 
approximately 20–54% of TSC patients (Rodrigues et al. 2012; Northrup and 
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Krueger 2013; Rabito and Kaye 2014) (Figure 1.2C). Ungual fibroma (Koenen 
tumours) (skin-coloured or reddish nodules adjacent to or underneath the nails, 
present in approximately 15–20% of TSC patients (Rabito and Kaye 2014) (Figure 
1.2D). Fibrous cephalic plaques (thickened bundles of reticular collagen with little or 
no elastic fibres) stereotypically develop on the forehead (about 40% of cases - but 
can also occur in non-forehead sections of the face and scalp mostly on the left-
hand side) of TSC patients and are found in 36% of TSC patients.  
 
 
Figure 1.2 Skin Manifestations of TSC. A selection of skin manifestations of TSC including (A) 
hypomelanotic macules, (B) angiofibromas, (C) Shagreen patch and (D) Ungual fibroma. Image 
taken from Taveira-DaSilva and Moss (2015) 
 
During clinical trials using mTORC1 inhibitors in TSC patients, it was noticed 
that facial angiofibromas were markedly reduced in size upon treatment. This has 
led to topical skin applications with mTORC1 inhibitors, which recently showed 
promise in clinical trials (Koenig et al. 2012). Different pharmaceutical formulations 
of treatment were tried at different rapamycin concentrations (0.003–1%), from 
crushed tablets to oral solution, where all formulations were reported to cause 
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patient improvement to facial angiofibromas (cosmetic results) with minimal side 
effects (Madke 2013; Neri et al. 2014; Bouguéon et al. 2015). However, there were 
several problems caused through inconsistent percutaneous absorption and 
systemic diffusion. A 0.1% (w/v) rapamycin topical cream was later developed for 
the treatment of angiofibromas (Bouguéon et al. 2016). 
Loss of either TSC1 or TSC2 heterozygosity within angiofibromas was 
discovered to be associated with UV-induced DNA damage of the remaining allele 
(Tyburczy et al. 2014), which would cause hyperactivation of mTORC1. This has a 
huge impact on the care of TSC patients, where reducing sun exposure as a 
preventative would reduce the formation of angiofibromas. Given the current therapy 
(reducing fibrous growth and erythema, (Salido-Vallejo et al. 2014)) finding 
additional treatments for the skin is less of a research priority. DNA-damage from 
UV has been found to be sufficient in causing the formation of angiofibromas. This 
finding would also argue against the use of genotoxic chemotherapy to treat TSC-
associated tumours, as DNA-damaging agents such as oxaliplatin and doxorubicin 
would likely promote further tumour formation through loss of heterozygosity of 
either TSC1 or TSC2. 
 
1.1.2.3 Brain 
 
1.1.2.3.1 Neurological manifestations of TSC 
Epilepsy is one of the most common neurological complication associated with TSC 
and occurs in up to 90% of TSC patients. Epilepsy can occur within the first year of 
life (a critical timepoint in neurological development) with the average age of 
seizures onset being around 5.6 months (Williams et al. 2017). Around 45% of TSC 
patients have mild-to-profound intellectual disability (ID), with up to 50% of patients 
having Autism Spectrum Disorder (ASD) symptoms (Sahin 2012). For TSC patients 
with intellectual disability/ASD, epilepsy may be a leading cause of mental 
retardation as 67.39% of infants with infantile spasms developed mental retardation 
(Wang et al. 2017). 
TSC-associated neuropsychiatric disorders (TAND) is a term that was coined 
by the Neuropsychiatry Panel at the 2012 Tuberous Sclerosis Complex International 
Consensus Conference to help recognize the complex cognitive and behavioural 
manifestations of TSC and generate screening guidelines (de Vries et al. 2015). The 
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most common neuropsychiatric conditions associated with TSC are depression, 
anxiety, attention-deficit and hyperactivity disorder and aggressive/disruptive 
disorders. Behavioural manifestations of TSC can range from mild (poor eye 
contact) to severe with the most common being aggression (45% of cases) and self-
injury (10%) (Gipson and Johnston 2017). 
Epilepsy becomes refractory to medical therapy over time (Wei et al. 2018), 
with refraction rates ranging from  25% - 60% (Cardamone et al. 2014; French et al. 
2016) with refraction typically developing at the age of 2 (Evans et al. 2012). TSC2 
mutations are associated with a more severe epilepsy phenotype compared to 
TSC1 mutations (Zeng et al. 2011) while the presence of cortical tubers (described 
later in this chapter) with TSC2 mutations are associated with refractory epilepsy 
(Chu-Shore et al. 2009). The type of seizure also plays a role in epilepsy refraction 
as in patients with focal epilepsy, drug resistance was reported in 59.6% of cases, 
with focal seizure onset prior to age 1 year while infantile spasms were incompletely 
responsive to therapy and associated with an increased likelihood of refraction 
(Jeong et al. 2017). 
However, mTORC1 inhibitors have shown to reduce the severity of seizures. 
EXIST-3 was randomised double-blind, placebo-controlled phase III trial designed 
to assess the efficacy and safety of two trough exposure concentrations of 
Everolimus, 3–7 ng/mL (low exposure) and 9–15 ng/mL (high exposure), compared 
to placebo as adjunctive therapy for treatment-resistant focal-onset seizures in TSC 
patients. Results showed that treatment significantly reduced seizure frequency 
(14.9% with placebo versus 29.3% with low-exposure everolimus and 39.6% with 
high-exposure everolimus) with a tolerable safety profile compared to placebo in 
patients (French et al. 2016). In TSC patients with refractory epilepsy, the target 
concentration of everolimus to use was shown to be 5-7 ng/ml initially but possibly 
5-15 ng/ml in cases of an inadequate clinical response but patients have a 
favourable risk-benefit profile (Franz et al. 2016). 
TSC-associated seizures are highly responsive to Vigabatrin, an antiepileptic 
drug used in the US (since 2009). Vigabatrin was shown to have an approximate 
95% efficacy at stopping infantile spasms (Curatolo et al. 2001). Cannabidiols (CBD) 
may also be useful for the treatment of TSC-associated seizures. After 3 months of 
treatment, patients with TSC-associated refractory seizures were shown to have a 
decrease in the weekly frequency of seizures (in all seizure types of patients in the 
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study) and improved cognitive ability (85.7%) and behaviour (66.7%) (in patients 
with baseline cognitive and/or behavioural problems) (Hess et al. 2016). Cytotoxic 
agents are clinically less likely to be used for this indication, while drugs that restore 
disease state would be better. While it is currently unclear what pathways might 
trigger seizures, endoplasmic reticulum (ER) stress and inflammatory signals have 
been suggested as possible mechanisms. 
 
1.1.2.3.2 Brain Tumours 
Brain lesions are found in approximately 90% of TSC patients and manifest in 
several different types (Mühlebner et al. 2016); cortical tubers, subependymal 
nodules (SENs) and subependymal giant astrocytomas (SEGAs).  
Cortical tubers have been reported in up to 90% of patients (Katz et al. 2017). 
Tubers are focal developmental abnormalities. They can form as single or multiple 
lesions (Crino 2013). They may be found in any cortical region but found 
predominately in frontal and temporal regions. Tubers can also be detected during 
foetal life. Foetal tubers have been identified as early as 20 weeks gestation (Park 
et al. 2002) and in older children and adults. Tubers may calcify and undergo cystic 
degeneration. The presence of cortical tubers is often associated developmental 
delays, autism and treatment-resistant epilepsy (Katz et al. 2017)  
SENs are asymptomatic periventricular nodular lesions (Figure 1.3), which 
may evolve postnatally and throughout early adulthood into SEGAs (Zordan et al. 
2018). SENs have been reported in between 80% to nearly 100% of patients (Hu et 
al. 2016). SENs frequently show calcifications, particularly at an early stage. They 
are typically less than 1 cm in diameter and are better detected by computerized 
tomography (CT) (Çelenk et al. 2005; Hu et al. 2016).  
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Figure 1.3 CT Scan of subependymal nodules (SENs). Black arrows indicate the locations of the 
SENs in the patient’s brain. Image taken from (Samueli et al. 2015). 
 
SEGAs are a rare slow growing glioneuronal tumours which develop from 
SENs in about 20% of TSC patients with a peak of incidence in the second decade 
of life (Franz et al. 2013; Cardamone et al. 2014) (Figure 1.4). SEGAs tend to occur 
in the wall of the lateral ventricle and foramen of Monro and, rarely, in the third 
ventricle. While SEGAs are defined as low-grade tumours (WHO grade I) or even 
benign (Weidman et al. 2015; Dadey et al. 2016), growth and location of tumours 
can result in obstructive hydrocephalus and intracranial pressure, sequelae 
including seizures and focal neurological deficits which can result in death (Cuccia 
et al. 2003; Appalla et al. 2016; Katz et al. 2017; Zordan et al. 2018). SEGAs are 
not responsive to chemotherapy or radiation therapy. Currently, standard treatment 
for SEGAs involves resection, however 48.9% of patients suffer from postoperative 
complications which have been associated with the extent of dissection required to 
access the deep location of SEGAs (Beaumont et al. 2012; Sun et al. 2012). 
Incomplete resection of SEGAs will typically lead to recurrence (Roszkowski et al. 
1995). 
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Figure 1.4 CT Scan of subependymal giant astrocytoma (SEGA). White arrow indicates the 
location of the SEGA into patient’s brain. Image taken from (Franz et al. 2013). 
 
mTORC1 inhibitors have some shown clinical promise for the treatment of 
brain tumours. In 3 TSC patients with large intracranial SEGAs, the use of oral 
rapamycin as a pre-treatment prior to surgery was shown to allow for easier 
resection of tumours as the border between tumour and healthy tissue became well-
differentiated because of tumour size reduction (Du et al. 2017). Rapamycin was 
hypothesized to decrease the flow of blood to the tumours and as a result reduce 
the risk of postsurgical cerebrospinal fluid diversion. 
EXIST-1 was a multicentre, randomized, double-blind, placebo-controlled 
phase III trial with an open-label extension evaluating the efficacy and tolerability of 
Everolimus in 117 patients with TSC-associated SEGA. 27 (35%) patients in the 
Everolimus cohort had at least 50% reduction in the volume of SEGAs versus none 
in the control placebo cohort. Adverse events were mostly grade 1 or 2 (fever, 
fatigue, stomatitis (aphthous ulcers of the mouth), mucositis, rash, loss of appetite, 
diarrhoea, arthralgias, thrombocytopenia and blood lipid abnormalities) and no 
patients discontinued treatment because of adverse events (Franz et al. 2013). 
Additional analysis of data has shown Everolimus to be a safe therapeutic option for 
patients aged <3 years (as Everolimus was initially approved for patients >3 years 
of age) (Jóźwiak et al. 2016) and prolonged usage was shown to lead to sustained 
reduction in tumour volume, and new responses were observed for SEGA and renal 
angiomyolipoma (Franz et al. 2016).  
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 Investigations were carried out into using Everolimus as a maintenance 
therapy after a higher dose of therapy caused a reduction in SEGA tumour volume 
(Trelinska et al. 2017). To reach a trough concentration of 5-15 ng/ml in patients, 
Everolimus was administered 3 times a week (rather than administering daily, as 
done in standard therapy). This EMINENTS study involved 10 patients with TSC-
associated SEGAs. Observations over a period of 360 days (with checks on days 
0, 90, 120 and 360) showed no regrowth of tumours. Adverse effects were also 
noted as being significantly less severe and less frequent during maintenance 
compared with the standard therapy. 
 
1.1.2.4 Lung  
LAM (Figure 1.5) is a rare multisystem neoplastic disease characterized by the 
proliferation of oestrogen receptor alpha (ERα)- and progesterone receptor (PR)-
positive abnormal smooth muscle like cells (LAM cells). This leads to cystic 
destruction of the lungs, and the formation of lymphatic tumours such as chylous 
effusions and lymphangioleiomyomas (Chu et al. 1999; Matsui et al. 2000; Johnson 
et al. 2010; Gao et al. 2014; Taveira-DaSilva and Moss 2015). LAM can occur in 
two forms; sporadic or as a pulmonary manifestation of TSC (Seyama et al. 2016).  
 
 
Figure 1.5 CT scan of lymphangiomyomatosis (LAM). White arrows indicate sample of the LAM 
lesions found in the patients lung. Image taken from (Badawi and Geddes 2003). 
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LAM predominately affects women of child-bearing age (average age of 
diagnosis is approximately 35 years). There are very few case of male TSC patients 
developing LAM (Costello et al. 2000; Ryu et al. 2006; Johnson et al. 2010; Oprescu 
et al. 2013). The prevalence of TSC-associated LAM is an issue of debate as it 
initially thought to affect 1-4% of female patients (Dwyer et al. 1971; Sheperd et al. 
1991; Castro et al. 1995). However, in the 2000s, studies into LAM demonstrated a 
prevalence of 28-38% in female patients (Costello et al. 2000; Franz et al. 2001; 
Moss et al. 2001). This may also be a further underrepresentation, as one study 
reported that prevalence may be as high as 80% of female TSC patients 
(Adriaensen et al. 2011). 
LAM affects the lung function of patients as decline in function rates are two 
to four times higher than rates seen typically associated with age (Johnson and 
Tattersfield 1999; Urban et al. 1999; Taveira-DaSilva et al. 2004). Respiratory failure 
is a principal cause of death in sporadic and TSC-associated LAM patients 
(Courtwright et al. 2017). The median transplant-free survival is approximately 29 
years from the onset of symptoms, with a 10-year transplant-free survival of 86% 
(Ryu et al. 2006; Galvin et al. 2007; Oprescu et al. 2013). Clinical symptoms of this 
progressive disease includes dyspnoea, cough, recurrent pneumothorax, 
haemoptysis and chylothorax with most patients requiring oxygen supplementation 
within 10 years of symptom onset (McCormack et al. 2016; Moir 2016). LAM patients 
also appear to be at an increased risk of respiratory infections (Courtwright et al. 
2017)(McCormack et al. 2011; Chang et al. 2014; Radzikowska et al. 2015a). 
LAM patients who receive lung transplants can still developed LAM lesions 
post-transplant (Karbowniczek et al. 2003). This indicates that LAM cells do not 
originate in the lungs but instead originate in a different organ before travelling to 
the lungs (Gao et al. 2014). The original source of LAM cells remains unknown 
(Prizant and Hammes 2016). The predominant histological features of LAM are the 
abundance of lymphatic vessels and the proliferation of LAM cells (Seyama et al. 
2016). Research by Kumasaka et al. (2005) suggested that lymphangiogenesis-
mediated fragmentation of LAM lesions and shedding of LAM cell clusters (LCCs) 
in the lymphatic stream may play a role in the metastatic progression of LAM.  
On the molecular level, LAM cells have very specific defects. LAM cells have 
mutations in either TSC1 or TSC2 (Prizant and Hammes 2016). Sporadic LAM is 
caused by two acquired mutations while TSC-associated LAM is caused by one 
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germline mutation and one acquired mutation (Moir 2016). Approximately 60% of 
women with sporadic LAM also have renal AMLs (Ryu et al. 2012) and in these 
cases mutations (loss of heterozygosity) were only found in TSC2 and in many 
cases these TSC2 mutations were identical in both kidney and lung samples (Yu et 
al. 2001; Carsillo et al. 2002). Mutations in TSC1/2 also causes increased Rho-A 
GTPase activity and likely contributes to enhanced cellular migration and 
proliferation (Li et al. 2011). 
Hormones, such as estradiol, play an important pathological role in LAM. 
LAM which is found nearly exclusively in women of child bearing age, can progress 
during pregnancy or treatment with oestrogen. LAM is stabilised or disease progress 
slowed in postmenopausal women (Radzikowska 2015). Metabolomic profiling 
identified an estradiol-enhanced prostaglandin biosynthesis signature in Tsc2-
deficient cells. Estradiol increased the expression of cyclooxygenase-2 (COX-2), a 
rate-limiting enzyme in prostaglandin biosynthesis, which was also increased at 
baseline in Tsc2-deficient cells and was not affected by mTORC1 inhibition with 
rapamycin treatment (Li et al. 2014). In Tsc2-deficient cells, estradiol was found to 
reactivate ambra signalling and increased levels of glucose-6-phosphate 
dehydrogenase (G6PD), the rate limiting enzyme of the pentose phosphate pathway 
(Sun et al. 2014). Oestrogen is also known to activate mitogen-activated protein 
kinase (MAPK) and promoted the survival of TSC2-null LAM-like cells as well as to 
enhance the expression of matrix metalloproteinase-2 (MMP-2), which attributes to 
the invasiveness of LAM cells (Li et al. 2013). Progesterone involvement has been 
shown to have varied results. For instance, Sun et al. (2014) showed that 
progesterone alone (and synergistically with estradiol) activated AKT and ERK 
pathways and increased proliferation in ELT-3 cells (a rat TSC model cell line) and 
could cause lung metastasis and invasiveness in vivo. However, Glace et al. (2009) 
and Hodges et al. (2002) showed in ELT3 cells that progesterone suppressed the 
oestrogen-induced gene expression and inhibited oestrogen-induced cell 
proliferation. 
mTOR inhibitors are used as a treatment for LAM, with rapamycin being FDA 
approved for LAM. Rapamycin has been shown to inhibit cell growth and the 
production of VEGF, while at the same time stabilizing lung function. Problems can 
arise in this scenario based on the cytostatic nature of rapamycin. Whether or not 
rapamycin can also prevent LAM migration is also unknown. As a result, further 
research into cytotoxic alternatives are needed to treat LAM.  
19 
 
1.2 mTORC1 in tumour growth 
 
1.2.1 mTOR  
 
1.2.1.1 mTORC1 and mTORC2 
mTOR is a downstream target of TSC1/TSC2 and is a drug target for the treatment 
of TSC. mTOR is an evolutionary preserved atypical serine/threonine kinase that 
acts as a master regulator of several key functions including growth, proliferation 
and metabolism (Laplante and Sabatini 2009b), which are processes linked to the 
pathology of TSC. In the 2000s, mTOR was found to function as a core protein of at 
least two distinct multi-protein complexes, mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) and will be further discussed in this chapter (Laplante and 
Sabatini 2009; Blenis 2017).   
mTORC1 is a multi-protein complex composed of several components that 
interact with the mTOR kinase. mTORC1 is known for its control of cellular growth, 
translation, transcription and autophagy (Sulaimanov et al. 2017). mTORC1 adopts 
a cage-like, dimeric architecture with the mTOR kinase domain located near the 
centre of the assembly (Aylett et al. 2016). Rapamycin has been shown to be 
selective for mTORC1 inhibition. Rapamycin inhibits mTORC1 via formation of a 
gain-of-function complex with 12-kDa FK506-binding protein (FKBP12), that binds 
to the FKBP12/rapamycin-binding (FRB) domain of mTOR in mTORC1 only. When 
this occurs the rapamycin/FKBP12 complex causes dissociation of Raptor from the 
mTOR causing loss of contact between mTORC1 and it substrate, resulting in 
pathway shutdown (Ehninger and Silva 2011; Chiarini et al. 2015). The components 
of mTORC1 that interact with mTOR are found in Table 1.1. 
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Table 1.1 Components of mTORC1 complex. List of the component and their function of the 
mTORC1 complex 
Regulatory-
associated 
protein of 
mammalian 
target of 
rapamycin 
(Raptor) 
150 kDa protein found exclusive in mTORC1 and functions as a 
scaffold protein that interacts with downstream substrates, S6K1 
and 4E-BP1 - which will be discussed later in the chapter. 
mTORC1 substrates, contain mTOR signalling (TOS) motifs that 
helps with mTORC1-dependent phosphorylation of those 
substrate. Raptor is also needed to assist with the localization of 
the mTORC1 to the lysosome (Chong, 2015; Tee, Sampson, Pal, 
& Bateman, 2016).    
Proline-rich AKT 
substrate 40 kDa 
(PRAS40) 
mTORC1 exclusive protein with a TOS motif that is a negative 
regulator of mTORC1. PRAS40 interacts with Raptor and 
competitively binds to S6K1 and 4E-BP1. AKT phosphorylates 
PRAS40 causing PRAS40 to bind to protein 14-3-3 (causing 
PRAS40 inactivation) resulting in increased mTORC1 activity 
(Cho, 2011; Chong, 2015)    
mLST8 See Table 1.2. 
 
Deptor See Table 1.2. 
 
mTORC2 is found to be proximally located to the endoplasmic reticulum (ER) (close 
to the ribosomes), mitochondria, mitochondria-associated ER-membrane (MAM) 
and the nucleus in mammalian cells (Liu et al. 2015c). mTORC2 was initially defined 
for its role in regulating cell skeletal organisation but mTORC2 also promotes cell 
proliferation and survival through the phosphorylation of AKT (Liu et al. 2013).While 
rapamycin may be regarded as an mTORC1 selective inhibitor (as 
rapamycin/FKBP12 complex does allosterically inhibit mTORC2) rapamycin is able 
to inhibit mTORC2 activity after prolonged exposure (over 24 h), when high 
concentrations of rapamycin are used, or due to variation in the expression levels 
of FK506 binding proteins (especially FKBP12 and FKBP51) (Sarbassov et al. 2006; 
Efeyan and Sabatini 2010; Li et al. 2014b; Schreiber et al. 2015). TSC2 positively 
regulates mTORC2 in a manner independent of the GTPase-activating protein 
activity the complex has towards Rheb and can physically associate with mTORC2 
but not mTORC1 (Huang et al. 2008). mTORC2 also promotes survival in TSC2-
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null cell proliferation and survival through RhoA GTPase and Bcl2 proteins (Li et al. 
2011). The components of mTORC2 (including mTOR) are found in Table 1.2. 
  
Table 1. 2 Components of mTORC2 complex. List of the component and their function of the 
mTORC2 complex 
Rapamycin-insensitive companion 
of mTOR (Rictor) 
An mTORC2 exclusive component that 
is involved in the activation of AKT via 
direct phosphorylation of Ser473, a 
priming site that enables PDK1 to 
phosphorylate Thr308 (Sarbassov et al. 
2005).  
Mammalian stress-activated protein 
kinase interacting protein (mSIN1) 
A negative regulator exclusive to the 
mTORC2 complex that prevents mTOR 
kinase activity by interacting with and 
inhibiting the mTOR kinase domain. 
mSIN1 is regulated by PIP3 (Liu et al. 
2015c). 
Protein observed with Rictor-1 
(Protor-1) 
Protor-1 is a Rictor-binding subunit 
required for the activation of serum- and 
glucocorticoid-induced protein kinase 1 
(SGK1) (Chong 2015) 
Mammalian lethal with Sec13 
protein 8 (mLST8) 
Also called G protein β-subunit like 
protein (GβL). mLST8 structurally has 
seven WD-40 repeats and is located on 
endosomal or Golgi membranes. 
mLST8/GβL associates with mTORC2 
by binding to the kinase domain of 
mTOR and plays several roles in 
stability, assembly, and mTOCR2 
activity towards AKT and protein kinase 
Cα (PKCα) (Cho 2011). 
DEP domain containing mTOR 
interacting protein (Deptor) 
A negative regulator of mTORC2, which 
binds to the FAT domain of mTOR 
(Chong, 2015). 
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1.2.1.2 Signalling upstream of mTOR  
Upstream of mTOR is the Phosphoinositide 3-kinase (PI3K)/acutely transforming 
retrovirus AKT8 in rodent T cell lymphoma (AKT, also known as protein kinase B) 
pathway. PI3K is a class IA member of the lipid kinase family which is activated by 
tyrosine kinase receptors which is activated by insulin (or insulin-like growth factor), 
which generates phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) from 
phosphatidylinositol-4, 5 bisphosphate (PIP2) (Hassan et al. 2013; Huang and 
Fingar 2014).  
PIP3 is an important lipid messenger that is used to allosterically regulate 
several components upstream of mTOR. Activated PIP3 recruits and allows 
phosphoinositide-dependent kinase 1 (PDK1 – a serine/threonine kinase) to 
phosphorylate AKT. PIP3 also interacts with the mTORC2 complex via 
mSIN1interaction that causes mSIN1 to release its inhibition of the mTOR kinase 
domain leading to activation of mTORC2. PIP3 is negatively regulated by 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN), which 
dephosphorylates PIP3 back to PIP2 (Huang and Fingar 2014; Dibble and Cantley 
2015; Liu et al. 2015; Zhang et al. 2016). 
AKT is a serine/threonine protein kinase that is a key intracellular mediator 
of diverse cellular processes (Cho, 2011). AKT becomes fully activated via direct 
phosphorylation by mTORC2 and PDK1. AKT activates mTORC1 via direct 
phosphorylation of TSC2 at five residues (Ser939, Ser981 Ser1130, Ser1132 and Thr1462 
- all of which exist outside of the GTPase activating protein (GAP) domain of TSC2) 
(Dibble and Cantley 2015). AKT also regulates cellular levels of ATP. Activated AKT 
maintains a high level of ATP by promoting glucose metabolism through hexokinase 
phosphofructokinase activity stimulation and translocation of glucose transporters 
(Glut1 and Glut4) to the cell surface. This triggers a decrease in the AMP/ATP ratio, 
resulting in AMPK inactivation and as a result, prevents activation of TSC2 (Figure 
1.6) (Hahn-windgassen et al. 2005; Perluigi et al. 2015; Hung et al. 2017) 
23 
 
 
Figure 1.6 Upstream activation of the mTORC1. Growth factors/Insulin activates PI3K which 
catalyses the transformation of PIP2 to PIP3. PIP3 allows mTORC2 and PDK1 to interact with AKT 
and causes AKT to become phosphorylated. Phosphorylated AKT disrupts TSC complex via 
phosphorylation of TSC2. The TSC complex regulates Rheb via GTPase activity which converts 
Rheb to an inactive GDP-bound state. Phosphorylation of TSC2 by activated AKT prevents GTPase 
activity, which allows for the activation of mTORC1 
 
1.2.1.3 Downstream of mTORC1 complex 
mTORC1 has 2 main downstream mediators p70 ribosomal protein S6 kinase 1 
(S6K1) and eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-
BP1) (Qin et al. 2016; Calkins et al. 2018) (Figure 1.7). 
S6K1 is a serine/threonine kinase and is a member of the AGC kinase family 
(Tavares et al. 2015). The main target of S6K1 is ribosomal protein S6 (rpS6) which 
is a component of the 40S ribosomal subunit (Tavares et al. 2015). S6K1 can also 
enhance de novo synthesis of pyrimidines via phosphorylation of carbamoyl-
phosphate synthase 2, aspartate transcarbamoylase and dihydroorotase (CAD) 
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(Ben-Sahra et al. 2013). Direct S6K1 phosphorylation (at Thr389) by mTORC1 
activates S6K1 which, in turn, phosphorylates several downstream targets involved 
in mRNA translation including eIF4B (a positive regulator of the 5’-cap binding eIF4F 
complex) and PDCD4 (an inhibitor of eIF4B which is degraded following 
phosphorylation) (Saxton and Sabatini 2017). 
 4E-BP1 in a hypo-phosphorylated state, prevents translation initiation by 
binding to the translation factor, eukaryotic initiation factor 4E (eIF4E). eIF4E 
interacts with the 7-methyl-guanosine 5′-cap structure, m7GpppX (where X is any 
nucleotide) at the 5-end of the mRNA. eIF4E regulates cap-mediated mRNA 
translation by forming a multi-subunit complex called eIF4F (eIF4E associated with 
eIF4G (a scaffold protein), eIF4B and eIF4A (which unwinds the secondary structure 
in the 5’-untranslated regions (5’-UTR) of mRNAs)). The eIF4F complex is involved 
in the recruitment of 40S ribosomal subunits to the 5’-cap of the mRNA. mTORC1 
activation phosphorylates 4E-BP1 and causes dissociation of 4E-BP1 from eIF4E, 
allowing the recruitment of eIF4G to form the eIF4F complex that then promotes 
translation initiation (Morita et al. 2015; Qin et al. 2016; Tee et al. 2016; Calkins et 
al. 2018). While mTORC1 controls global protein synthesis by regulating eIF4F 
assembly, eIF4E preferentially stimulates the translation of select groups of mRNAs 
through “eIF4E-sentitive" mRNAs (Koromilas et al. 2018). These eIF4E-sensitive 
mRNAs include several mRNAs encoding proteins involved in cell survival and 
proliferation, such as cyclins, ornithine decarboxylase (ODC), VEGF and Myc 
(Nandagopal and Roux 2014). 
Protein synthesis is essential for cell growth and proliferation. However, 
aberrant levels of protein synthesis can cause the accumulation of unfolded, 
misfolded, insoluble, or otherwise damaged proteins. Accumulation of unfolded 
protein can cause cell stress. If cells cannot accommodate the increased demand 
of newly synthesised proteins (either by increasing the capability to fold proteins or 
by getting rid of damaged proteins via autophagy and the proteasome), recovery of 
stress caused from this accumulation of unfolded proteins occurs in the endoplasmic 
reticulum (ER). This stressed condition is discussed in detail later in this chapter. 
Protein synthesis is also the largest consumer of ATP. As a result, energy stress 
can occur if protein synthesis is enhanced and cells cannot find other means to 
ensure a sufficient replenishment of energy.  
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Figure 1.7 The mTORC1 pathway. Inactive mTORC1 is translocated to the surface of the lysosome 
(via with Rag guanosine triphosphatases (Rag GTPases or RAGs)). At the lysosome, mTORC1 
interacts with Rheb (in its GTP-bound state) causing activation of the mTORC1 complex. Activated 
mTORC1 has several downstream effects. These include increased protein translation (via inhibition 
of 4E-BP1), increased mRNA biogenesis (via S6K1), decreased autophagy (via inhibition of ULK1), 
increased angiogenesis (via HIF1α activation), lipogenesis/adipogenesis, and membrane 
biogenesis. 
 
1.2.2 mTORC1 and angiogenesis 
As previously mentioned above, HIF1α plays a role in vascularisation and 
angiogenesis and is defined as a master transcriptional factor of cellular and 
developmental response to hypoxia. In normoxic conditions, HIF1α undergoes 
ubiquitination and proteasomal degradation, while HIF1α accumulates and plays a 
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role in transcription during hypoxia (Zhang et al. 2015). When mTORC1 is 
hyperactive, HIF1α drives VEGF gene-expression to high levels. TSC patients have 
been shown to have elevated baseline levels of VEGF-D in their blood. This data 
can be used as a diagnostic biomarker to demonstrate a sensitivity to mTORC1 
inhibitor therapy. (Dabora et al. 2011; Malinowska et al. 2013). mTORC1 activation 
causes an accumulation of HIF1α via direct phosphorylation of STAT3 on Ser727 
(Dodd et al. 2015), resulting in VEGF accumulation (Figure 1.7).  
Different components of mTORC1 control protein expression of HIF1α and 
VEGF (Dodd et al. 2015). Protein translation of HIF1α is regulated by S6K1 and 4E-
BP1, while VEGF is primarily under the control of 4E-BP1 and eIF4E. The 
relationship between mTORC1 and HIF1α is also important in foetal lung 
development, as Scott et al. (2010) showed HIF1α-driven vasculogenesis is linked 
to the cross-talk between mTORC1 and the fibroblast growth factor (FGF) 10/FGF-
receptor2b/Spry2 regulator of airway branching.  
mTOR inhibitors effectively blocked Ser727 phosphorylation of STAT3, and 
abolishment of HIF-1α expression was achieved by targeting JAK2-mediated Tyr705 
phosphorylation site and mTORC1-mediated Ser727 site on STAT3 (Dodd et al. 
2015).  
 
1.2.3 mTORC1 and lipogenesis  
mTORC1 plays a role in lipogenesis (Figure 1.7). Lipid biosynthesis is essential for 
the maintenance of cellular homeostasis. The lipids produced by cells (glycerolipids, 
fatty acids, phospholipids, cholesterol, spingolipids) are used in different ways; as 
an energy source/reserve, as building blocks for membrane biosynthesis, as 
precursor molecules for the synthesis of various cellular products and also as 
signalling molecules (Laplante and Sabatini 2009). Following their activation, 
mTORC1 facilitates the accumulation of triglycerides by promoting adipogenesis 
and lipogenesis and by shutting down catabolic processes such as lipolysis and β-
oxidation (Caron et al. 2015).  
 mTORC1 controls lipogenesis via regulation of Lipin-1 entry into the nucleus. 
Lipin-1 is a phosphatidic acid phosphatase involved in the cleavage of phosphatidic 
acid, an integral step in triacylglycerol synthesis (Huffman et al. 2002). Lipin-1 also 
regulates sterol regulatory element binding protein 1 (SREBP1) activity. SREBP1 is 
a transcription factor that is critical for the regulation of fatty acid and cholesterol 
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biosynthetic gene expression (Horton et al. 2002). While located in the nucleus, 
Lipin-1 inhibits lipogenesis by SREBP1 (Peterson et al. 2011). When mTORC1 is 
activated, mTORC1 directly phosphorylates Lipin-1 preventing translocation of 
Lipin-1 into the nucleus, allowing SREBP1 activity to proceed in de novo 
lipogenesis.  
mTORC1 also contributes to lipogenesis via SR protein kinase 2 (SRPK2), a 
key regulator of RNA-binding SR proteins. S6K1 phosphorylates SRPK2 at Ser494, 
which primes Ser497 phosphorylation by Casein kinase 1 (CK1). Activated SRPK2 is 
then translocated to the nucleus and activates SR proteins and U1-70K to promote 
splicing of lipogenic transcripts (Chavez et al. 2017). 
Significant lysophosphatidylcholine (LPC) – a lysoglycerophospholipid 
accumulation was found in TSC2-deficient cells relative to TSC2-expressing control 
cells (Priolo et al. 2015). These changes occurred alongside changes in other 
phospholipid and neutral lipid species. mTORC1 shuts down catabolic processes 
involved in lipid metabolism such as lipolysis and β-oxidation (Caron et al. 2015) 
while at the same time, autophagy regulating intracellular lipid stores via 
macrolipophagy (Singh et al. 2009). Constitutive activation of mTORC1 (via TSC1/2 
mutation) prevents lipid metabolism and inhibits autophagy causing an 
accumulation of lipids in the cell which in turn could lead to an energy crisis as cells 
cannot utilise lipid components to generate much needed energy to compensate for 
protein biogenesis. The regulation of energy crisis is regulated in TSC1/2-deficient 
cells is discussed later in this chapter. 
 
1.2.4 mTORC1 and autophagy  
Autophagy is a conserved self-degrading process which is a well-established 
survival mechanism to maintain cellular homeostasis in both a normal and stressed 
environment (Wataya-Kaneda 2015). Unc-51-like kinase 1 (ULK1) is a 
serine/threonine kinase that functions in a complex with Atg13, FIP200 and Atg101 
to form the highest upstream component of the mammalian autophagy pathway 
(Dunlop and Tee 2013). In stressed conditions (e.g. nutrient starvation) autophagy 
is activated by the phosphorylation of Atg13 and FIP200 and by the 
autophosphorylation (at Ser1047) of ULK1 (Dunlop and Tee 2013; Dunlop and Tee 
2014).  
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mTORC1 inhibits autophagy via phosphorylation of ULK1 on Ser758 (Kim and 
Guan 2015; Gallagher et al. 2016) (Figure 1.7). Interestingly, different types of 
mTORC1 inhibition affect dephosphorylation of ULK1. Nutrient starvation causes a 
complete dephosphorylation of ULK1 compared to mTORC1 inhibitors such as 
rapamycin (Wong et al. 2015). This is possibly because nutrient starvation causes 
a complete shutdown of mTORC1 while mTOR inhibitors can only cause a partial 
mTORC1 inhibition. However ULK1 is also known to phosphorylate Raptor in a form 
of signal feedback at Ser696, Thr706, Ser855, Ser859, Ser863, Ser877 and Ser792 that can 
potently block mTORC1 activity (Dunlop and Tee 2013). 
 Another possible mechanism of mTORC1-mediated ULK1 regulation is via 
the disruption of ULK1 stability through inhibitory phosphorylation of 
autophagy/beclin 1 regulator 1 (AMBRA1) (Nazio et al. 2013). mTORC1 also 
regulates autophagy at the transcriptional level by modulating the localisation of 
transcription factor EB (TFEB), a master transcriptional regulator of lysosomal 
biogenesis and autophagy genes (Kim and Guan 2015).  
Depending on the cellular context, autophagy can either promote or inhibit 
tumorigenesis. In terms of TSC, It was proposed that the AMPK/p27 axis might be 
promoting a survival mechanism in Tsc2-null cells as AMPK stabilises p27 and p27-
dependent activation of autophagy is involved in Tsc2-null cell survival under 
rapamycin treatment (Campos et al. 2016). Inhibition of AMPK and p27 depletion 
were observed to reduce activation of autophagy by rapamycin in Tsc2-null cells 
(Campos et al. 2016). Parkhitko et al. (2011) observed inhibiting both mTORC1 and 
autophagy inhibition was more effective than either treatment alone in terms of 
inhibiting the survival of TSC2-null cells, growth of TSC2-null xenograft tumours 
(which also trigger large amounts of necrosis), and development of spontaneous 
renal tumours in Tsc2(+/-) mice. The authors also showed that down regulation of 
p62 (the autophagic substrate that accumulates in TSC2-deficient cells has its 
expression reduced via autophagic inhibition. Hippo-Yes-associated protein 1 (YAP) 
was shown to accumulate in TSC1/TSC2-deficient cells due to impaired degradation 
of the protein by the autophagosome/lysosome system. The data also showed that 
YAP inhibition blunts abnormal proliferation and induces apoptosis of TSC1–TSC2-
deficient cells, both in culture and in mosaic Tsc1 mutant mice (Liang et al. 2014). 
Autophagy inhibition combined with enhanced protein synthesis and the 
inability to use lipids as an energy source, causes TSC1/2-null cells to become 
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energy stressed. In the next two sections of this chapter, how energy stress is 
managed will be discussed. 
 
1.2.5 mTORC1 and energy metabolism 
mTORC1 responds to intracellular and environmental stresses that are incompatible 
with growth such as reduction in cellular energy charge (e.g. during glucose 
deprivation or in low ATP environments). Energy starvation is the result of protein 
and lipid biosynthesis in TSC. This activates the stress responsive metabolic 
regulator AMPK, which inhibits mTORC1 both indirectly, through phosphorylation of 
TSC2 leading to GAP activity, as well as directly, through the phosphorylation of 
Raptor at Ser722 and Ser792, leading to 14-3-3 protein binding and mTORC1 
inhibition (Dunlop and Tee 2013; Saxton and Sabatini 2017).  
5' adenosine monophosphate-activated protein kinase (AMPK) is a trimeric 
complex that acts as a highly conserved master regulator of metabolism, which 
restores energy balance during metabolic stress both at the cellular and 
physiological levels (Garcia and Shaw 2017). AMPK becomes activate in the 
presence of high AMP: ATP and ADP: ATP ratios, via allosteric binding of AMP and 
ADP to the γ-subunit of AMPK. This confirmation change of AMPK then promotes 
Thr172 phosphorylation in the activation loop of the kinase domain by the 
serine/threonine kinase LKB1 (liver-kinase-B1) (Hawley et al. 2003; Woods et al. 
2003; Shaw et al. 2004). AMPK promotes glucose uptake by phosphorylating 
TBC1D1 (TBC domain family, member 1) and TXNIP (thioredoxin-interacting 
protein), which controls the translocation and cell-surface levels of glucose 
transporters GLUT4 and GLUT1. AMPK also acutely regulates glycolysis in some 
tissue types by phosphorylating PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3) (Hardie 2013; Wu et al. 2013). At the same time, AMPK controls 
overall cellular lipid metabolism through direct phosphorylation of ACC1 (acetyl-CoA 
carboxylase 1) and ACC2, resulting in the suppression fatty acid synthesis while 
simultaneously promoting fatty acid oxidation by relieving the suppression of CPT1 
(carnitine palmitoyltransferase 1) by malonyl-CoA (Ahmadian et al. 2011; Abbott et 
al. 2016) (Figure 1.8).  
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Figure 1.8 Energy metabolism. In the presence of low energy levels, AMPK is activated by several 
factors including SESN2 and LKB1. Activated AMPK causes increased mitochondrial biogenesis (via 
PGC1α), increases glucose uptake (via increase GLUT4), regulates lipid metabolism by promoting 
fatty acid oxidation (via cPT1) and suppresses mTOR pathway (via TSC2). 
 
1.2.6 mTORC1 and mitochondrial biogenesis  
To compensate for the high energy demand caused by protein synthesis and 
lipogenesis, TSC1/2-null cells enhance ATP generation by increasing mitochondrial 
biogenesis. mTORC1 controls mitochondrial activity and biogenesis by selectively 
promoting translation of nucleus-encoded mitochondria-related mRNAs via 
inhibition of 4E-BP1. The translation of nucleus-encoded mitochondria-related 
mRNAs stimulates an increase in the generation of ATP, which is a required energy 
source for translation (Morita et al. 2013). AMPK (activated as a result of low ATP 
levels) is also responsible for the activation of PGC1α (peroxisome proliferator-
activated receptor gamma, coactivator 1α), a master regulator of mitochondrial 
biogenesis, via direct phosphorylation of PGC1α and by promoting NAD+-
dependent activation of PGC1α by Sirt1 (sirtuin 1) (Speer et al. 2012) (Figure 1.8). 
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1.2.7 Potential vulnerabilities of TSC 
Understanding the pathophysiology of TSC-diseased cells gives potential insights 
into signalling pathways that could be therapeutically targeted to restore disease 
status. Understanding the key signalling pathways involved in homeostatic balance 
in TSC-diseased cells might also reveal potential avenues of therapy that could have 
cytotoxic effect. 
 
1.2.7.1 TSC and the lysosome 
While inactive, mTORC1 is found in the cytoplasm, in the presence of amino acids, 
mTORC1 is translocated to the surface of the lysosome, where Rheb (in its GTP-
bound state) is located, which in turns activates mTORC1. This is due to mTORC1 
association with Rag guanosine triphosphatases (Rag GTPases or RAGs) (Wataya-
Kaneda 2015). RAGs (identified by Kim et al. (2008) and Sancak et al. (2008)) exist 
as heterodimers of either RagA or RagB bound to either RagC or RagD that in turn 
binds to Raptor in mTORC1 (Chong 2015). Association only occurs if RagA/B is in 
a GTP-bound state (and RagC/D is in a GDP-bound state) (Shimobayashi and Hall 
2016) (Figure 1.7).  
Rags don’t contain a membrane-targeting sequence but are able to bind to 
the lysosomal surface due to the presence of the Ragulator complex (Groenewoud 
and Zwartkruis 2013). The Ragulator complex is a pentametric complex that is 
comprised of LAMTOR (late endosomal/lysosomal adaptor, MAPK (mitogen 
activated protein kinase) and mTOR activator)1,2 and 3 (also known as p18, p14 
and MP1 (MAPK scaffold protein 1)), HBXIP (hepatitis B virus X-interacting protein) 
and C7orf59 (Groenewoud and Zwartkruis 2013; Saxton and Sabatini 2017). The 
Ragulator complex also acts as an amino acid-stimulated GEF (guanine nucleotide-
exchange factor) for RagA/B that brings these GTPases to their active GTP-bound 
state.  
The GAP for RagA/B is the Gap Activity TOward Rags (GATOR) complex. 
This complex is involved in amino acid sensing activity and is composed of two 
subcomplexes, GATOR1 and GATOR2 function as negative and positive regulators 
of mTORC1, respectively. GATOR1 is the GAP component of the complex and is 
composed of DEPDC5 (DEP domain-containing protein 5, which is the GAP 
subunit), NPRL2 (nitrogen permease regulator 2-like protein) and NPRL3 (nitrogen 
permease regulator 3-like protein). Proteins that regulate the GATOR complex 
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include sestrin2 (which releases, GATOR1 from GATOR2), (Baldassari et al. 2016; 
Shimobayashi and Hall 2016). The amino acid leucine is especially important for 
GATOR complex as leucine binds to the GATOR complex, which causes the 
GATOR complex to become tethered to the lysosome (Saxton and Sabatini 2017). 
 The GAP for RagC/D is folliculin (FLCN), that promotes the active 
conformation of RagC/D. FCLN is bound to the lysosome in an amino acid-starved 
environment when RagA/B is inactive. When RagA/B is active, FLCN disassociates 
from the lysosome with FLCN-interacting protein (FNIP) that promotes mTORC1 
translocation to the lysosome (Shimobayashi and Hall 2016).   
 Chloroquine-induced inhibition of lysosomal function caused an upregulation 
in the expression of cholesterol homeostasis genes in TSC2-deficient cells while 
simultaneous inhibition of the lysosome and endosomal trafficking (using 
chloroquine and SAR405) inhibits the proliferation of TSC2-deficient cells (Valvezan 
et al. 2017). Accumulation of chloroquine in the lysosome contributed to cytotoxicity 
of a chloroquine/nelfinavir combination against Tsc2-/- MEFs (Johnson et al. 2015).  
 
1.2.7.2 TSC and energy stress  
Tsc1/2-null cells are hypersensitive to glucose deprivation. mTORC1 inhibition 
during glucose deprivation prevented cell death (Choo et al. 2010). It was also found 
that mTORC1 hyperactive cells became highly dependent on glutamate 
dehydrogenase-dependent glutamine metabolism via the TCA cycle for survival. In 
TSC-diseased cells, constitutive activation of mTORC1 causes cells to become 
sensitised to glucose starvation and DNA damage (which in this case was triggered 
by the introduction of DNA-alkylating agent methyl methane sulfonate (MMS), which 
causes base mispairing and replication blocks) (Lee et al. 2007). The combined 
starvation and DNA damage resulted in enhanced p53 activation (via stabilising 
phosphorylation), leading to cell death.  
 2-deoxy-D-glucose (2-DG) which is a glucose analog missing in which the 2-
hydroxyl group has been replaced by hydrogen, preventing it from undergoing 
glycolysis leading to reduced cellular ATP levels and cell growth and a 
carbohydrate-free diet were tested on LEF2 cells from a Tsc2-null rat tumour in mice 
(Jiang et al. 2011). The authors showed that exposure of these cells to 2-DG 
resulted in a decreased cell viability at low glucose concentration. This analysis 
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shows that cells lacking TSC2 are vulnerable to conditions that result in energy 
stress. 
 
1.2.7.3 TSC and ER stress 
 
1.2.7.3.1 ER stress 
The endoplasmic reticulum (ER) is a multifunctional organelle which is involved in 
several key roles such as lipid biosynthesis, calcium storage and protein folding and 
processing.  It has two different surfaces: the ribosomal stubbed outer layer (or 
rough ER), which is involved in protein synthesis and secretion. The smooth ER 
layer that has no ribosomes and is mostly involved in the synthesis of proteins, fatty 
acids and phospholipids synthesis, assembly of lipid bilayers, the metabolism of 
carbohydrates, and the regulation of calcium homeostasis (Schönthal 2012).  
Several physiological and pathological conditions and a variety of 
pharmacological agents can disturb the proper function of the ER resulting in ER 
stress. Several adaptive mechanisms bring the folding capacity of the ER and its 
unfolded protein burden into line and return the ER to its normal physiological state: 
(1) upregulation of ER folding capacity through induction of ER-resident molecular 
chaperones and foldases; (2) increase the  ER size through membrane expansion; 
(3) down-regulation of the biosynthetic load of the ER through inhibition of protein 
synthesis at a transcriptional and translational level; (4) and increased clearance of 
unfolded proteins from the ER through the upregulation of ER associated 
degradation (ERAD) (Harding et al. 1999; Friedlander et al. 2000; Travers et al. 
2000; Martínez and Chrispeels 2003; Pakula et al. 2003; Zúñiga et al. 2004). 
Endoplasmic-reticulum-associated protein degradation (ERAD) can occur in two 
different ways. The first is where damaged proteins are exported back into the 
cytoplasm and delivered to the proteasome for degradation. The second way is via 
aggresome formation, where damaged proteins are compacted together with other 
cellular debris into juxtanuclear complexes and then recycled via autophagy 
(Schönthal 2012).  
The accumulation of unfolded, misfolded, insoluble, or otherwise damaged 
proteins can irreparably damage cellular functions and thus pose a proteotoxic 
threat to the survival of the cell. Due to this cytotoxic risk several cellular sensors 
and pathways have evolved to respond to this threat 
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1.2.7.3.2 PERK pathway  
Protein kinase RNA-like endoplasmic reticulum kinase (PERK) is a type I 
transmembrane protein and is activated by the release by the release of binding 
immunoglobulin protein (BiP also called GRP78) from its ER luminal domain 
(Schröder and Kaufman 2005). Upon BiP release, PERK undergoes 
homodimerization and autophosphorylation before phosphorylating the α subunit of 
eukaryotic initiation factor 2 (eIF2α) at Ser51 (Rojas et al. 2015). Phosphorylation of 
eIF2α converts eIF2-GDP into a competitive inhibitor of eIF2B (guanine nucleotide 
exchange factor). This prevents the recycling of eIF2 between successive rounds of 
protein synthesis and results in the inhibition of the protein translation initiation 
pathway (Hinnebusch 2000; Clemens 2013; Bogorad et al. 2017).  
Phosphorylation of eIF2α also triggers the promotion of mRNA translation for 
mRNA encoding specific stress response factors such as activating transcription 
factor 4 (ATF4) which in turn leads to the transcription of downstream CCAAT-
enhancer-binding protein homologous protein (CHOP) and growth arrest and DNA 
damage-inducible protein 34 (GADD34, also called PPP1R15A) and activating 
transcription factor 3 (ATF3), which also contributes to the expression of CHOP and 
GADD34 (Jiang et al. 2004; Rojas et al. 2015). 
CHOP is an important proapoptotic transcription factor. Expression of CHOP 
in ER stress is up-regulated by ATF6, and preferential synthesis of ATF4 (Ma et al. 
2002). In normal cells, CHOP levels are kept very low level, however, increased  
expression and accumulation of CHOP occurs in as a response to unfolded protein 
response (UPR) and integrated stress response (ISR) (CHOP levels can also be 
increased by growth arrest, DNA damage, nutrient deprivation, hypoxia and 
genotoxic agents) (Li et al. 2014c; Yang et al. 2017). The full pro-apoptotic effects 
of CHOP won’t occur unless ER stress is constitutive and cannot be subdued. If ER 
stress cannot be subdued, CHOP will upregulate proapoptotic members of the Bcl-
2 family such as Bim and the down regulation of the of Bcl-2 transcription 
(McCullough et al. 2001; Tabas and Ron 2011). CHOP also upregulates expression 
of death receptor 5 (DR5) which sensitizes cells to apoptotic stimulation by a variety 
of conditions that cause ER stress (Yamaguchi and Wang 2004) GADD34 
expression is stimulated by CHOP (Kojima et al. 2003) and is expressed late in ER 
stress. GADD34 regulates the phosphatase activity of protein phosphatase 1 (PP1) 
via its C-terminal domain. GADD34 acts as a scaffold for PP1 accepts eIF2α as 
substrate and causes dephosphorylation of eIF2α (Figure 1.9). 
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Figure 1.9 PERK pathway. Activation of the PERK pathway phosphorylates EIF2α which inhibits 
protein translation. EIF2α phosphorylation triggers the promotion of mRNA translation for mRNA 
encoding specific stress response factors such as ATF4. ATF4 production, in turn, leads to the 
transcription of downstream products such as CHOP and GADD34. 
 
1.2.7.3.3 ATF6 
Cyclic AMP-dependent transcription factor ATF-6 (ATF6) exists as two homologous 
proteins ATF6α and ATF6β. ER transmembrane-localized ATF6 contains a basic 
leucine zipper (bZIP) motif and has transcriptional properties. Upon the release of 
BiP, the Golgi localization sequence is unmasked and ATF6 is translocated to the 
Golgi complex. At the Golgi complex, ATF6 is modified by two separate enzymes; 
the luminal domain of ATF6 is cleaved by serine protease site-1 protease (S1P) 
while the N-terminal (which is anchored in the Golgi membrane) is cleaved by 
metalloprotease site-2 protease (S2P). The N-terminal cleavage results in the 
release of the cytosolic bZIP transcription factor domain from the Golgi membrane 
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and translocates to the nucleus. ATF6 is responsible for the stimulation of several 
genes whose protein products contribute to protein folding, protein secretion, and 
ERAD include BiP and Glucose-regulated protein 94 (GRP94 – a HSP90-like protein 
that specialised in protein folding and ER quality control), protein disulphide 
isomerase (PDI – ER chaperone), x-box binding protein 1 (XBP1), and C/EBP 
homologous protein (CHOP) (Schröder and Kaufman 2005; Schönthal 2012) 
(Figure 1.10).  
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Figure 1.10 The ATF6 pathway. ATF6 is translocated to the Golgi Apparatus and cleaved by S1P 
and S2P. Cleaved ATF6 translocates to the nucleus and stimulates several genes involved in protein 
folding, protein secretion, and ERAD. 
 
1.2.7.3.4 IRE-1α pathway  
Inositol-requiring enzyme 1 (IRE1) pathway regulates chaperone induction, ERAD 
and ER expansion in times of ER stress and exist as two paralogues in mammals; 
IRE-1α and IRE-1β (where expression is limited to the gut) (Schröder and Kaufman 
2005; Tsuru et al. 2016). IRE-1α signalling is the most conserved signalling branch 
of ER stress (Patil and Walter 2001; Kohno 2010). It possesses a luminal sensor 
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domain and a cytosolic effector domain containing kinase and RNase subdomains 
(Tsuru et al. 2016). IRE-1α is suppressed by BiP and upon release from BiP, IRE-
1α will undergo homodimerization and autophosphorylation as part of its activation 
process (Parmar and Schröder 2012). 
Activated IRE-1α cleaves a 26-base fragment from the mRNA encoding 
XBP1, resulting in a spliced product called XBP1s (a frameshift that generates an 
alternative C-terminus of XBP1 with enhanced transcriptional activation potential 
(Walter and Johnson 1994)). XBP1 is a potent transcription factor controlling the 
expression of genes involved in ERAD and protein folding, and  the synthesis of 
phospholipids that are required for the expansion of ER membranes during ER 
stress (Schönthal 2012). The XBP-1 splicing is also dependent of the PERK 
pathway as ATF4 influences the expression of IRE-1α (i.e., the higher the ATF4 
expression, the higher the IRE-1α which in turn leads to higher XBP-1 splicing ) 
(Tsuru et al. 2016) (Figure 1.11). 
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Figure 1.11 The IRE-1α pathway. Activated IRE-1α cleaves XBP1 (a transcription factor) resulting 
in a spliced product with enhanced transcriptional activation potential. 
 
1.2.7.3.5 TSC and ER stress 
Loss of TSC1 or TSC2 causes ER stress and activates the unfolded protein 
response (UPR) (Ozcan et al. 2008). mTORC1 further enhances the burden of ER 
stress through autophagy repression, as autophagy removes unfolded protein 
aggregates to restore the protein folding environment within the ER (Høyer-Hansen 
and Jäättelä 2007). Crosstalk between autophagy and ER homeostasis showed that 
induction of ER stress by thapsigargin was through impairment of autophagosome–
lysosome fusion (Ganley et al. 2011). Insulin is major stimulus for many biosynthetic 
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pathways including protein synthesis, the action of feedback inhibition of insulin in 
the presence of ER stress is likely to represent an adaptive response and might 
even be considered part of the UPR. ER stress and activation of the UPR pathway 
are important pathological feature of TSC and contributes to critical functional 
abnormalities in insulin/IGF1 action and cell survival. UPR contributes to a negative 
feedback signal in TSC-deficient cells, at least in part, through the activation of c-
Jun NH2-terminal kinases (JNK), which plays a role in inhibition of IRS-1 activity and 
the development of insulin resistance both in vitro and in vivo (Chang et al. 2002; 
Hotamisligil 2005).  
Elevated cell stress is common in cancer cells and could be exploited (Hanahan 
and Weinberg 2011) as compromised stress recovery pathways in cancer cells may 
confer sensitivity to stress‐inducing drugs as many cancer cell lines are sensitive to 
ER stress‐inducers, where excessive or prolonged ER stress leads to cell death 
(Johnson et al. 2015). 
TSC1/2-null cells are naturally ER stressed because of the enhanced protein 
synthesis and the inhibition of autophagy. The introduction of known ER stress 
inducers/enhancers could be a potentially viable treatment to investigate. In the next 
section of this chapter, one such ER stress enhancer, nelfinavir will be discussed as 
potential treatment for TSC after it was observed to have success in enhancing ER 
stress in several cancer cell lines   
 
1.3 Nelfinavir  
 
1.3.1 General Introduction 
Nelfinavir is a clinical approved retroviral aspartic proteasome inhibitor which has 
been approved the treatment of HIV approved by the FDA in 1997. Kaldor et al. 
(1997) showed that Nelfinavir was able to prevent the proteolytic cleavage of viral 
precursor proteins to their mature forms. Nelfinavir forms part of the highly active 
antiretroviral therapy (HAART) (Brüning 2011).  
Nelfinavir has been shown to cause ER stress (although this was only a 
partial response as there was an absence of detectable PKR-like endoplasmic 
reticulum kinase (PERK) or ATF6 activation or accumulation of misfolded proteins 
within the ER. By interfering with proteostasis, nelfinavir triggers ER stress. 
Nelfinavir has been shown to cause a decrease in protein translation and cause 
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promotion of transcriptional program which is characteristic of the integrated stress 
response (ISR). Nelfinavir activates elongation factor 2 kinase (eEF2K) through 
phosphorylation, leading to the phosphorylation and inhibition of the elongation 
factor eEF2, resulting in a reduction in mRNA translation. At the same time, 
nelfinavir contributes to phosphorylation of eIF2α which in turn leads to the 
translation of ER stress markers, ATF4 and GADD34 (which dephosphorylates 
eIF2α via interactions with protein phosphatase-1 (PP1c)). However, nelfinavir does 
not cause direct activation of the eIF2α stress kinases but instead relies on the 
inhibition of the constitutive eIF2α dephosphorylation and down-regulation of the 
phosphatase cofactor CReP (Constitutive Repressor of eIF2α Phosphorylation; also 
known as PPP1R15B) to cause phosphorylation of eIF2α (Martinon et al. 2015; De 
Gassart and Martinon 2017). 
 
1.3.2 Nelfinavir controversy   
Between May 2007 and July 2008, nelfinavir production was accidentally polluted 
with ethyl methyl sulfone. This is a highly toxic compound which has been shown to 
have mutagenic, carcinogenic, and teratogenic effects by reacting with guanine in 
DNA, forming O-6-ethylguanine which, during DNA replication, causes DNA 
polymerases to place thymine, instead of cytosine, opposite O-6-ethylguanine) 
(Gocke et al. 2009). The risks of adverse outcomes such as cancer in this patient 
cohort were measured and found to be statistically insignificant when compared to 
patients treated with the drug in other years (Boettiger et al. 2016) while in in utero 
exposure, incidence of malformation was similar to that in the cohort as a whole with 
different drug exposures and no children developed cancer after 9 years of follow-
up (Blanche et al. 2016). 
   
1.3.3 Nelfinavir and cancer 
Nelfinavir has been shown to have a variety of anticancer properties. Nelfinavir has 
been shown to inhibit the PI3K/AKT/mTOR pathway especially in the case of solid 
tumours reported by (Blumenthal et al. 2014). It has also been shown to inhibit 
HSP90 via inhibiting the association between AKT and HSP90 (Choi et al. 2016b).  
Nelfinavir was shown to be able to cause two types of cell death in non-small cell 
lung cancer (NSCLC); caspase-dependent apoptosis and caspase independent 
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death that was characterized by induction of ER stress and autophagy (Gills et al. 
2007).  
Nelfinavir was shown to be able to inhibit the proliferation of primary human 
melanoma cell lines as it induced cell cycle arrest at the G1 phase (via inhibition of 
cyclin dependent kinase 2 (CDK2) and concomitant dephosphorylation of 
retinoblastoma tumour suppressor) and promoted apoptosis (Jiang et al .2007). 
Inhibition of CDK2 was shown to be caused by proteasome-dependent degradation 
of Cdc25A phosphatase. Nelfinavir was able to profoundly sensitize BRAF and 
NRAS mutant melanoma cells to MAPK-pathway inhibitors via suppressions of 
MITF (the melanoma survival oncogene) expression (Smith et al. 2016).  
Nelfinavir was able to cause cell death in a variety of malignant glioma cell 
lines via potent stimulation of ER stress (as observed in the increased expressions 
of CHOP and GRP78) which lead to activation of caspase 4-mediated cell death 
(Pyrko et al. 2007). Inhibition of glioma growth via ER stress was also observed in 
vivo, as nelfinavir inhibited the growth of a xenografted human malignant glioma, 
with concomitant induction of CHOP. Nelfinavir enhanced ER stress in glioblastoma 
multiforme cells (as seen with increased expression of CHOP and ATF4), which 
lead to an increase in DR5 receptor expression. This increased receptor expression 
caused cells to be sensitized to Tumour Necrosis Factor-related Apoptosis-inducing 
Ligand (TRAIL) and induced apoptosis (Tian et al. 2011).  
 In thyroid cancer cell lines FT133, BCPAP and SW1736, at 10 μM, nelfinavir 
increased the time required for cell passage through the phases of cell cycle (as 
seen in accumulation of cells in G0/G1 phase, downregulation of cyclin D1 and 
cyclin-dependent kinase 4 (CDK4)) and induced DNA fragmentation (as seen in the 
expression of γH2AX and p53BP1) (Jensen et al. 2017). At 20 μM, nelfinavir was 
shown to cause apoptosis (via caspase-3 cleavage) and decreased the levels of 
total and phosphorylated AKT in PTEN-deficient FTC133 cells. Nelfinavir was 
shown to have no significant effects on total ERK and p-ERK in BRAF-positive 
BCPAP and SW1736 cells or on the expression of EMT markers (Twist, Vimentin, 
E- and N-Cadherin), but inhibited the migration and decreased the abilities of thyroid 
cancer cells to survive in non-adherent conditions. In medullary thyroid cancer, at 
10 μM, nelfinavir was shown down regulate RET tyrosine kinase signalling pathway, 
cause cell cycle arrest and trigger caspase 3 cleavage. Nelfinavir also induced 
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metabolic stress, AMPK activation and increased autophagic flux (Kushchayeva et 
al. 2014).   
Nelfinavir (along with ritonavir, saquinavir and lopinavir) was able to induce 
proteotoxic stress in human monocytic leukaemia cell lines, THP-1, HL-60 and U937 
(Kraus et al. 2014). It could also sensitise cells to proteasome inhibitors such as 
bortezomib and carfilzomib at low molecular micromolar drug concentrations as 
nelfinavir reduced proteasome activity by 50% at concentrations of 20-40 μM. 
Nelfinavir was shown, in vitro, to be able to induce apoptosis and necrosis in ovarian 
cancer cell lines SKOV-3, OVCAR-3, and A2780 while being well tolerated by 
fibroblasts or peripheral blood mononuclear leukocytes used as controls. They also 
showed that nelfinavir was able to cause an upregulation of the tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL) receptor DR5. Nelfinavir sensitized 
ovarian cancer cells to treatment with an apoptosis-inducing TRAIL receptor 
antibody as in a phase I trial for liposarcoma, nelfinavir was well-tolerated with 
minimal toxicities and 6 out of 10 patients were observed to clinical benefit in terms 
of complete response, partial response and stable disease (Pan et al. 2012). 
 In a phase III clinical trial, nelfinavir, as a single agent, used to treat patients 
with recurrent adenoid cystic carcinomas no patient showed partial or complete 
response (Hoover et al. 2015). Nelfinavir was shown to be able to selectively inhibit 
HER2-positive breast cancer cells (including trastuzumab and lapatininb-resistant) 
in vitro and in vivo via HSP90 inhibition (Shim et al. 2012). Nelfinavir inhibited 
proliferation and induced apoptosis of castration-resistant prostate cancer through 
inhibition of site-2 protease (S2P) activity, which leads to suppression of regulated 
intramembrane proteolysis (Guan et al. 2015). Nelfinavir has selective anticancer 
effects such as induction of autophagy and apoptosis possibly through the induction 
of ER stress as well as interfering with cell signalling pathways, including mTOR 
across a range of leukaemia cell lines (SEM, C1, Molt3, TIB202, Molm13, and MV4-
11). (Kattel et al. 2015).  
As seen with the above-mentioned trials and tests, nelfinavir has limited use 
as a single agent for the treatment of tumour cells. However, the use of nelfinavir, 
in a combination therapy (be it with other drugs or treatment types), against tumour 
cells is promising/has potential. 
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1.3.4 Nelfinavir and radiotherapy 
The introduction of nelfinavir to radiotherapy has shown success across a range of 
cancer cell types. In a phase I trial for rectal cancer, nelfinavir 750 mg BID (bis in 
die) was shown to be the recommended phase II dose in combination with 
capecitabine and 50.4 Gy pre-operative radiotherapy as the first tumour response 
evaluations were observed to be promising as 3 patients (out of 11) achieved a 
pathological complete response (pCR) (Buijsen et al. 2013). The use of oral 
nelfinavir before and during radiotherapy was well tolerated by patients with 
advanced rectal cancer (Hill et al. 2016). 5 out of 9 patients tested in this trial 
exhibited good tumour regression on MRI (assessed by tumour regression grade 
(mrTRG)).  
Nelfinavir sensitized pancreatic ductal adenocarcinoma (PDAC) cells (Panc-
1, MiaPaCa-2, PSN-1) alone and cocultured with pancreatic stellate cells (PSC) to 
radiotherapy (Al-Assar et al. 2016). The presence of PSCs played a role in how 
strong the sensitization was as in Panc-1 and PSN-1 cells radiosensitization was 
larger when cells were in the presence of PSCs. PSCs were also sensitized by NFV 
via reduced p-FAK levels. In PSN-1 xenografts, the presence of PSC led to faster 
tumour regrowth after radiation compared to just tumour cells. The regrowth delay 
effect of nelfinavir after radiation was dramatically larger in the presence of PSCs 
(time to reach 250 mm3 183% vs 22%). In a phase II trial, a combination of nelfinavir 
and chemoradiation showed acceptable toxicity and promising survival rates in 
patients with locally advanced inoperable pancreatic cancer (Wilson et al. 2016). 
 
1.3.5 Nelfinavir and TSC 
Nelfinavir selectively targets TSC2-deficient angiomyolipoma-derived cells (621-
101) (Medvetz et al. 2015). Previous work within the research group of nelfinavir-
based combinations have shown these combinations can be very successful against 
cell lines which are mTORC1 hyperactive, especially cells with TSC2 mutations. A 
combination of salinomycin and nelfinavir selectively caused cell death in TSC2-null 
cells while being while being well-tolerated by control cells. This combination 
targeted the cells by tipping the protein homeostasis balance of the already 
metabolically stressed TSC2-deficient cells in favour of cell death. The salinomycin 
and nelfinavir combination was also able to cause cell death in sporadic cancer cell 
lines with mTORC1 hyperactivity (NCI-H460 and HCT116) (Dunlop et al. 2017).  
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 A combination of chloroquine and nelfinavir caused selective cell death in 
TSC2-null cells while being while being well-tolerated by control cells and able to 
cause cell death in several cell line models with hyperactive mTORC1. The 
chloroquine/nelfinavir combination was also shown to enhance ER stress and 
entrapment of chloroquine to acidified lysosomal/endosomal compartments was 
necessary for cytotoxicity (Johnson et al. 2015).  
 
1.4 Aims of Thesis 
As previously mentioned, the current drug therapies available for TSC have been 
shown to excel at shrinking tumours and decreasing vascularisation while at the 
same time improving neurological aspects of the disease (such as epilepsy). 
However, these drugs are cytostatic in nature and tumours regrow upon cessation 
of treatment. Because of this, there is a strong demand to develop cytotoxic 
treatments, that can eradicate tumours and prevent the need for long-term treatment 
(and the side effects that come with such treatment). its rarity within the global 
population (1:6000) means that it is not currently seen as a high research priority. 
This status means there are reduced resources available to develop new TSC-
exclusive treatments. As a result, finding already clinical approved drugs (that can 
selectively target mTORC1 hyperactive cells, while being tolerated by normal 
healthy cells) is a good starting point for identifying potential treatments for TSC. 
As mentioned in this chapter, nelfinavir enhances cell death when used in 
combination with other drugs (such as chloroquine and salinomycin). Data from 
multiple studies indicates that enhancing ER stress is an incredibly valid target for 
the treatment of mTORC1 hyperactive cells.  Nelfinavir and ER stress enhancement 
alone is not enough to generate the desired levels of cytotoxicity in mTORC1 
hyperactive cells. While nelfinavir is less effective as a single agent, there is 
evidence that nelfinavir has more cytotoxicity when combined in drug combination 
targeting mTORC1 hyperactive cells. 
As a result, two main unanswered research questions need to be asked: 1) 
what signalling pathways can be targeted (in combination with nelfinavir) to cause 
cytotoxicity? and 2) can these drug combinations also selectively target the 
diseased mTORC1 hyperactive cell lines while also being tolerated by the normal 
healthy cells? 
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In terms of potential pathways, several have been discussed in this chapter 
such as the autophagy (which has already been shown to be sensitive to drugs in 
Tsc2-/- cells) and energy stress (i.e., Tsc2-/- cells have already been shown to be 
sensitive to glucose starvation). But what about other pathways such as 
proteasomal degradation, reactive oxygen species (ROS) management or perhaps 
other forms of cellular drug accumulation (e.g., P-glycoprotein)? Could drugs be 
identified that target mTORC1 itself and can these drugs be useful for the TSC 
treatment?  
Because of these questions, the main aims of this thesis are defined as 
follows: 
1. Identifying novel drug combinations (with nelfinavir) which can selectively target 
Tsc2-/- cells while being well tolerated by healthy control cells. 
2. Upon identifying novel combinations, optimising these combinations and 
determining if the combinations are synergistic. 
3. Testing this combination in a 3D environment (i.e., tumour spheroids) to prevent 
the establishment of new tumours and can to target previously established 
tumours. 
4. Considering that mTORC1 hyperactivity can also occur in a wide variety of 
sporadic tumours, can these novel drug combinations also be used to cause 
cytotoxicity is mTORC1 hyperactive sporadic cancer cell lines. 
5. Identify the mechanism(s) of drug action that causes cytotoxicity in Tsc2-/- cells. 
Such fundamental understanding is required to determine the vulnerabilities of 
TSC-diseased cells that could lead to better therapies. Techniques used to do 
this include RNA sequencing. 
 
Over the next several chapters, a series of nelfinavir-based drug combinations will 
be tested with these aims in mind to determine the answers to these questions 
mentioned above.
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Chapter 2: Materials and Methods 
 
2.1 Materials:  
 
2.1.1 Cell culture 
Tsc2+/+ p53-/- and Tsc2-/- p53-/- mouse embryonic fibroblasts (MEFs) were kindly 
provided by David J. Kwiatkowski (Harvard University, Boston, USA). Tsc2-/- ELT3 
(Eker rat leiomyoma-derived cells) and ELT3-Tsc2 cells with Tsc2 re-expression (to 
use as control cells) were kindly provided by Cheryl Walker (M.D. Anderson Cancer 
Centre, Houston, USA). Human breast cancer cells (MCF7), human colorectal 
cancer cells (HCT116) and human lung carcinoma cells (NCI-H460) cells were 
purchased from American Type Culture Collection (ATCC), (Middlesex, U.K.). 
MEFs, ELT3, HCT116 and NCI-H460 cell lines were cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) (Lonza™ BioWhittaker™ DMEM high glucose with Ultra 
Glutamine, catalogue number: BE12-604F). The MCF7 cell line was incubated in 
Roswell Park Memorial Institute (RPMI) 1640 medium (Lonza™ RPMI 1640, with L-
Glutamine, catalogue number: BE12-702F). All media types were supplemented 
with 10% (v/v) foetal bovine serum (FBS) and 1% (v/v) Penicillin/Streptomycin 
(Pen/Strep). All cell lines were incubated at 37 oC, 5% (v/v) CO2 in a humidified 
incubator. All media types, FBS and Pen/Strep were purchased from Life 
Technologies Ltd. (Paisley, UK). 
 
2.1.2 Drugs 
Nelfinavir mesylate hydrate, chloroquine di-phosphate salt, mefloquine 
hydrochloride, bafilomycin-A1, piperlogumine, paroxetine hydrochloride, 
hemihydrate, trifluoperazine dihydrochloride, BPTES, luteolin, cepharanthine, 17-
AAG, trequinsin, rapamycin, etoposide dimethyl sulfoxide (DMSO) and thapsigargin 
were purchased from Sigma–Aldrich Company Ltd. (Dorset, UK). Chelerythrine 
Chloride and doxorubicin hydrochloride were purchased from Merck Millipore 
(Hertfordshire, UK). Etoposide was dissolved in DMSO at 100 mM stock solution. 
Mefloquine was dissolved in DMSO at 50 mM stock solution. Nelfinavir, 
piperlongumine, paroxetine, trifluoperazine, BPTES and luteolin were dissolved in 
DMSO at 30 mM stock solutions. Chelerythrine chloride and cepharanthine were 
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dissolved in DMSO at 15 mM stock solution. Thapsigargin was dissolved in DMSO 
at 10 mM stock solution. 17-AAG was dissolved in DMSO at 1 mM stock solutions. 
Trequinsin was dissolved in water at 30 mM stock solution. Doxorubicin was 
dissolved in water at 10 mM stock solution. Rapamycin was dissolved in ethanol at 
100 µM stock solution. Chloroquine was dissolved in fresh culture medium to a 100 
mM stock and further diluted in culture medium to the required concentrations for 
use. All solutions (except doxorubicin) were aliquoted and stored at -20 oC. 
Doxorubicin was aliquoted and stored at 4 oC. 
 
2.2 Methods: 
 
2.2.1 Cell proliferation assay 
To determine the level of cell proliferation in the presence of drugs, a CyQUANT cell 
proliferation assay was performed. The CyQUANT assay is a highly sensitive 
fluorescence-based method for quantifying cells and assessing cell proliferation and 
cytotoxicity by measuring DNA content to directly quantify cells without relying on 
metabolic activity. 5000 cells in 180 µl of media were added into the wells of a 96-
well plate and incubated for over several h to allow the cells the adhere to the plate. 
The outer layer of wells was filled with 200 μl media per well to reduce evaporation 
occurring within the inner wells. 20 µl of media containing 10 x concentration of 
chosen drug or DMSO was added to each well giving a total volume of 200 µl per 
well and a final 1x concentration of DMSO or drug in each well. Cells were returned 
to the incubator for 48 h. After 48 h, all the media was removed, and the plate was 
snap frozen at -80 oC until needed. Proliferation assays were carried out using the 
CyQUANT Cell Proliferation Assay kit (Life Technologies). While the 96-well plates 
were being thawed at room temperature, 40 ml of CyQUANT GR working solution 
was made by adding 2 ml of the 20 X cell-lysis buffer stock solution to 38 ml of 
nuclease-free distilled water before 100 μl of the CyQUANT GR stock solution was 
added and mixed thoroughly. Working solution was protected from light during 
preparation. To each well, 200 µl of working solution was added and incubated for 
2–5 min at room temperature, protected from light. The fluorescence was read using 
a FLUOstar OPTIMA fluorimeter (BMG LABTECH, Buckinghamshire, UK)) set at 
480 nm excitation and 520 nm emission. To confirm the proliferation assay was 
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working, a range of serial dilutions (50000, 25000, 10000, 5000, 2500, 1000, 500, 
250 and 0 cells per well) were also testing alongside test samples. 
 
2.2.2 Flow cytometry  
Trypsinised cells were plated onto a 24–well plate. 500 µl of media was added to 
each well. Cells were returned to incubator overnight to allow cells to adhere to the 
wells. Culture media was removed and 1 ml of media containing either drug or 
DMSO was added to wells. Cells were returned to the incubator for either 24 or 48 
h (depending on the length of the experiment). After the time point, media was 
transferred into labelled 5 ml polystyrene round-bottom tubes (Corning, 
Amsterdam, Netherlands). Cells were washed in 250 µl of trypsin and the wash 
was transferred into designated tubes. Cells were trysinised by adding 250 µl of 
trypsin per well and returning cells to the incubator for 5 mins at 37 oC. After 
incubation, add 500 µl of media to wells to neutralise trypsin. Cells were collected 
and transferred to tubes. Tubes were then centrifuged at 900 RCF for 5 min. 
Supernatant was removed, and pellet was loosened by gentle flicking. Cell pellet 
was resuspended in 500 µl of media. 5µl of 300 µM DRAQ7 (far-red emitting, 
anthraquinone compound that stains nuclei in dead and permeabilized cells) (final 
concentration 3 µM) (Biostatus, Leicestershire, UK)) was added to cells and 
incubated at room temperature for 10 min. Flow cytometry was performed using a 
FACS Calibur flow cytometer (available from Becton Dickinson, Cowley, UK)) with 
excitation set at 488 nm and detection of fluorescence in log mode at wavelengths 
greater than 695 nm. Cell Quest Pro software was used for signal acquisition. A 
minimum of 10,000 events were collected. Data was analysed using FlowJo 
software (FlowJo LLC). Data was first analysed in Front scatter (FSC) versus Side 
scatter (SSC) were data was gated to eliminate cell debris and fragments from 
final analysis. Revised data was then analysed in FSC (x axis) versus FL4 (sensor 
with a 675 nm band pass filter which is used to detect far red fluorescent dyes) (Y 
axis) and data was gated in viable and non-viable populations using 101 on the Y 
axis as an approximate cut off point between the populations. 
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2.2.3 Drug synergy assay 
Trypsinised Tsc2+/+ and Tsc2-/- MEFs were plated into each well of a 24 –well 
plate. 500 µl of media was added to each well. Cells were returned to incubator 
overnight to allow cells to adhere to the wells. After overnight incubation, media was 
removed, and 1 ml of media was added containing the following: 
Mefloquine (in μM):  
• For mefloquine/nelfinavir testing; 0.1, 1, 10, 100 
• For mefloquine/17AAG testing; 2.5, 5, 10, 20, 40 
17AAG (in μM); 0.25, 0.5, 1, 2, 4   
Cepharanthine (in μM); 0.625, 1.25, 2.5, 5, 10  
Nelfinavir (in μM):  
• For mefloquine/nelfinavir testing; 0.1, 1, 10, 100 
• For cepharanthine/nelfinavir testing; 2.5, 5, 10, 20, 40 
Cells were returned to incubator for 48 h. Flow Cytometry was carried out as 
previously mentioned. Synergy was determined using the Chou-Talalay Method 
(Ting-Chao Chou 2010). CI value (which determines the level of synergy) were 
calculated using CompuSyn programme (CompuSyn is available from CombuSyn 
Inc) using a non-constant ratio (except for mefloquine and 17AAG testing which 
used a constant ratio). 
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2.2.4 Western blotting  
Antibodies used in western blotting are listed in Table 2.1.   
 
Table 2.1: List pf primary antibodies, molecular weight and suppliers. All primary antibodies 
have a stock concentration of 1 mg/ml. 
Antibody Molecular Weight Supplier 
Ribosomal protein S6 (rpS6) 32 Cell Signalling Technology 
(Danvers, USA) 
Phospho-rpS6 (Ser235/236) 32 Cell Signalling Technology 
p70-S6 kinase 1 (S6K1) 70, 85 Cell Signalling Technology 
Phospho-S6K1 (Th389) 70, 85 Cell Signalling Technology 
Inositol-requiring and ER-to-nucleus 
signalling protein 1α (IRE1α) 
130 Cell Signalling Technology 
C/EBP homologous protein (CHOP) 27 Cell Signalling Technology 
Caspase-3 17, 19 (cleaved), 
35 (uncleaved) 
Cell Signalling Technology 
Caspase-7 20 (cleaved), 
35 (uncleaved) 
Cell Signalling Technology 
Caspase-8 18, 43 (cleaved), 
57 (uncleaved) 
Cell Signalling Technology 
Caspase-9 35, 37 (cleaved), 
47 (uncleaved) 
Cell Signalling Technology 
Poly ADP ribose polymerase (PARP) 89 (cleaved), 
116 (uncleaved) 
Cell Signalling Technology 
Growth arrest and DNA damage-inducible 
protein (GADD34) 
75 Cell Signalling Technology 
Activating transcription factor 4 (ATF4) 49 Cell Signalling Technology 
TSC2 200 Cell Signalling Technology 
β-actin 45 Cell Signalling Technology 
Sestrin 2 56 Cell Signalling Technology 
Acetyl-CoA Carboxylase (ACC) 280 Cell Signalling Technology 
Phospho-ACC (Ser79) 280 Cell Signalling Technology 
AMP-activated protein kinase (AMPKα) 62 Cell Signalling Technology 
Phospho-AMPKα (Thr172) 62 Cell Signalling Technology 
LC3 19 Novus Ltd. (Cambridge, 
UK) 
Ubiquitin-binding protein p62 (p62) 47 Progen Biotecknik 
(Heidelberg, Germany) 
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444,444 Tsc2+/+ and 333,333 Tsc2-/- MEF cells were plated onto 35 mm2 plates 
(TTP, Switzerland). 2 ml of media was added to each plate. Plates incubated 
overnight to allow cells to adhere to plates. After incubation, media was removed 
and replaced with 2 ml of media containing DMSO or drug. Plates were then 
incubated for a designated time period (3, 6, 16, 24, 48 h depending on whether 
target protein expression is being analysed for a specific time point or being 
analysed over several time points). After designated incubation period, media was 
removed. Cells were washed in ice-cold phosphate buffered saline (PBS) and then 
lysed in cell lysis buffer (20 mM Tris (pH 7.5), 125 mM Sodium Chloride (NaCl), 50 
mM Sodium Fluoride (NaF), 5% (v/v) glycerol, 0.1% (v/v) Triton X-100. Lysis buffer 
was supplemented with 1 mM dithiothreitol (DTT), 1 µg/ml pepstatin, 20 µM 
leupeptin, 1 mM benzamidine, 2 µM antipain, 0.1 mM phenylmethane sulfonyl 
fluoride (PMSF), 1 mM sodium orthovanadate and 1 nM okadaic acid prior to cell 
lysis). and left to incubate in buffer for approximately 5 min on ice. Cells were 
scrapped off and transferred to labelled 1.5 ml Eppendorf tube and stored at -80 oC 
until needed. With regards to samples which were incubated for 24 h or longer, 
removed media and washes were transferred to labelled 15 ml tube and centrifuged 
at 1,500 RCF for 10 min. Supernatant was discarded, and pellet was resuspended 
in lysis buffer from Eppendorf tubes and transfer back to tubes. Samples were 
sonicated at high power using a diagenade bioruptor (Diagenade, Seraing, Belgium) 
three times at 30 s on, 30 s off.  Samples were then centrifuged at 13,300 RCF for 
8 min. Protein concentration per sample was then determined using Bradford assay 
(Thermo Fisher Scientific, Paisley, UK). 25 µl of 200 mM DTT in NuPAGE™ LDS 
Sample Buffer (4X) (Themofisher Scientific)  
Samples were stored at -20 oC until needed. Samples were heated at 70 oC 
for 10 min. Samples were centrifuged briefly before loading. 20 µl of sample was 
then loaded into each well of a NuPage 4-12% Bis-Tris Gel (Thermo Fisher 
Scientific). Gel ran in running buffer (380 ml of ddH2O with 20 ml of 20x NuPage 
MES SDS Running buffer (Life Technologies)) for 1 h 15 min at 150 V. Proteins 
were transferred from gel to Polyvinylidene fluoride (PVDF) membrane (which has 
been activated in 100% methanol for 1 min before being washed in transfer buffer 
prior to usage). Transfer buffer was made up as follows; 350-375 ml ddH2O, 50 ml 
10x transfer buffer (2 M Glycine, 250 mM Tris base and 7 mM SDS) and 75-100 ml 
of methanol (amount of methanol varied depending on the size of the target protein). 
Proteins were Transfer was carried out for 2 h 50 min at 25 V. When transfer was 
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completed, membrane was blocked via incubated in 5% (m/v) milk solution (made 
in tris-buffered saline (TBS) with Tween 20 (TBS-T)) for 2 h at room temperature on 
a moving shaker. Membrane was rinsed 3 times in ddH2O to remove milk solution 
and primary antibodies (1:1000 dilution (although dilution varied based on 
antibodies being used) in TBS-T with 5% bovine serum albumin (BSA) (Sigma 
Aldrich)) were added onto membrane. The membrane was incubated in antibodies 
at 4 oC on a moving shaker overnight. Primary antibodies were and returned to 
storage and the membrane was washed 3 times (5 min per wash) in TBS-T on a 
moving shaker at room temperature. Secondary antibodies (1:10000 dilution in 5% 
(m/v) milk solution was added to membrane and incubated at room temperature for 
one hour on a shaker. Antibodies were removed, and the membrane was washed 3 
times (5 min per wash) in TBS-T. The membrane was incubated in Luminata 
western horse radish peroxidase (HRP) substrate (Merck Millipore) for 2 min before 
being developed on Fuji medical x-ray film (Tokyo, Japan). Strength of HRP 
substrate (Classico (weakest), Crescendo, Forte (strongest)) used depended on the 
target protein being tested.  
   
2.2.5 Rescue assays 
Trypsinised cells were plated into each well of a 24 –well plate. To each well, 500 µl 
of media was added. Cells were returned to incubator overnight to allow cells to 
adhere to the wells. In testing with Bafilomycin A1, after overnight incubation, media 
was removed and 1 ml of media containing either drug, drug containing 100 nM of 
bafilomycin A1 or DMSO was added to wells. In testing with methyl pyruvate, after 
overnight incubation, media was removed and 1 ml of media containing either drug, 
drug containing 8mM of methyl pyruvate or DMSO was added to wells. When testing 
with rapamycin, after overnight incubation, cells in selected wells were pre-treated 
for 1 h with 50 nM of rapamycin. After pre-treatment, media was removed and 1 ml 
of media containing either drug, drug with rapamycin or DMSO was added to 
designated wells. Cells were returned to incubator for designated time period (24 or 
48 h). Flow Cytometry was carried out as previously mentioned. Western blotting 
for Phopho-RPS6 (for rapamycin rescue) Phospho-ACC, Phospho-AMPK, Sestrin 
2 (for methyl pyruvate) and LC3 and p62 (for bafilomycin rescue) were carried out 
to show that rapamycin, methyl pyruvate and bafilomycin A1 were working as 
expected. 
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2.2.6 mRNA extraction and reverse transcription 
1,000,000 Tsc2+/+ and 750,000 Tsc2-/- MEF cells were plated onto 60 mm2 plates 
(TPP) and 5 ml of media was added to each plate. Plates were incubated overnight 
to allow cells to adhere. After incubation, media was removed and 5 ml of media 
containing drug or DMSO was added and plates returned to incubator for 6 h. After 
incubation, cells were washed in 500 µl of chilled PBS then lysed using 500 µl 
Qiagen RNAprotect Cell Reagent. Samples stored at -80 oC until needed. RNA was 
extracted using the RNeasy Plus mini kit and homogenized using Qiashredders 
during the procedure (Qiagen). The concentration of RNA was determined by 
measuring the absorbance of 1µl of sample at 260 nm and 280 nm in a Nanodrop 
spectrophotometer with the results given in ng/µl. Total RNA from each sample (1 
μg) was transcribed into cDNA using Quantitect reverse transcription kit. An initial 
volume of 14 μl per sample used was calculated as follows: 
1. 1,000 / ng/µl reading = amount of sample in µl 
2. 12 µl – amount of sample µl = amount RNase-free water µl 
3. 2 µl gDNA was added to all samples to make a total of 14 µl / tube 
Samples were incubated at 42 °C for 2 min to remove gDNA in an Applied 
Biosystems GeneAmp 9700 PCR system (Thermo Fisher Scientific). 6 µl of reverse 
transcriptase master mix (1µl Primer mix, 1 µl Quantiscript reverse transcriptase and 
4 µl Quantiscript RT buffer 5x per sample) were added to each sample to give a final 
volume of 20 μl. Samples were incubated at 42 °C for 15 min followed by 95 °C for 
3 min. All reagents used for mRNA extraction and reverse transcription were 
purchased from Qiagen (West Sussex, U.K). 
 
2.2.7 XBP-1 splicing 
XBP1 primers [Forward: 5′-AAA CAG AGT AGC AGC TCA GAC TGC-3′; Reverse: 
5′-TCC TTC TGG GTA GAC CTC TGG GA-3′] were synthesised through MWG 
Operon-Eurofin (Ebersberg, Germany). Mouse ACTB (β-actin) primers were 
purchased from Thermofisher Scientific. For  XBP-1 splicing carried out in chapter 
3, a master mix for XBP-1 (5 µl 10x buffer (200 mM Tris-HCl pH 8.4, 500 mM KCl), 
1 µl 10 mM deoxyribonucleotide triphosphates (dNTPs), 2.5 µl forward XBP-1 primer 
(100 pmol/μl), 2.5 µl reverse XBP-1 primer (100 pmol/μl), 1.5 µl 50 mM Magnesium 
Chloride (MgCl), 36.3 µl ddH20 and 0.2 µl Taq DNA polymerase (5 U/μl) per sample) 
and β-actin ((5 µl 10x buffer, 1 µl dNTPs, 5 µl β actin primers, 1.5 µl MgCl, 36.3 µl 
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ddH20 and 0.2 µl Taq DNA polymerase (5 U/μl)  per sample) was prepared. For 
splicing carried out in chapter 6, a master mix for XBP-1 (2.5 µl 10x buffer, 0.5 µl 
dNTPs, 0.25 µl forward XBP-1 primer (100 pmol/μl), 0.25 µl reverse XBP-1 primer 
(100 pmol/μl), 0.75 µl MgCl, 19.5 µl ddH20 and 0.25µl (5 U/μl) Taq DNA polymerase 
per sample) and β-actin ((2.5 µl 10 x buffer, 0.5 µl dNTPs, 5µl β actin primers, 0.75 
µl MgCl, 19.5 µl ddH20 and 0.25 µl Taq DNA polymerase (5 U/μl) per sample) was 
prepared. Taq DNA polymerase, dNTPs and MgCl were purchased from 
Thermofisher Scientific.  
49 µl of master mix was added to 1 µl of cDNA. Samples were mixed well 
and centrifuged to eliminate air bubbles from samples. PCR was performed in an 
Applied Biosystems GeneAmp 9700 PCR system. For splicing in Chapter 3, the 
following settings were used: initial denaturation step (94 °C, 3 min); 31 cycles of 
denaturation (94 °C, 45 s); annealing step (60 °C, 30 s); extension step (72 °C, 1 
min): final extension step (72 oC, 10 min). For splicing in Chapter 6, the following 
settings were used: initial denaturation step (95 °C, 5 min); 32 cycles of denaturation 
(95 °C, 30 s); annealing step (61 °C, 30 s); extension step (72 °C, 45 s): final 
extension step (72 oC, 8 min).   3% (w/v) agarose (Appleton, Birmingham, UK) 1× 
Tris-acetate-EDTA (40 mM Tris-base (pH 8.0), 1.27 mM EDTA and 1.7 ml acetic 
acid in 1 L deionized water) was made with 0.005% (v/v) GelRed nucleic acid stain 
(Biotium, Fremont, CA, USA). DNA samples were loaded with Orange G loading 
buffer (15 ml 30% (v/v) glycerol, 100 mg Orange G powder, deionized water, total 
volume 50 ml) and resolved on the gel at 100 V. After 1 h, β-actin samples were 
analysed and recorded. After an additional 1-2 h (depending on degree on 
separation) XBP-1 splicing was analysed and recorded. PCR products of XBP1 
were 480 base pairs (bp), unspliced, and 454 bp, spliced. 
 
2.2.8 RNA sequencing  
Total RNA quality and quantity was assessed using Agilent 2100 Bioanalyser and a 
RNA Nano 6000 kit (Agilent Technologies, Stockport, Cheshire, UK). 100-900 ng of 
Total RNA with a RIN value >8 was used as the input and the sequencing libraries 
were prepared using the Illumina® TruSeq® RNA sample preparation v2. (Illumina 
Inc., Fulbourn, Cambridge, UK). The steps included 2 rounds of purification of the 
polyA containing mRNA molecules using oligo-dT attached magnetic beads 
followed by RNA fragmentation, 1st strand cDNA synthesis, 2nd strand cDNA 
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synthesis, adenylation of 3’ ends, adapter ligation, PCR amplification (15-cycles) 
and validation. The manufacturer’s instructions were followed. The libraries were 
validated using the Agilent 2100 Bioanalyser and a high-sensitivity kit (Agilent 
Technologies) to ascertain the insert size, and the Qubit® (Life Technologies) was 
used to perform the fluorometric quantitation. Following validation, the libraries were 
normalized to 4 nM and pooled together. The pool was then sequenced using a 75-
base paired-end (2x75 bp PE) dual index read format on the Illumina® HiSeq2500 
in rapid mode according to the manufacturer’s instructions. Quality control checks 
of the resultant reads were performed using FastQC before mapping to the UCSC 
mouse mm10 reference genome using Tophat and Bowtie. Differentially expressed 
transcripts were identified using a DeSeq2 analysis on normalised count data with 
the design formula setup to analyse all pairwise comparisons in the dataset using 
contrasts. The resultant p-values were corrected for multiple testing and false 
discovery issues using the FDR method. Genes involved in cell survival were 
selected based on GO:0008219 (cell death) from the complete list on AmiGo 2. Data 
analysis and heat map generation was carried out using Genview2. Data collected 
was then plotted as volcano plots using Microsoft Excel. RNA sequencing and initial 
bioinformatics was carried out by Wales Gene Park (Cardiff, Wales). 
 
2.2.9 Rhodamine 123 assay 
Rhodamine 123 is a cell-permeant, cationic, green-fluorescent dye that is readily 
sequestered by active mitochondria without cytotoxic effects. While it is classically 
used to measure mitochondrial integrity, it is also a substrate of P-glycoprotein (an 
ATP-binding cassette (ABC) membrane transporter acting as a drug efflux pump 
which exhibits multiple resistance to a wide variety of structurally-unrelated 
anticancer drugs). Rhodamine 123 has been shown to be useful for determining the 
inhibitory potential of drugs against P-glycoprotein activity as 14 known p-
glycoprotein inhibitors (including verapamil, cyclosporin A, elacridar, zosuquidar) 
were found to increase rhodamine 123 accumulation in p-glycoprotein-
overexpressing MCF7R cells, thus allowing the determination of their p-glycoprotein 
inhibitory potential. Inhibitory effects on p-glycoprotein activity are determined by 
measuring intracellular accumulation of rhodamine 123 in the absence or presence 
of drugs (Lee et al. 1994; Vee et al. 2015; Jouan et al. 2016).  
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12,500 Tsc2+/+ and 10,000 Tsc2-/- cells in 200 µl of media were plated into 
wells of a 96-well plate and incubated overnight. The outer wells of the plate were 
filled with media to prevent evaporation occurring in inner wells. The next day, 100 
µl of media was removed and 100 μl of media containing 2x the target concentration 
of drug treatment (with 10.5 μM rhodamine 123) or DMSO (with 10.5 μM rhodamine 
123) was then added to each well giving a total volume of 200 µl per well and a final 
1x concentration of DMSO or drug (and 5.25 μM rhodamine 123) in each well. Cells 
were returned to the incubator and incubated for 30 min. After 30 min, all media was 
removed. Plate was washed three times with 200 μl of chilled 1x PBS. After washing, 
cells were lysed in 200 μl of warmed deionised water (37 oC) and was returned to 
incubator for 15 min. Fluorescence was read on Cytation 3 Imaging reader (Biotek, 
Swindon, UK) with the following measurements; excitation at 480 nm and emission 
at 520 nm.  
 
2.2.10 Tumour formation assay 
A 1.2% (w/v) Agar solution was made in 1x PBS using Difco Agar Noble (BD, Oxford, 
UK). The solution was boiled to dissolve Agar into PBS. Solution was then 
transferred to 50 ml tube and place in an incubator at 50 oC to prevent the solution 
from cooling. 2.5 ml of a 1:1 mixture of media and agar was made and added to 
wells in a 6 well plate and allowed to cool for 20 min. 100,000 (used in chapter 6) - 
150,000 (used in chapter 3) Tsc2-/- MEFs were added to a 1:4 mixture agar/media 
mixture and 3 ml of mixture was added to wells and allowed to cool for 1 h. Plates 
incubated overnight. 2 ml of media contain drugs or DMSO was added the next day. 
After 48 h, plates were refreshed with new media containing drug or DMSO. Plates 
were then treated every 2-3 days with DSMO or drug for 14 days. Images were 
taken using an EVOS XL Core camera (Life Technologies). Tumour size (diameter) 
analysed using ImageJ. Software (developed at the National Institutes of Health 
(NIH)).   
 
2.2.11 Tumour outgrowth assay 
A 1.5% Agarose solution was made in PBS. Solution was boiled to dissolve agarose. 
While the solution was still hot, 70 µl of solution was added to each well of a 96 well 
plate and allowed to cool and harden. After hardening, 1000 Tsc2-/- MEFs in 140 μl 
of media were added to each well. Plate was then incubated overnight. Plate was 
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examined the next day and any wells which failed to form a single spheroid (e.g., 
have 2 or more spheroids or no spheroids) were discarded from future analysis. 
Plate was returned to incubator for another 48 h. Wells were imaged to give a 0 h 
time point. After imaging, 70 µl of media was removed and replace with 70 µl of 
fresh media containing 2x concentration of drug or DMSO to each well. Plate was 
incubated for 48 h. 70 µl of media was removed and fresh media contain 1x 
concentration drug or DMSO and 6 µM of DRAQ7 (to give a final concentration of 3 
µM DRAQ7). Plate was incubated for another 48 h. Dual channel images were 
acquired using a Zeiss Axio Observer Z1 microscope (Carl Zeiss Microimaging, 
Gottingen, Germany) with a black box chamber (Solent Scientific Ltd, Segensworth, 
U.K.) at 0 and 96 h timepoints. Spheroid size (transmission mode) and DRAQ7 
labelling (fluorescence excitation 488 nm/emission above 695 nm) were assessed 
using MetaMorph acquisition software. Following imaging, spheroids were 
transferred to a standard, tissue culture coated 24 well plate with 1 ml of fresh culture 
media (no drug treatments) and imaged using an EVOS XL Core camera (Life 
Technologies) after 0, 24, 48 and 72 h. Total outgrowth area from the spheroid was 
measured using ImageJ. software. 
 
2.2.12 ROS production analysis 
ROS Production was analysed using the DCFDA/H2DCFDA - Cellular Reactive 
Oxygen Species Detection Assay Kit from Abcam (Cambridge, U.K.). 25,000 
Tsc2+/+ and 22,000 Tsc2-/- MEFs were plated into a black flat-bottom 96-well plate. 
Plate was placed in incubator overnight to allow cells to adhere to the wells. After 
overnight incubation, cells were washed in 100 µl per well of 1x Assay buffer 
(provided by kit and warmed to 37 oC prior to use). Cells were then stained in 100 
µl of 25 µM of 2’, 7’ –dichlorofluorescin diacetate (DCFDA) for 45 min at 37 oC in the 
dark. After DCFDA incubation, cells were washed with 100 µl per well of 1x Assay 
buffer. Cells were then treated with the chosen drugs for 4 h in incubator at 37 oC. 
After incubation, cells were analysed in a Cytation 3 Imaging reader (Biotek, 
Swindon, UK) as plate was measured at excitation at 485 nm and emission at 535 
nm in endpoint mode using Gen5 microplate reader and imager software (version 
3.02, Biotek). Results were carried out in duplicate and the average was taken.  
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2.2.13 Protein synthesis assay 
444,444 Tsc2+/+ and 333,333 Tsc2-/- cells were grown in were plated into 35 mm2 
plates (TTP, Switzerland). 2 ml of media was added to each plate. Plates incubated 
overnight to allow cells to settle. After incubation, media was removed and replaced 
with 2 ml of methionine-free media containing DMSO or drug. Plates were then 
incubated for 6 h. After incubation period, cells were labelled via pulse-chase with 
12.5 mCi/ml 35S-methionine for 20 min prior to harvesting in extraction buffer. The 
protein concentrations in the extracts were then quantified using the Bradford assay. 
Aliquots (20 μl) of cell extract were applied to 161 cm squares of 3MM filter paper 
(Whatman) which were then washed three times for 1 min in boiling 5 % (w/v) 
trichloro-acetic acid containing a trace of cold L-methionine. Filters were rinsed once 
in ethanol and dried before radioactivity was determined by scintillation counting in 
Econofluor (Packard). Data were normalized to the protein content of each extract. 
 
2.2.14 Statistical analysis 
All experiments were carried out 3 times. Where applicable, results were written as 
mean +/- the standard deviation or if stated otherwise in the figure legend, as mean 
+/- the standard error of the mean (SEM) depending on the experiment type 
performed. Depending on the experiment type and the factors involved, either two-
way ANOVA (with Bonferroni’s multiple comparison post-test) or unless otherwise 
stated in the figure legend, one-way ANOVA (with Tukey’s multiple comparison 
post-test) were used to determine statistical significance of results. Significance was 
reported as a p value <0.05 (*), <0.01 (**) or <0.001 (***).
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Chapter 3: Mefloquine and nelfinavir combination caused 
selective cell death in mTORC1 hyperactive cells 
 
3.1 Introduction:  
 
3.1.1 Mefloquine 
 
3.1.1.1 General Properties of mefloquine 
Mefloquine is a highly lipophilic 4-quinolinemethanol antimalarial drug (Figure 3.1) 
that comes in a white/almost-white crystalline compound that is structurally similar 
to quinine. It is slightly water soluble but soluble in alcohols (such as methanol and 
ethanol), and in DMSO. It is a chiral drug with two dissimilar asymmetric centres that 
exist as two racemic forms, erythro and threo. The erythro forms of the drug have 
been in used in all clinical trials and treatments as a 50:50 racemic mixture of (-)-
(R,S) mefloquine and (+)-(R,S) mefloquine (Alisky et al. 2006; Schlagenhauf et al. 
2010; Xiao 2013).   
 
 
Figure 3.1: Structure of Mefloquine. Chemical structure of Mefloquine. Taken from (Osonwa et al. 
2017) 
 
 
61 
 
3.1.1.2 Mefloquine and Malaria 
Malaria is a mosquito-borne infectious disease that continues to be a major cause 
of illness and death worldwide. In 2015, the World Health Organisation (WHO) 
reported 214 million cases of the disease, which in turn, caused 438,000 deaths 
globally (Peixoto et al. 2016). The disease is caused by the parasite genus 
Plasmodium (Du Plessis et al. 2014), with the most severe form of the disease being 
caused by Plasmodium falciparum (Dwivedi et al. 2016). Chemotherapy using 
quinolines, such as chloroquine and primaquine were successfully used in the early 
days of malaria treatment (Graves 2003). However, resistance to these drugs 
developed with the first case of chloroquine-resistance reported in 1957 (Dwivedi et 
al. 2016).  
Mefloquine was developed by the U.S. Army’s Antimalarial Drug Program in 
1968 over concerns of chloroquine resistance (Nevin 2012). Mefloquine was made 
available for malarial chemoprophylaxis in 1985 in Europe and in the U.S.in 1990 
(Schlagenhauf et al. 2010). Mefloquine is currently sold under the trademark name 
Lariam by Hoffman La-Roche. Mefloquine is used as part of a combination therapy 
with artesunate in Africa (except Northern Cameroon), South America and South 
East Asia (except Northern Cambodia). Mefloquine is not used in northern 
Cameroon and Cambodia due to high levels of resistance to the drug being reported 
in these regions in the 1990s (Schlagenhauf et al.  2010; Veiga et al. 2010; Dwivedi 
et al. 2016). Mefloquine is the only antimalarial approved of chemoprophylaxis in 
Japan, although it is not widely accepted among Japanese travellers and Japanese 
travel health advisors, possibly due to concerns over adverse effects caused by the 
drug  (discussed later) (Fujii et al. 2007). Mefloquine is used for the treatment of 
mild to moderate acute malaria caused by Plasmodium falciparum. While 
mefloquine’s exact mode of action against malarial parasites is still unknown, 
research evidence suggests that mefloquine targets the 80S ribosome to inhibit 
protein synthesis of Plasmodium falciparum (Wong et al. 2017). 
Mefloquine has been recommended for malaria treatment in children by 
major global authorities, such as WHO, CDC, DTG, UK, French and Canadian 
expert groups as they recognise mefloquine as a valuable chemoprophylaxis for 
small children weighing < 20 kg although dosage schedules should be based on 
weight of the child (Schlagenhauf et al. 2011). There is evidence showing that 
children have a similar predictable pharmacokinetic mefloquine profile compared to 
adults, although clearance is higher in older children (5-12 years) compared to 
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younger children (24 months – 6 years) (Singhasivanon et al. 1992; Singhasivanon 
et al. 1994). 
Mefloquine treatment has been used in chloroquine-resistant regions as 
pregnant women are at an increased risk (especially in first or second pregnancies) 
and infection is also associated with adverse outcomes for both mother (severe 
anaemia) and infant (low birth weight, neonatal mortality). In these regions, patients 
treated with mefloquine were shown to have significantly lower risk of persistent or 
breakthrough malarial infection and significantly lower risk of having parasitaemia 
at delivery in the maternal peripheral blood, placental blood and infant umbilical cord 
blood compared to chloroquine-treated patients (Steketee et al. 1996; González et 
al. 2018). However, mefloquine usage for pregnant women has become a tale of 
conflicting reports. On the one hand, the WHO sanctioned the use of mefloquine in 
pregnant women in their second and third trimester. Mefloquine is also considered 
appropriate chemoprophylaxis for pregnant women of all gestational ages in high-
risk malaria endemic regions by several organisations including U.S. Centre for 
Disease Control (CDC) and the French Reference Centre for Teratogenic Agents 
(CRAT). The use of mefloquine, in this way however, should be based on a 
risk/benefit analysis of adverse effects (such as dizziness and vomiting) 
(Schlagenhauf et al. 2010; González et al. 2014). On the other hand, Nevin et. al. 
(2012) reported an increased risk of miscarriages and stillbirths in women in the first 
trimester treated with mefloquine. Nevin et. al. presented the cause of this increased 
risk is due to mefloquine’s ability to block gap junction protein alpha 1 (GJA1) gap 
junction intercellular communication (GJIC). This communication was thought to be 
crucial to successful embryonic implantation and early placental development. 
González et al. (2018) suggested that these conflicting reports were due to a lack 
of double-blind randomized controlled tests that were carried out as in the 18 articles 
they reviewed, they only found one article was double-blinded.   
 
3.1.1.3 Mefloquine and other parasites 
Although mefloquine has been primarily used as a treatment for malaria, research 
has also shown its uses against other parasitical infections. Echinococcosus is a 
genus of tapeworm which is responsible for two life-threatening conditions, alveolar 
echinococcosis which is caused by E. multilocularis (small fox tapeworm) and cystic 
echinococcosis which is caused by E. granulosus (small dog tapeworm). These 
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diseases are caused by the growth of “cyst-like” larvae on the liver, lungs and other 
organs (Hemphill et al. 2014). Mefloquine has shown evidence of being a suitable 
treatment for the disease as in vitro studies showed that treatment of 5-10 μg/ml of 
mefloquine (but no less than 1 μg/ml) caused E. granulosus larval death within 24 h 
after administration (Liu et al. 2015a). However, in terms of murine models, when 
Liu et. al. tried to administer mefloquine to mice orally (200 and 400 mg/kg twice 
weekly for two weeks), they observed no reduction in parasite weight. This would 
appear more to a problem with the method of delivery as opposed to drug efficacy 
as Küster et al. (2011) showed that intraperitoneal application of mefloquine (25 
mg/kg twice a week) showed a reduction in parasite weight in infected mice. 
 Schistosomiasis is a widespread disease of the tropics and sub-tropics which 
caused by a parasitic flatworm called schistosomes that can result in liver damage, 
kidney failure, infertility and bladder cancer. In 2008, a Belgian group were the first 
to suggest that mefloquine could have antischitosomal activity as mice (infected with 
Schistosoma mansoni) treated with mefloquine had significantly less eggs (although 
there was no effect seen on parasite burden) (Van Nassauw et al. 2008). This data 
was also confirmed by Keiser et al. (2009), as they used 200 and 400 mg/kg of 
mefloquine (as opposed to 150 mg/kg used by Van Nassauw) and saw that 
mefloquine had a potent effect on both juvenile and adult schistosomes (indicating 
that lower doses work well at targeting eggs while higher concentrations of 
mefloquine are needed to target the actual parasites). Mefloquine has also been 
shown to have antischitosomal activity against other species of schistosomes (S. 
haematobium and S. japonicum) (Keiser et al. 2014).   
 Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating 
disease of the central nervous system which is caused by the JC polyoma virus (JC 
virus). PML occurs in patients who are immunocompromised either due to HIV/AIDS 
(of which 85% of PML patients have a concurrent infection), autoimmune disease, 
organ transplant or haematological malignancies (in particular, the use of rituximab 
in the treatment of non-Hodgkin’s lymphoma). A screening of 2000 drugs showed 
that mefloquine was able to inhibit JC Virus infection via inhibiting viral replication 
(after cell entry) and its ability to transfer into the cerebral spinal fluid. Combining 
mefloquine with mirtazapine (a serotonin receptor blocker) for the treatment of PML 
have also shown positive results in clinical studies (Yoshida et al. 2014; Sano et al. 
2015; Silverio and Patel 2015). 
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3.1.1.4 Mefloquine and Cancer 
Mefloquine has shown plenty of potential to be used as an anti-cancer drug either 
as a single agent or in combination. P-glycoprotein plays an important role in 
multidrug resistance in several different tumour types and involves overexpression 
of the MDR1 gene (the gene responsible for P-glycoprotein). As seen with malaria 
treatment, inhibition of P glycoprotein plays a role in the anticancer properties of 
mefloquine. A multi-drug resistant subline of human oral squamous carcinoma KB, 
KBV20C, when treated with mefloquine, caused cells to become extremely sensitive 
to several drugs including the microtubule targeting anticancer agents vinblastine, 
colchicine and halaven (a drug recently developed to overcome resistance to 
antimitotic drugs), all via the same mechanism of blocking P-glycoprotein activity 
(Choi et al. 2016; Kim et al. 2013; Cheon et al. 2016). 
 In gastric cancer cell lines mefloquine (whether as a single agent or in 
combination with paclitaxel) caused apoptosis in in vitro cell studies. In two 
independent gastric cancer xenograft mouse in vivo models, apoptosis occurred, 
via suppression of the PI3K-Akt-mTOR pathway. There was a decreased 
phosphorylation of PI3K, Akt and mTOR in cell lines where there was no constitutive 
overexpression of Akt. This mode of action was shown to be dependent on calyculin 
A, a protein phosphatase.   
 PC3 cells (the most commonly used prostate cancer cell line) are sensitive 
to mefloquine. A single 10 μM dose of mefloquine was able to achieve the IC50 at 24 
h, although no further toxicity was detected either 48 or 72 h. Mefloquine at 40 μM 
was shown to cause 30% cell death at 60 min. Experimental observations showed 
that the cells were killed in a non-apoptotic manner, which was caused by a 
significant increase in reactive oxygen species (ROS) production (Yan et al. 2013). 
 Mefloquine has been shown to inhibit autophagy, trigger ER stress and 
induced cell death in both hormone receptor positive (T47D) and negative (MDA-
MB-231) breast cancer cells. Mefloquine was observed to cause a mixture of 
caspase-dependent and independent cell death as a rescue assay with pan-
caspase inhibitor (ZVAD-FMK) only caused partial rescue of treated cells. 
Mefloquine was shown to be more potent than chloroquine, where effective 
concentrations of mefloquine used fell between 2.5-15 μM compared to higher 
concentrations of 30 μM to over 100 μM with chloroquine (Sharma et al. 2012). 
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 Mefloquine was shown to be more potent at killing glioblastoma cells 
regardless of TP53 (also known as p53) status compared to the more readily 
available chloroquine, and also had superior penetration of the blood-brain barrier 
compared to chloroquine (Geng et al. 2010). Cell death was apoptotic in nature 
which is the result of autophagy inhibition. These results were validated after a drug 
screen of quinolone-based antimalarial drugs was carried out on glioma cell lines 
(LN229, U251 and U87) (Schönthal et al. 2015). Mefloquine was shown to be the 
second most cytotoxic drug (just behind quinacrine, while chloroquine was observed 
to be the second least effective drug, just above quinine) in both drug-sensitive and 
drug-resistant (including to temozolomide) cell lines. Cell death observed in this 
research was similar to that seen by Geng et al. (2010) (apoptotic and caused by 
autophagy inhibition), although enhanced ER stress was also observed. In the 
cancer setting, mefloquine is currently in a phase I clinical factorial trial 
(NCT01430351) in combination with the DNA-damaging agent temozolomide for 
glioblastoma multiforme. 
 
3.1.2 Hypothesis 
Results from Johnson et al. (2014) showed that a combination of chloroquine (20 
μM) and nelfinavir (20 μM) was able to selective kill Tsc2-/- MEFs over a 24 h period 
via entrapment of chloroquine to acidified lysosomal/endosomal compartments, 
causing cells to become sensitised to nelfinavir‐induced death. While investigating 
the cytotoxic potential of this combination, a mefloquine (10 μM) and nelfinavir (20 
μM) combination was also tested and was shown to not only to have selective 
cytotoxicity for Tsc2-/- MEFs but was more potent than chloroquine/nelfinavir 
combination over a 24 h period. The purpose of this chapter was to further 
investigate this finding by optimising and determining synergy of a mefloquine and 
nelfinavir combination. Once an optimised combination was determined, the focus 
of this chapter was to identify the mechanism of drug action, and to explore the 
potency of this drug combination against Tsc2-/- deficient cells and sporadic cancer 
cell lines that are known to have aberrant activation of the mTORC1 signalling 
pathway. 
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3.2 Results: 
 
3.2.1 An optimized combination of mefloquine and nelfinavir synergises to 
selectively target mTORC1 hyperactive cells and causes caspase-
independent cell death. 
To determine a suitable combination of mefloquine and nelfinavir that can selectively 
kill Tsc2-/- cells, while being tolerated by Tsc2+/+ cells, various combinations of 
each drug were tested either as a single agent, or in combination (using a range of 
varying concentrations). Cells were incubated for 48 h as a median ground to 
observe both short and long-term effects of drugs on cells.  
To determine the drugs effect on cell proliferation, a CyQUANT assay was 
carried out. Results were calculated as a % of total cell number that was normalised 
to 100% for DMSO treated cells. Results from the assay showed that mefloquine as 
a single agent and mefloquine/nelfinavir combinations over a range of various 
concentrations were able to selective inhibit cell proliferation of Tsc2-/- MEF cells 
compared to Tsc2+/+ MEFs (Figure 3.2A). Nelfinavir, on the other hand, only 
selectively inhibited Tsc2-/- MEFs when treated with concentrations over 10 µM.  A 
combination of 2.5 μM mefloquine and 5 μM nelfinavir showed the greatest 
selectivity for inhibiting cell proliferation (47.13% +/- 7.88 SEM cell proliferation of 
Tsc2+/+ MEFs vs 21.84% +/- 4.62 SEM cell proliferation of Tsc2-/- MEFs compared 
to DMSO-treated cells). However, when this selected drug combination was tested 
for cell death using flow cytometry, the combination failed to cause cell death in 
Tsc2-/- MEFs (i.e., the combination of drugs at these concentrations was cytostatic 
not cytotoxic properties). Therefore, drug combinations were retested with flow 
cytometry using 10 µM nelfinavir as the minimum concentration for combinations.  
 To determine the effectiveness of combinations in terms of cell death, both 
Tsc2-/- and Tsc2 +/+ MEFs were treated with several combinations of mefloquine 
and nelfinavir as well as single agents. Etoposide (a topoisomerase II inhibitor) was 
used as a positive control to induce cell death through the induction of DNA damage. 
Results were written as % cell death. As single agents, mefloquine and nelfinavir 
failed to cause significant cell death in either cell line with no single agent treatment 
causing more than 20% cell death. Results showed that combinations of 10 µM 
mefloquine and 10 µM nelfinavir, and 5 µM mefloquine and 20 µM nelfinavir showed 
the highest level of selective cell death (Figure 3.2B). While both combinations 
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showed somewhat similar results in Tsc2+/+ MEF cell death (37.62% +/- 11.79 SD 
in 10 µM mefloquine and 10 µM nelfinavir combination and 30.36% +/- 8.67 SD in 5 
µM mefloquine and 20 µM nelfinavir combination respectively) the 10 µM mefloquine 
and 10 µM nelfinavir combination had a much higher level of cell death amongst 
Tsc2-/- MEFs (96.09% +/- 1.98 SD vs 79.95% +/- 12.13 SD) compared to the 5 µM 
mefloquine and 20 µM nelfinavir combination. Because of this, most of the 
characterisation experiments using this drug combination for the rest of this chapter 
used the 10 μM mefloquine and 10 μM nelfinavir combination.  
 To identify how synergistic the combined mefloquine/nelfinavir treatment 
was, a range of mefloquine and nelfinavir concentrations were tested via flow 
cytometry. Results were then processed in CompSyn to generate a Combination 
Index (CI) value where a score of less than 1 is considered synergistic, a score of 1 
is additive and more than 1 is antagonistic. Results showed that the combined 
mefloquine and nelfinavir treatment was highly synergistic in Tsc2-/- MEFs (CI value 
= .03) while being antagonistic in Tsc2+/+ MEFs (CI value =1.10) (Figure 3.2C (iv)). 
The 100 µM mefloquine and 10 µM nelfinavir combination also appears to act 
synergistically to induce cell death in both cell lines (CI values = 0.20 and 0.69 in 
Tsc2+/+ and Tsc2-/- MEFs respectively), while in combinations containing less than 
10 µM mefloquine, the CI values showed drug combinations to be extremely 
antagonistic (CI values = 20.36 and 11.40 in Tsc2+/+ and Tsc2-/- MEFs treated with 
1 μM mefloquine combination and CI values = 37.66 and 15.76 in Tsc2+/+ and Tsc2-
/- MEFs treated with 0.1 μM mefloquine combination (Figure 3.2C (iv)). 
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Figure 3.2: Optimization and synergy of mefloquine and nelfinavir. (A) CyQUANT Assay to 
determine the effects of mefloquine (MQ) and nelfinavir (NFV) on Tsc2+/+ and Tsc2-/- MEFs as 
single agents at various concentrations and in combination (MQ/NFV) using various concentrations 
of mefloquine and nelfinavir on cell proliferation after 48 h treatment. Fluorescence was read on a 
plate reader with excitation maximum at 480 nm and emission maximum at 520 nm. Statistical 
significance is shown between Tsc2+/+ MEFs and Tsc2-/- MEFs (n=3; mean +/- SEM). (B) Flow 
cytometry (with scatter blots) was performed to measure cell death in Tsc2+/+ and Tsc2-/- MEFs 
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treated with dimethyl sulfoxide (DMSO), etoposide (ETO), mefloquine (MQ) or nelfinavir (NFV) as 
single agents at various concentrations or in combination (MQ/NFV) at various concentrations after 
48 h treatment (n=3; mean +/- SD). (C)  Dose response curves were performed in Tsc2+/+ and Tsc2-
/- MEFs using flow cytometry to measure cell death following treatment with (i) nelfinavir (NFV); (ii) 
mefloquine (MQ) and (iii) combined mefloquine with a fixed concentration of 10 µM nelfinavir 
(MQ/NFV). Synergy was then calculated using CompuSyn and graphed (iv) as F(a) value vs CI value. 
Statistical significance is shown with combination or single agent treated Tsc2-/- MEFs compared to 
their wild-type controls (n=3; mean +/- SD). 
   
To confirm that Tsc2 loss was responsible for the induction of cell death, the 
mefloquine/nelfinavir combination was tested using ELT3 cell lines (both null type 
(V3) and Tsc2 re-expressed (T3)) via flow cytometry. Results showed a similar cell 
death pattern to results seen in MEFs, although cell death was lower in V3 cells 
compared to Tsc2-/- MEFs (76.27% +/- 6.26 SD vs 96.09% +/- 1.98 SD 
respectively). Mefloquine also appeared to be less tolerated by both cell lines 
compared to the MEFS (39.44% +/- 7.43 SD vs 51.07% +/- 15.17 SD in ELT3 cell 
lines compared to 18.91% +/- 10.87 SD vs 11.47% +/- 4.72 SD in MEF cell lines 
respectively) (Figure 3.3A). 
 To determine if the combination could be used to target sporadic cancers, 
the mefloquine/nelfinavir combination was tested against three different types of 
mTORC1 hyperactive cancer cell lines (breast, colorectal and lung). The cell lines 
used were previously shown to be mTORC1 hyperactive by previous work by the 
lab group; NCI-H460 was used by (Johnson et al. 2015) and HCT116 and MCF7 
were used by (Johnson et al. 2018). Results from the flow cytometry showed that 
the combination caused high levels of cell death in all sporadic cancer lines tested 
(95.64% +/- 1.95 SD in HCT116 (colorectal), 88.05% +/- 2.74 SD in NCI-H460 (lung) 
and 65.98% +/- 8.30 SD in MCF7 (breast) cells). HCT116 and NCI-H460 cells also 
appeared to be sensitive to mefloquine as a single agent (81.39% +/- 5.50 SD and 
65.21% +/- 3.97 SD cell death in HCT116 and NCI-H460 cells respectively) (Figure 
3.3B).  
 To determine the manner of cell death, western blots were carried out to 
determine if cell death was intrinsically (characterized by permeabilization of the 
mitochondria and release of cytochrome c into the cytoplasm) or extrinsically 
(mediated by tumour necrosis factor (TNF) induction or Fas-Fas ligand mediation) 
apoptotic. Tsc2+/+ and Tsc2-/- MEFs were incubated in treatment for 48 h. Results 
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from western blots showed that no caspase cleavage occurred in either extrinsic 
(caspase 8) or intrinsic (caspase 9) pathways, in samples treated with the 
combination or single agents, i.e., the combination was killing cells in a caspase-
independent manner.  
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Figure 3.3: The combination of mefloquine and nelfinavir caused cytotoxicity in mTORC1 
hyperactive tumour cells and cell death in MEFs is caspase-independent. (A) ELT3-T3 and 
ELT3-V3 (n=3; mean +/- SD); (B) MCF7, HCT116 and NCI-H460 were treated with either DMSO, 
100 μM etoposide (ETO), 10 µM mefloquine (MQ), 10 µM nelfinavir (NFV) or combination (MQ/NFV) 
for 48 h. Cells were then tested by flow cytometry and cells were separated into viable and non-
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viable cell populations via DRAQ7 staining (n=3; mean +/- SD). (C) Tsc2+/+ and Tsc2-/- MEFs were 
treated with DMSO, 1 μM thapsigargin (TPG) MQ, NFV or MQ/NFV for 48 h. Caspase cleavage 
activity was then measured via western blot. Blots are representative of n=3 runs. Statistical 
significance is shown with combination treated ELT3-V3 cells compared to their wild-type controls 
and (calculating by one-way ANOVA) comparing single drug treatment of mefloquine and 
combination with the ELT3-V3, MCF7, HCT116 and NCI-H460.  
 
3.2.2 Mefloquine/nelfinavir combination prevented tumour colony formation 
and prevented tumour regrowth from treated spheroids. 
To determine the effects of mefloquine/nelfinavir combination in a 3D environment, 
Tsc2-/- MEFs were either plated in either agar (for tumour colony formation assay) 
or agarose (for tumour outgrowth assay).  
To determine if the drug combination could prevent the formation of tumour 
colonies, Tsc2-/- MEFs were treated with drugs for 14 days before being 
photographed and measured. Results for the colony assay showed that the 
mefloquine/nelfinavir combination significantly reduced the size of tumour colonies 
compared to single agents, or in the presence of DMSO (Figure 3.4A).  
 For the tumour outgrowth assay, Tsc2-/- MEFs were incubated for 72 h to 
form spheroids and were photographed before being treated with drugs for 96 h (the 
last 48 h including DRAQ7) before being photographed again and spheroid were 
placed in fresh non-drug media for 72 h (photographed every 24 h). Results show 
that there no change in size between any of the treatment conditions after 96 h of 
treatment. The morphologies of DMSO and nelfinavir treated cells remained the 
same, however, samples treated with either mefloquine or mefloquine/nelfinavir 
combination changed to a “fluffier” appearance, where the cells at the edge of the 
spheroid appeared less compacted. Both groups were also divided based on the 
amount of DRAQ7 fluorescence as combination and mefloquine have similar values 
(1423.71 +/- 404 SEM and 1215.70 +/- 328 SEM Mean Fluorescent units (MFU)) 
compared to nelfinavir and DMSO samples (767.62 +/- 214 SEM and 668.15 +/- 
146 SEM MFU, respectively) (Figure 3.4B). Once placed back into clean media, 
spheroids incubated in drug combination failed to grow out into the media (indicating 
that there are no viable cells left in the spheroid) after 72 h. All other spheroids did 
eventually grow out into media (indicating the presence of viable cells left in the 
spheroid), although mefloquine grew at a much slower rate compared to DMSO and 
nelfinavir samples (Figure 3.4C).    
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Figure 3.4: Mefloquine/nelfinavir combination prevented tumour formation and tumour 
spheroid growth. Colony formation was tested in Tsc2-/- MEFs seeded on soft agar that were 
treated for 14 days with Dimethyl Sulfoxide (DMSO), 10 µM mefloquine (MQ), 10 µM nelfinavir (NFV) 
or in combination MQ/NFV. Tumour diameters were measured using Image J. Significance was 
observed when comparing combined nelfinavir and mefloquine treatment to DMSO vehicle control 
(n=3: mean +/- SD). (B) Tsc2−/− MEF spheroids were grown for 72 h before being treated under the 
same conditions as (A) for 96 h. DRAQ7 was supplemented for the final 48 h to monitor cell death 
before images were taken and DRAQ7 fluorescence quantified (n=3; mean +/- SEM). (C) Spheroids 
treated in (B) were re-plated onto standard tissue culture plates and grown in drug-free media. 
Images were taken every 24 h and the area of outgrowth was calculated using Image J., scale bar 
represents 200 μm and outgrowth area was graphed. Statistical significance (calculated by one-way 
ANOVA) is shown with combination treated tumour colony size compared to their wild-type controls, 
comparing fluorescence emitted by combination treated spheroids to nelfinavir and DMSO treated 
spheroids and comparing outgrowth of combination treated spheroids to single agent and DMSO 
treated spheroids (n=3). 
  
74 
 
3.2.3 Mefloquine/nelfinavir combination targeted Tsc2-/- cells in a mTOR and 
autophagy/lysosomal-independent manner.  
To determine if mTORC1-hyperactivity was important for the induction of cell death, 
flow cytometry was carried out on Tsc2-/- MEF, HCT116 and NCI-H460 and MCF7 
cell lines treated with DMSO, drug combination, or drug combination with 50 nM 
rapamycin for 48 h. Results showed that the introduction of rapamycin failed to 
rescue cell death in Tsc2-/- MEF, HCT116 and NCI-H460 cell lines. In MCF7 cells, 
the introduction of rapamycin led to a slight nonsignificant increase in cell death 
(88.83% +/- 11.01 with rapamycin vs 75.44% +/- 4.63 without rapamycin). To 
confirm if rapamycin was inhibiting mTORC1 activity, western blots were carried on 
the previously mentioned cell lines treated in the same conditions as the flow 
cytometry. Results showed that samples treated with combination and rapamycin 
showed a complete or near complete inhibition of RPS6 phosphorylation, confirming 
rapamycin was successfully inhibiting the mTORC1 pathway (Figure 3.5A). 
 To determine if the autophagy flux was altered by the combination, western 
blots were carried out on Tsc2+/+ or Tsc2-/- MEFs treated for 3 h. A combination of 
20 µM chloroquine with 20 µM nelfinavir was used as a positive control as this drug 
combination has previously been proven to prevent autophagy (Johnson et al. 
2015). Results showed that the mefloquine/nelfinavir combination caused LC3-II 
accumulation but was less when compared to chloroquine/nelfinavir combination in 
Tsc2-/- MEFs. Furthermore, there was more pronounced LC3-II accumulation in 
Tsc2+/+ MEFs, which was also less than the samples treated with 
chloroquine/nelfinavir. SQTSM1/p62 was basally elevated in Tsc2-/- MEFs 
compared to Tsc2+/+ MEFs and did not appear to be significantly affected by 
combined treatments with either mefloquine or chloroquine (Figure 3.5B).  
 To determine if the drug combination affected lysosomal function, Tsc2+/+ 
and Tsc2-/- MEFs were treated for 24 h (to observe short term effects of 
combination) with either DMSO, drug combination or drug combination with 100 nM 
bafilomycin A1 (a v-ATPase inhibitor) before being analysed via flow cytometry. V-
ATPases are ATP-driven proton pumps that function within both intracellular 
compartments and the plasma membrane in a wide array of normal physiological 
and pathophysiological processes. V-ATPase plays an important role in keeping low 
intralysosomal pH, which is essential for lysosomal hydrolase activity (Mauvezin et 
al. 2015). Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-
dependent acidification and Ca-P60A/SERCA-dependent autophagosome-
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lysosome fusion (Mauvezin and Neufeld 2015). Members of the quinone family 
(chloroquine, hydrochloroquine and mefloquine) have all been shown to accumulate 
in the lysosome. Bafilomycin A1 has been shown to prevent the build-up of 
chloroquine and MEFAS (a synthetic salt derived from mefloquine and artesunate) 
in the lysosome (Glaumann et al. 1992; Kaufmann and Krise 2007; de Pilla Varotti 
et al. 2008; Harhaji-Trajkovic et al. 2012). Results showed that bafilomycin A1 failed 
to rescue cell death after nelfinavir and mefloquine, but instead caused an increase 
in the level of cell death (51.23% +/- 11.23 SD vs 63.80% +/- 3.79 SD in the 
presence of bafilomycin A1 compared to 43.53% +/- 10.58 SD vs 58.57% +/- 13.39 
SD in just mefloquine/nelfinavir treatment). To confirm that the concentration of 
bafilomycin A1 was sufficient to block autophagy, western blots were carried out 
with both cell lines to determine LC3-II and p62 accumulation, treated for either 3 h 
or 24 h. Western blots showed that samples treated with bafilomycin A1 had an 
accumulation of LC3 and p62 at both 3 and 24 h timepoints compared to just 
mefloquine and nelfinavir or DMSO treatment indicating that bafilomycin A1 was 
blocking autophagy (Figure 3.5C). 
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Figure 3.5: mTORC1 hyperactivity was not associated with Mefloquine/nelfinavir combination 
induced cell death and caused minimal inhibition of autophagy. (A(i)) Tsc2-/- MEFs, (A(ii)) NCI-
H460, MCF7 and HCT116 cells were pre-treated with 50 nM rapamycin (RAP) for 1 h, where 
indicated, before being treated with either 10 μM nelfinavir (NFV) and 10 µM mefloquine (MQ) or 
MQ/NFV with RAP for 48 h. Cell death was determined using flow cytometry (n=3; mean +/- SD). 
Statistical significance (calculated by one-way ANOVA) is shown control cells, cells treated MQ/NFV 
and MQ/NFV treated cells and RAP treated cells. (A(iii)) To determine if RAP was functioning as 
expected, western blotting was carried out to determine rp-S6 phosphorylation at Ser235/236 in the 
cells treated in (A) after 48 h of treatment. (B) Tsc2+/+ and Tsc2-/- cells were treated with DMSO, 10 
µM mefloquine (MQ), 20 µM chloroquine (CQ), 10 µM mefloquine combined with 10 µM nelfinavir or 
20 µM chloroquine combined with 20 µM nelfinavir for 3 h. Accumulation of lipidated LC3-II and p62 
was analysed by western blot. (C(i)) Tsc2--− and Tsc2+/+ MEFs were treated with 10 μM nelfinavir 
(NFV) and 10 µM mefloquine (MQ) or MQ/NFV with 100 nM bafilomycin A1 (BAF) for 24 h. Cell death 
was determined using flow cytometry (n=3; mean +/- SD). (C(ii)) To determine if BAF was functioning 
as expected, western blotting was carried out to determine the accumulation of lipidated LC3-II and 
p62 in the cells treated in (A) after 3 h and 24 h of treatment. Total protein levels of β-actin were used 
as a loading control. All Blots in figure 3.5 are representative of n=3 runs. Statistical significance is 
shown between combination treated Tsc2+/+ and Tsc2-/- MEFs. 
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3.2.4 Mefloquine and nelfinavir as single drug agents, as well as in 
combination, blocked P-glycoprotein activity in Tsc2+/+ and Tsc2-/- MEFS. 
P-glycoprotein is a 170 kDa membrane glycoprotein which is associated with 
multidrug resistance in cancer cells as it acts as an ATP-dependent drug efflux 
protein. A substrate of P-glycoprotein is nelfinavir which causes increased 
expression of the P-glycoprotein and is a possible mechanism reducing drug 
exposure after multiple doses. Another substrate of P-glycoprotein is mefloquine 
which has been shown to inhibit the functional activity of P-glycoprotein (Riffkin et 
al. 1996; Faucette et al. 2004). To determine if mefloquine could inhibit P-
glycoprotein activity and cause accumulation of nelfinavir in cells, contributing to cell 
death, both Tsc2+/+ and Tsc2-/- MEFs were treated with either mefloquine/nelfinavir 
combination or control, with all treatments containing 5.25 µM of rhodamine123 
(which is a substrate of P-glycoprotein) for 30 min at 37 oC. Samples were then 
lysed in warmed deionised water and a fluorescence reading was taken. Results 
were recorded as a % of DMSO treated control (which was normalised to 100%). 
Results showed that mefloquine, as a single agent was able to increase rhodamine 
123 uptake (i.e., inhibited P-glycoprotein activity) compared to DMSO in both Tsc2-
/- and Tsc2+/+ MEFs (188.31% +/- 8.61 SEM in Tsc2+/+ MEFs and 198.55% +/- 
3.22 SEM in Tsc2-/- MEFs compared to 100% in DMSO treated cells respectively). 
Nelfinavir, as a single agent caused partial inhibition of P-glycoprotein activity which 
was seen in a slight increase in rhodamine 123 uptake in Tsc2+/+ cells but caused 
a large inhibition of P-glycoprotein activity (in the form of a large uptake of rhodamine 
123) in Tsc2-/- cells (120.11% +/- 13.82 SEM in Tsc2+/+ MEFs compared to 
210.36% +/- 3.22 SEM in Tsc2-/- MEFs). The combination of mefloquine and 
nelfinavir failed to stop P-glycoprotein activity (evident by the slight increase in 
rhodamine 123 uptake) in Tsc2-/- MEFs but caused massive inhibition of p-
glycoprotein activity (as seen in the large uptake of rhodamine 123) in Tsc2+/+ 
MEFs (223.04% +/- 8.49 SEM in Tsc2+/+ MEFs compared to 114.09% +/- 13.15 
SEM in Tsc2-/- MEFs) (Figure 3.6).   
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Figure 3.6: Mefloquine/nelfinavir combination affected rhodamine 123 uptake. Rhodamine 123 
is a substrate of P-glycoprotein and can be used to observe if a drug can inhibit P-glycoprotein activity 
and to what extent. The inhibitory effects of target drug on P-glycoprotein is determined the amount 
of intracellular Rhodamine 123 accumulation (written as Rhodamine 123 uptake %). In this 
experiment, Tsc2+/+ and Tsc2-/- MEFs were treated with DMSO, 10 μM mefloquine, 10 μM nelfinavir 
or a combination of mefloquine and nelfinavir (all containing 5.25 μM rhodamine 123) for 30 min at 
37 oC before being lysed in warmed deionised water. Fluorescence was analysed via plate reader at 
excitation maximum at 480 nm and emission maximum at 520 nm (n=3; mean +/- SEM). Statistical 
significance is shown between combination treated Tsc2+/+ and Tsc2-/- MEFs.  
 
3.2.5 Mefloquine/nelfinavir combination induced enhanced and prolonged ER 
stress in Tsc2-/- cells via the PERK pathway. 
Nelfinavir is a well-known ER stress enhancer. To determine the effects the 
combination would have on ER stress pathways in both Tsc2+/+ and Tsc2-/- MEFs, 
western blots were performed on Tsc2+/+ and Tsc2-/- MEFs treated for 6 h with 
drugs. Tharsigargin was used as a positive control drug that induced ER stress. 
Results showed that there was a large difference in expression of ER stress makers 
between Tsc2+/+ and Tsc2-/- MEFs. There was a higher basal level of IRE1α 
protein expression in the Tsc2-/- MEFs when compared to the Tsc2+/+ MEFs that 
was unchanged with drug treatment. In the Tsc2-/- MEFs, there was higher level of 
protein expression of several components of the PERK pathway after drug 
treatments, such as GADD34, CHOP and ATF4. The level of protein expression of 
these ER stress markers was higher in the presence of drug combination when 
compared to single mefloquine treatments. However, there is no significant 
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difference in expression levels between nelfinavir-treated Tsc2-/- MEFs and Tsc2-/- 
MEFs treated with the mefloquine/nelfinavir combination. Components of the 
mTORC1 pathway were also tested. Results showed a higher basal level of S6K1 
phosphorylation in Tsc2-/- MEFs compared to Tsc2+/+ MEFs. Results also 
confirmed that Tsc2-/- MEFs had no TSC2 expression. The nelfinavir and 
mefloquine drug combination failed to cause any form of significant change in S6K1 
phosphorylation when compared to single drug treatments (Figure 3.7A).  
 To determine how long ER stress persisted after treatment, western blots 
were carried out on Tsc2+/+ and Tsc2-/- MEF samples treated for either 6 h or 48 
h. In Tsc2+/+ MEF samples treated with drug combination, data showed an 
increased expression of CHOP and ATF4 at 6h. However, at the 48 h time point, 
CHOP and ATF4 expression was no longer apparent, indicating that the Tsc2+/+ 
MEFs had recovered from the ER stress. Like the Tsc2+/+ MEFs, Tsc2-/- MEFs 
showed high protein expression levels of ATF4, CHOP and GADD34 at the 6 h time 
point (higher than seen in the Tsc2+/+ MEFs). However, unlike the Tsc2+/+ MEFs, 
a higher level of protein expression was still evident at the 48 h time point, indicating 
that these Tsc2-/- MEFS were unable to fully recover from the drug induced ER 
stress (Figure 3.7C). 
 To confirm that ER stress was occurring, XBP1 splicing was investigated (an 
event which only occurs in an ER stress-induced environment due to activation of 
IRE1α). MEFs were treated for 6 h with DMSO, mefloquine, nelfinavir or 
mefloquine/nelfinavir combination, using tharsigargin as a positive control. mRNA 
was extracted and then converted to cDNA. The cDNA was used as a template to 
analyse XBP1 splicing by PCR. PCR products were resolved on an agarose gel, 
where the unspliced XBP1 size was 480 base pairs and the spliced XBP1 product 
size was 454 base pairs. Results showed a higher degree of XBP1 splicing in the 
Tsc2-/- MEFs compared to Tsc2+/+ MEFs in both untreated and treated conditions. 
With Tsc2-/- cells, splicing occurred in samples treated with drug combination at a 
much higher rate when compared to single agents or DMSO (Figure 3.7B(i)). To 
confirm that the PCR products were XBP1, spliced and unspliced samples were 
subjected to Pst1 restriction digests (which cleaved DNA at the recognition 
sequence 5′-CTGCA/G-3′, which is found in unspliced but not spliced XBP1). 
Results showed digestion occurred in unspliced samples treated with XBP1 
confirming XBP1 was being tested (Figure 3.7B(ii)). 
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 To determine the transcriptional effects of nelfinavir and mefloquine drug 
treatments on the level of RNA expression, RNA sequencing was carried out on 
Tsc2+/+ and Tsc2-/- MEFs treated for 6 h in either DMSO, 20 µM nelfinavir or drug 
combination with nelfinavir and mefloquine. A Heat map was generated for a panel 
of ER stress associated genes. The Heat map represents RNA expression as low 
levels of expression (or no expression) were represented by blue (were the darkest 
blue represents lowest level of expression (a score of 0)). Increased RNA 
expression is represented by a colour shift from blue to white to red were the darkest 
red represents the highest RNA expression score (in this case, a score of 6767). A 
selection of genes was then further graphed and analysed. The overall RNA 
sequencing data was represented in a volcano plot where chosen ER stress genes 
were highlighted. Colours represent differences in expression levels which have at 
least a 1-fold difference in Tsc2+/+ MEFs (Blue) and Tsc2-/- MEFs (Red). Genes 
which are involved in cell survival such as CREBREF and IMPACT (negative 
regulators of ER stress) were shown to have a 2-3-fold increase in expression in 
Tsc2+/+ MEFs when compared to Tsc2-/- MEFS, especially in the presence of drug 
treatment. Conversely, pro-ER stress genes linked to cell death, such as DDIT4 
(also known as CHOP), ERO1L, ATF3 and TRIB3 (which inhibits transcriptional 
activity of CHOP and is involved in CHOP-dependent cell death during ER stress) 
were expressed at a much higher level within the Tsc2-/- MEFs. FAM129A (which 
is responsible for Niban which regulates phosphorylation of several proteins 
involved in translation regulation) and DDIT4L (which translates REDD2 which 
inhibits cell growth by regulating the mTORC1 signalling pathway upstream of the 
TSC1-TSC2 complex and downstream of AKT) were almost exclusively expressed 
in Tsc2-/- MEFS compared to Tsc2+/+ MEFs. Results show that the introduction of 
the mefloquine/nelfinavir combination was able to significantly influence RNA 
expression of nearly all genes within Tsc2-/- MEFs compared to Tsc2-/- MEFs 
treated with DMSO (except CREBRF and DDIT4L). The mefloquine/nelfinavir 
combination was also able to significantly influence RNA expression of SESN2, 
IMPACT, DDIT4 and ERO1L within Tsc2+/+ MEFs compared to Tsc2+/+ MEFs 
treated with DMSO. Results also showed elevated expression levels of SESN2 gene 
(which translates the Sestrin 2 protein, involved in the communications between ER 
stress and energy stress) were basally enhanced (nearly 10-fold) in Tsc2-/- MEFS 
compared to Tsc2+/+ MEFS. When treated with nelfinavir and mefloquine, there 
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was nearly a two-fold change in expression of SESN2 mRNA in Tsc2-/- MEFS 
compared to control Tsc2-/-MEFs (Figure 3.7D-F). 
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Figure 3.7: The effects of mefloquine/nelfinavir combination on ER stress. (A) (i) Tsc2+/+ and 
Tsc2-/- MEFs were treated with either DMSO, 1 µM thapsigargin (TPG), 10 µM mefloquine (MQ), 10 
µM nelfinavir (NFV), or mefloquine and nelfinavir combination (MQ/NFV) for 6 h, where indicated. 
Total protein levels of TSC2, IRE1α, ATF4, CHOP, GADD34, S6K1 and β-actin and S6K1 
phosphorylated at Thr389 were detected by western blot. (A) (ii) Densitometry of western blots for 
ATF4, CHOP and GADD34 measured. Statistical significance is shown comparing DMSO treated 
Tsc2-/- MEFs to TPG treated Tsc2-/- MEFs (ATF4, CHOP, GADD34), comparing DMSO treated 
Tsc2-/- MEFs to NFV treated Tsc2-/- MEFs (ATF4) and comparing DMSO treated Tsc2-/- MEFs to 
MQ/NFV treated Tsc2-/- MEFs (ATF4). (B) (i) Xbp1 mRNA splicing was determined from the same 
treatments as described in (A) (ii) Pst1 restriction digestion to confirmed XBP-1. PCR products were 
resolved on agarose gels (unspliced = 480 bp upper band, spliced = 454 bp lower band). (C) Tsc2+/+ 
and Tsc2-/- MEFs were treated with DMSO or mefloquine (MQ) and nelfinavir (NFV) combination for 
6 h and 48 h. Total protein levels of ATF4, IRE-1α, GADD34, CHOP and β-actin were determined by 
western blot. All blots in figure 3.7 are representative of n=3 runs. (D–F) RNQ sequencing. Tsc2+/+ 
and Tsc2-/- MEFs were treated with either DMSO or mefloquine and nelfinavir combination 
(MQ/NFV) for 6 h. A heat map for a panel of ER stress-linked genes is shown (D). Heat map shows 
expression as dark blue for low levels of RNA expression while dark red (via going from blue to white 
to red) represents high levels of RNA expression. A selection of genes from the ER stress panel 
were then further graphed in (E) (n=3; mean +/- SD). (F) A volcano plot showing the entire RNA 
sequencing where genes shown in (E) are highlighted. Statistical significance is shown comparing 
combination treated Tsc2+/+ and Tsc2-/- MEFs and comparing DMSO treated Tsc2+/+ and Tsc2-/-, 
comparing Tsc2+/+ MEFs treated with either DMSO or MQ/NFV and Tsc2-/- MEFs treated with either 
DMSO or MQ/NFV.  
 
 To determine if mefloquine could be used with inhibitors of other components 
of the UPR, nelfinavir was replaced with 1 µM 17AAG (a HSP90 inhibitor). Tsc2+/+ 
and Tsc2-/- MEFs were treated for 48 h and tested via flow cytometry. Results 
showed that 17AAG as a single agent could selectively target Tsc2-/- MEFs while 
being well tolerated by Tsc2+/+ MEFs (69.23% +/- 10.23 vs 18.04% +/- 2.77, 
respectively). Results also showed that when used in combination with 10 µM 
mefloquine, cell death of Tsc2-/- MEFS rose to 86.39% +/- 3.51 compared to 20.79% 
+/- 12.25 in Tsc2+/+ MEFs (Figure 3.8A). To determine if this drug combination was 
synergistic, flow cytometry was carried on samples that were treated with either 
various concentrations of mefloquine, 17AAG or a drug combination that had a fixed 
ratio of 10 µM mefloquine: 1µM 17AAG. Results were analysed in CompuSyn. 
Results are presented in Table 3.1. Data showed that a concentration of 10 µM 
mefloquine and 1µM 17AAG failed to achieve the same level of cell death in Tsc2-
/- MEFs as seen in figure 3.8A (57.79% +/- 1.95 vs 69.23% +/- 10.23) and was 
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shown to be antagonistic in both cell lines (CI value = 1.28 in Tsc2+/+ MEFs and CI 
value = 1.12 in Tsc2-/- MEFs.). However, MQ/17AAG combinations were shown to 
be synergistic at 20 μM Mefloquine/ 2 μM 17AAG (CI value = 0.79 in Tsc2+/+ MEFs 
and CI value = 0.79 in Tsc2-/- MEFs.) and synergistic in Tsc2+/+ MEFs only at 40 
μM Mefloquine/ 4 μM 17AAG (CI value = 0.78 in Tsc2+/+ MEFs and CI value = 1.90 
in Tsc2-/- MEFs.) (Figure 3.8B-E). 
 
Table 3.1 Results of Mefloquine/17AAG synergy. Results for synergy assay for mefloquine and 
17AAG combinations. Results written as % Cell Death. Results also in CI value for combinations 
tested.  
 TSC2+/+ TSC2-/- 
Drug 
Average 
Cell 
Death 
(%) SD 
CI 
Value 
Average 
Cell 
Death 
(%) SD 
CI 
Value 
DMSO 1.50 0.40   3.58 1.08   
Mefloquine 40 μM 97.07 1.54   97.50 0.84   
Mefloquine 20 μM 65.65 19.01   98.18 0.60   
Mefloquine 10 μM 11.43 5.91   8.00 5.33   
Mefloquine 5 μM 2.42 0.84   2.87 1.31   
Mefloquine 2.5 μM 1.75 0.31   2.49 0.95   
17AAG 4 μM 32.92 5.91   52.35 4.80   
17AAG 2 μM 41.33 13.13   51.81 2.82   
17AAG 1 μM 23.61 6.23   41.88 6.07   
17AAG 0.5 μM 10.57 3.33   19.51 8.18   
17AAG 0.25 μM 4.31 0.71   6.42 3.17   
Mefloquine 40 μM/ 
17AAG 4 μM 97.18 0.91 0.78 90.93 4.94 1.90 
Mefloquine 20 μM/  
17AAG 2 μM 84.51 5.74 0.79 94.34 0.38 0.79 
Mefloquine 10 μM/  
17AAG 1 μM 33.53 4.56 1.28 57.79 1.95 1.12 
Mefloquine 5 μM/ 
 17AAG 0.5 μM 17.85 9.12 1.09 32.48 6.95 1.00 
Mefloquine 2.5 μM/ 
 17AAG 0.25 μM 5.52 2.10 1.50 15.91 8.77 0.93 
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Figure 3.8: Combination of mefloquine and 17AAG caused selective cell death in Tsc2-/- MEFs 
but did not synergise. (A) Flow cytometry (with scatter blots) performed to measure cell death in 
Tsc2+/+ and Tsc2-/- MEFs treated with dimethyl sulfoxide (DMSO), etoposide (ETO), mefloquine 
(MQ) or 1 μM 17AAG (17AAG) as single agents at various concentrations or in combination 
(MQ/17AAG) at various concentrations after 48 h treatment (n=3 mean+/- SD). (B-D)  Dose response 
curves were performed in Tsc2+/+ and Tsc2-/- MEFs using flow cytometry to measure cell death 
following treatment with (B) 17AAG (17AAG); (C) mefloquine (MQ) and (D) combined mefloquine 
with a fixed concentration of 10 µM nelfinavir (MQ/NFV): 1 μM 17AAG (n=3; mean +/- SD). Synergy 
was then calculated using CompuSyn and graphed (E) as F(a) value vs CI value. Statistical 
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significance is shown with combination or single agent treated Tsc2-/- MEFs compared to their wild-
type controls. 
  
3.2.6 Mefloquine/nelfinavir combination affects energy stress levels in Tsc2-/- 
cells. 
To explore alternative mechanisms that might be the cause of cell death, a more in-
depth analysis of the RNA sequencing data was carried to compare gene 
expression changes in the Tsc2+/+ and Tsc2-/- MEFs. A Heat map was generated 
for a panel of energy stress associated genes (Figure 3.9A). The Heat map 
represents RNA expression as low levels of expression (or no expression) were 
represented by blue (were the darkest blue represents lowest level of expression (a 
score of 0)). Increased RNA expression is represented by a colour shift from blue to 
white to red were the darkest red represents the highest RNA expression score (in 
this case, a score of 3445). A selection of genes was then further graphed and 
analysed (Figure 3.9C). The overall RNA sequencing data was represented in a 
volcano plot where chosen energy stress genes were highlighted (Figure 3.9B). 
Colours represent differences in expression levels which have at least a 1-fold 
difference in Tsc2+/+ MEFs (Blue) and Tsc2-/- MEFs (Red). Genes involved in the 
regulation of metabolism and energy homeostasis were shown to be up-regulated 
in the Tsc2-/- MEFs during combined treatment with nelfinavir and mefloquine. 
PPARGC1α (which is the gene for PGC1α (peroxisome proliferator-activated 
receptor gamma coactivator 1α), which is involved in mitochondrial biogenesis) was 
basally expressed at a higher level in Tsc2-/- MEFs when compared to the Tsc2+/+ 
MEFs. Genes regulated by PPARGC1α were observed to be more highly expressed 
in the Tsc2-/- MEFs when compared to Tsc2+/+ MEFs. These included genes 
involved in glucose and lipid metabolism, such as peroxisome proliferator-activated 
receptor delta (PPARδ) and gamma (PPARγ), where there is more than a 2-fold 
increase in PPARδ expression and a nearly 17-fold difference in PPARγ expression 
in the Tsc2-/- MEFs compared to the Tsc2+/+ MEFS. Expression of genes involved 
in glycolysis were also upregulated, indicating metabolic stress. This included 
pyruvate dehydrogenase kinase 1 (PDK1), pyruvate carboxylase (PCX), lactate 
dehydrogenase B (LDHB) and glycerol-3-phosphate dehydrogenase 1 (GPD1). 
AMP-dependent protein kinase (AMPK) is known to function upstream of PGC1α 
and is involved in the gene-expression of PGC1α as well as its transcriptional 
activity. AMPK-regulated genes involved in glucose metabolism/storage such as 
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acetyl-CoA carboxylase 2 (ACC2, encoded by the ACACB gene) and glycogen 
synthase 1 (GYS1) were expressed at a much higher level in Tsc2-/- MEFs and 
were further increased upon drug treatment with nelfinavir and mefloquine. HDAC5 
(which is involved in the AMPK regulation of the glucose transporter GLUT4) was 
found to be more highly expressed in Tsc2+/+ MEFs when compared to Tsc2-/- 
MEFs. However, when looking at the differences in RNA expression between cells 
treated DMSO and the mefloquine/nelfinavir combination, the introduction of the 
mefloquine/nelfinavir combination only cause significant differences in PPARGC1α, 
HAS2, GYS1 and RORA (in Tsc2-/- MEFs) and HDAC5 and HAS2 (in Tsc2+/+ 
MEFs) The overall increase of mRNA expression of key genes involved in energy 
metabolism gives evidence that the Tsc2-/- MEFs were likely energy stressed.   
To determine if the drug combination of nelfinavir and mefloquine influenced 
energy stress, flow cytometry was carried out in Tsc2-/- MEFs treated for 48 h with 
either DMSO or drug combination in the absence or presence of methyl pyruvate (a 
pyruvic ester, which can rescue cells from energy stress by freely crossing the inner 
membrane of the mitochondria and is cleaved by matrix esterases to generate 
intramitochondrial pyruvate. The additional pyruvate allows for the stimulation of 
ATP production (Gergely et al. 2009; Divakaruni et al. 2013). Methyl pyruvate was 
also shown to be more efficient than pyruvate in supporting the intramitochondrial 
conversion of pyruvate metabolites to amino acids (Jijakli et al. 1996)). Results 
showed that methyl pyruvate partially rescued cell death. To confirm that methyl 
pyruvate was restoring energy stress, western blots were carried on Tsc2-/- MEFs 
treated for 24 h in conditions identical to the flow cytometry experimentation. Results 
showed a reduction in the production of SESN2 and in the phosphorylation of both 
AMPK and ACC in Tsc2-/- MEFs treated with drug combination and methyl pyruvate 
compared to samples treated with just the drug combination.  
To determine the duration of the effects of energy stress management, 
western blots were carried on Tsc2-/- and Tsc2+/+ MEFs treated for 6 and 24 h with 
mefloquine and nelfinavir combination, in the presence or absence of methyl 
pyruvate. The data indicated that in Tsc2-/- MEFs treated with mefloquine/nelfinavir 
combination and methyl pyruvate and Tsc2+/+ MEFs had high levels of ACC 
phosphorylation at 6 h before declining at the 24 h time point. On the other hand, 
the level of ACC phosphorylation did not peak until the 24 h time point in the Tsc2-
/- MEFs treated with the drug combination only.  
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Figure 3.9: Mefloquine/nelfinavir combination affected energy metabolism and the 
introduction of methyl pyruvate rescued Tsc2-/- MEFs. (A) The RNA sequencing data used for 
Figure 3.7C−E was assessed for the expression of genes involved in energy homeostasis. A heat 
map for a panel of energy stress-linked genes was generated. Heat map shows expression as dark 
blue representing low levels of RNA expression while dark red (via going from blue to white to red) 
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represents high levels of RNA expression. A selection of genes from the Energy Stress panel were 
then further graphed in (C) (n=3; mean +/- SD). (B) A volcano plot showing the entire RNA 
sequencing where genes shown in (C) are highlighted. Statistical significance is shown comparing 
combination treated Tsc2+/+ and Tsc2-/- MEFs, comparing DMSO treated Tsc2+/+ and Tsc2-/- 
MEFs, comparing Tsc2+/+ MEFs treated with either DMSO or 10 μM mefloquine and 10 μM nelfinavir 
combination (MQ/NFV) and Tsc2-/- MEFs treated with either DMSO or MQ/NFV. (D) Tsc2-/- cells 
were treated with DMSO, MQ/NFV or mefloquine/nelfinavir combination with the addition of 8 mM 
methyl pyruvate (MQ/NFV/MP) for 48 h. Cells were then stained with DRAQ7 and % cell death 
determined by flow cytometry. Flow cytometry was carried out by Charlotte Johnson (McCann et al. 
2018) (n=3; mean +/- SD). Statistical significance (calculated by one-way ANOVA) is shown 
comparing combination treated Tsc2-/- and combination plus methyl pyruvate treated Tsc2-/- MEFs. 
(E) Tsc2-/- were treated with either DMSO or 10 μM mefloquine and 10 μM nelfinavir combination in 
the presence or absence of 8 mM methyl pyruvate for 24 h and total and phosphorylated ACC and 
AMPK and total SESN2 was determined by western blot. (F) Tsc2+/+ and Tsc2-/- cells were treated 
with either DMSO or 10 μM mefloquine and 10 μM nelfinavir combination in the presence or absence 
of 8 mM methyl pyruvate for 6 and 24 h, where indicated. Total protein levels of ACC, CHOP GADD34 
and ATF4 as well as phosphorylated ACC were detected by western blot. All Blots in figure 3.9 are 
representative of n=3 runs 
 
3.2.7 Mefloquine/nelfinavir combination did not affect the production of 
reactive oxygen species (ROS). 
To confirm if the combination was causing an effect on the production of reactive 
oxidative species (ROS), both Tsc2+/+ and Tsc2-/- MEFs were stained with DCFDA 
before being treated with several different treatments; DMSO, Tert-Butyl 
hydroperoxide (TBHP) (as a positive control), drug combination and drug 
combination with either methyl pyruvate or N-acetyl-L-cysteine (NAC) (both of which 
are known ROS scavengers so would act as negative controls). Results written as 
ROS Generation fluorescence (RGF). Results showed that the drug combination 
caused no major differences to ROS production compared to samples treated with 
just DMSO (Figure 3.10A). To determine if ROS production played a role in cell 
death, flow cytometry was carried out in Tsc2-/- MEFs treated for 24 h (as NAC is a 
short-lived inhibitor) with either DMSO, drug combination or drug combination with 
NAC. Results showed that the presence of NAC was able to partially rescue cells 
from death as cell death dropped just under 15% compared to death seen in cells 
treated with just mefloquine/nelfinavir combination (63.33% +/- 14.31 SD when 
treated with mefloquine/nelfinavir combination and NAC compared to 77.90% +/- 
15.42 SD when treated with just the combination) (Figure 3.10B). 
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Figure 3.10: Mefloquine/nelfinavir combination caused minimal effect on ROS production. (A) 
Tsc2+/+ and Tsc2-/- MEFs were stained in 25 μM 2’, 7’ –dichlorofluorescin diacetate (DCFDA) for 
45 min at 37oC. Cells were washed and treated with DMSO, tert-butyl hydroperoxide (H2O2), 
mefloquine and nelfinavir combination (MQ/NFV), combination plus N-acetyl-L-cysteine (MQ/NFV + 
NAC) or combination plus methyl pyruvate (MQ/NFV + MP) for 4 h. Fluorescence was read on a 
plate reader (excitation at 485 nm and emission at 535 nm) (n=3; mean +/- SEM). (B) Tsc2-/- MEFs 
were treated with DMSO, mefloquine and nelfinavir combination (MQ/NFV) or combination plus N-
acetyl-L-cysteine (MQ/NFV + NAC) for 24 h. Cell death was measured via flow cytometry using 
DRAQ7 staining. Statistical significance (calculated by one-way ANOVA) is shown between DMSO-
treated cells and MQ/NFV treated cells and between NAC-treated and MQ/NFV treated cells (n=3; 
mean +/- SD).  
   
3.3 Discussion: 
The purpose of this chapter was to determine an optimised concentration of 
mefloquine and nelfinavir and determine the mechanism of action that the 
mefloquine/nelfinavir combination used against Tsc2-/- MEFs. Initial experiments 
were designed to determine the optimum concentration of mefloquine and nelfinavir 
for synergistic action. This chapter also examined possible mechanisms of drug 
action to determine how the nelfinavir and mefloquine drug combination was 
selectively triggering cell death in the Tsc2-/- MEFs, while the Tsc2+/+ MEFs were 
survived treatment. 
Data from these experiments identified an optimal concentration of 10 µM 
mefloquine and 10 µM nelfinavir for inducing cell death. A second concentration of 
5 µM mefloquine and 20 µM nelfinavir was also sufficient for inducing a cell death 
response in Tsc2-/- MEFs but was less effective compared to the 10 µM mefloquine 
and 10 µM nelfinavir. Manipulating either of these concentrations caused either 
decreased effectiveness in causing cell death or loss of selective cytotoxicity to the 
Tsc2-/- MEFs. The data from these experiments have shown that the combination 
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of nelfinavir and mefloquine has a very narrow drug concentration range at which 
they are selectively cytotoxic to the Tsc2-/- MEFs. The concentrations of both drugs 
used in this study are clinically viable. As 10 µM falls within the concentration range 
of mefloquine found in patient serum (Kollaritsch et al. 2000). Regarding nelfinavir, 
the 10 µM concentration used in this study is higher than the manufacturer 
recommended trough concentration (1−3 µM). However, nelfinavir serum 
concentrations have previously been reported in HIV patients at a similar 
concentration to the 10 μM used in this chapter, ranging from 4.96 µM (Zhang et al. 
2001) up to 18 µM (Marzolini et al. 2001). In fact, it has been reported that nelfinavir 
is well tolerated in cancer patients at doses 2.5 times the FDA-approved dose for 
HIV management (Bernstein et al. 2015b).  
Previous investigations by the research team were carried out on the cytotoxic 
drug activities of a combination of nelfinavir and chloroquine (Johnson et al. 2015). 
The chloroquine/nelfinavir combination was able to block autophagy; however, the 
introduction of bafilomycin A1 prevented the accumulation of chloroquine in the 
lysosome. Since chloroquine and mefloquine belong to the same drug family, it was 
initially postulated that they should have a similar mode of drug action. Testing the 
mefloquine/nelfinavir combination for autophagic flux, results showed that this 
combination caused noticeably less autophagic inhibition in terms of LC3 
accumulation compared to chloroquine/nelfinavir combination. Levels of p62 in 
Tsc2-/- MEFs were also not altered by the mefloquine/nelfinavir combination,  
although chloroquine/nelfinavir also failed to cause any differences in protein levels 
of p62 in this project nor in published data (Johnson et al. 2015). There was also 
increased levels of cell death when bafilomycin A1 was introduced to the 
mefloquine/nelfinavir combination, contrasting with the results seen in 
chloroquine/nelfinavir treated cells (which rescued cell death). These contrasting 
findings may be explained by the use of mefloquine.  Shin et al. (2012) showed that 
inhibiting autophagy (e.g., by introducing bafilomycin A1) increased the cytotoxicity 
of mefloquine in neuroblastoma cells. Overall, these results showed that the 
combination of mefloquine/nelfinavir was unlikely to induce a cytotoxic drug activity 
by blocking autophagy, unlike chloroquine/nelfinavir combination. 
Instead, mefloquine and nelfinavir combination may trigger cell death via 
enhanced ER stress. After 6 h of mefloquine and nelfinavir treatment, Tsc2-/- MEFs 
showed robust activation of the PERK pathway (which was expected as nelfinavir is 
as a well-known ER stress enhancer (Gills et al. 2007). Results showed that the 
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mefloquine and nelfinavir combination induced higher expression levels of PERK 
pathway components compared to single agent treatments such as mefloquine. 
However, the mefloquine/nelfinavir combination only caused as a slight non-
significant increase in protein expression compared to nelfinavir, suggesting that 
nelfinavir is solely responsible for ER stress associated with the combination. The 
duration of ER stress was also investigated by examining the protein expression of 
ER stress components. The data from this experiment showed that the Tsc2-/- 
MEFs were still expressing ER stress markers at an elevated level after 48 h, a time 
point when the majority of these cells had undergone cell death. This data indicates 
that these cells were trying to recover from ER stress. To determine if ER stress is 
playing a role in cell death, a viable option would be to test cells using an ATF4 
inhibitor (since nelfinavir doesn’t effect PERK activity as discussed in chapter 1) 
such as Ursolic  acid and Tomatidine (Ebert et al. 2015) to determine if cells can be 
rescued from the mefloquine/nelfinavir treatment. While ER stress is unlikely to be 
the trigger of cell death, recovery from ER stress might contribute to the depletion 
of energy through de novo protein synthesis of chaperone and heat shock proteins 
as well as the actual protein unfolding and re-folding - processes that heavily 
consume ATP. A recent study showed that TSC2-knockdown leads to mitochondrial 
oxidative stress (Yang et al. 2018). This degree of energy stress is presumably why 
TSC2-deficent cells are vulnerable to conditions that induce energy starvation (Choo 
et al. 2010). 
During the RNA sequencing, expression of the gene PPARGC1A (that encodes 
PGC1α) was greatly increased in Tsc2-/- cells, especially when treated with the 
mefloquine/nelfinavir combination. PGC1α acts as a master regulator of 
mitochondrial biogenesis and also plays a role in energy regulation as it interacts 
with PPARγ  (Duncan 2011). PPARγ is involved with glucose metabolism and was 
also elevated in the RNA sequencing data carried out in this chapter. This study 
indicates that mitochondrial biogenesis is basally upregulated in Tsc2-/- MEFs 
compared to Tsc2+/+ MEFs, suggesting that these cells are more likely to 
experience energy deficiency when treated with nelfinavir and mefloquine. To 
confirm if energy deprivation was occurring in the treated Tsc2-/- MEFs, AMPK 
signalling was examined (which is activated when the ATP:AMP ratio in the cell 
favours higher levels of AMP (Hardie 2015)). Both the phosphorylation levels of 
AMPK and ACC (which regulates fatty acid biosynthesis) were increased in the 
presence of the nelfinavir and mefloquine drug combination supporting this 
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hypothesis. Supplementing methyl pyruvate to the media markedly reduced the 
level of AMPK and ACC phosphorylation and caused a significant recovery of cell 
death. To determine if this observed energy stress was connected to the increased 
ER stress, SESN2 levels were examined in the same manner as AMPK and ACC. 
SESN2 activates AMPK either via direct physical association or indirect 
transcriptional regulation (but only in the presence of ATF4 (Pasha et al. 2017)). 
Expression patterns for SESN2 matched those seen for both ACC and AMPK 
phosphorylation. As a result, it is possible that a combined spike in both ER and 
energy stress after mefloquine and nelfinavir treatment is responsible for cell death 
in Tsc2-/- MEFs. This may occur through caspase independent mechanisms 
triggered by PPARγ which has been shown above to be upregulated. A similar 
mechanism has been shown previously induced by Ciglitazone (a PPARγ agonist) 
(Kang et al. 2008).  
An unusual observation was made during the investigation of energy stress, in 
terms of when energy stress was at its highest. The response of Tsc2-/- MEFs 
treated with mefloquine/nelfinavir combination and methyl pyruvate (and Tsc2 +/+ 
MEFs), to increased energy stress were detected within 6 h of administration of 
mefloquine and nelfinavir combination to the cells (which coincides with the increase 
in ER stress markers at the 6 h time point), as seen in Figure 3.9F. The response 
appears to return to normal at 24 h that possibly coincides with ER stress cell 
recovery and survival in these cells. However, in Tsc2-/- MEFs treated with only the 
mefloquine and nelfinavir combination, energy stress response does not peak until 
after 24 h of treatment, showing that there is a delayed energy stress response 
compared to the other cells tested. It is possible that there is a signalling disconnect 
between mTORC1 and AMPK, which hampers effective energy sensing and causes 
energy starvation in the Tsc2-/- MEFs.  The reason for this possible delay in energy 
sensing is unknown and out of the scope of this chapter due to time restraints. 
Further investigations into why this occurs and whether this possible delayed 
response also occurs in mTORC1 hyperactive sporadic cancer cell lines should be 
investigated in the future. This will help to determine if this delayed response is a 
general mechanism for the mefloquine/nelfinavir combination or if it is cell-line 
specific.    
As ER stress and mitochondrial activity both generate ROS, the effects that the 
mefloquine and nelfinavir combination had on ROS production were tested. 
Experimental data showed that there was only a minor, non-significant increase in 
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ROS levels between control cells and Tsc2-/- MEFs treated with the 
mefloquine/nelfinavir combination. A minor, non-significant decrease in cell death 
was also observed in the rescue assay when NAC was introduced to the mefloquine 
and nelfinavir combination. Data from these two experiments showed evidence that 
ROS production may play a role (although a very minor role) in the cell death 
induced by mefloquine and nelfinavir treatment.   
One of the most interesting aspects that arose from these results was how the 
effects of mefloquine changed between cell lines. In the Tsc2-/- MEFs, mefloquine 
failed to cause significant cytotoxicity at 10 µM. However, when the same 
concentration of mefloquine was used to treat either NCI-H460 or HCT116 cells, a 
large amount of cell death was observed. One possible reason is due to AKT 
signalling. As mentioned in this chapter’s introduction, mefloquine was shown to be 
a suppressor of PI3K, AKT and mTOR via dephosphorylation of these proteins. In 
Tsc2-/- MEFs, signal transduction through AKT was decreased due to continuous 
activation of mTORC1, resulting in an increased activation of S6K1 and subsequent 
downregulation of IRS (Tavares et al. 2015). This lack of AKT activation prevents 
mefloquine working on these components in Tsc2-/- MEFs. In HCT116, NCI-H460 
cells, and MCF7 cells, on the other hand, mTORC1 hyperactivity is not due to 
mutations in TSC proteins but, instead, mutations further upstream in the PI3K-AKT 
pathway (e.g., PTEN).  
The original target population for treatment with the mefloquine and nelfinavir 
combination was TSC patients. However, complications could arise when 
considering this population for treatment. The main problem lies with mefloquine. 
Mefloquine was found to be neurotoxic in 2006 (McCarthy 2015). It was withdrawn 
from the U.S. market in 2009 by Hoffman La-Roche and has loss market shares in 
the U.K. and Australia (Remington L. Nevin 2012). Usage of mefloquine has been 
greatly curtailed by the U.S. Army in favour of doxycycline, and the British Defence 
Committee declared mefloquine to be a “drug of last resort” (Tickell-Painter et al. 
2017; Remington L. Nevin 2012). Mefloquine, on rare occasions, is known to cause 
several neuropsychiatric adverse effects, including cognitive disturbances, anxiety, 
depression, psychosis, and violence (Mawson 2013) that may persist even after 
discontinuing administration of the drug. Side effects associated with the central 
nervous system occur in 1:10,000 people although the odds rise when factors such 
as history of psychiatric problems, female sex, low body mass index and first-time 
usage are taken into account. Side effects appear to be dose-dependent  These 
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side effects may be due to mefloquine being able to potentiate dopamine, cause 
clinical anticholinergic syndrome, inhibit P-glycoprotein and interfere with calcium 
homeostasis and gap junction function in neurons (Alisky et al. 2006). Because of 
its ability to cross the blood-brain barrier, there is also a risk of mefloquine 
accumulation in the central nervous system which could worsen symptoms (Toovey 
2009). Mefloquine is not recommended for treatment in patients with a history of 
epilepsy as it has been reported to cause seizures. These reports mean that only 
20% of TSC patients could benefit from the use of the mefloquine/nelfinavir 
combination as most TSC patients suffer from some form of epilepsy and patients 
can develop TANDs (as discussed in Chapter 1) in later life.  
There are still plenty of opportunities for the mefloquine and nelfinavir 
combination as a treatment for mTORC1 hyperactive sporadic tumours. Results 
from this chapter showed that the mefloquine and nelfinavir combination worked 
exceptionally well on sporadic cancer cell lines such as HCT116 and NCI-H460. 
These initial observations showed that a mefloquine/nelfinavir combination could be 
a viable treatment option for these tumour types (i.e., colorectal and lung cancers) 
in the future should the mefloquine/nelfinavir combination pass pre-clinical and 
clinical trials. The MCF7 cell line is derived from drug resistant breast carcinoma 
cells. In the presence of the mefloquine/nelfinavir combination, cell death occurred 
in over 60% of treated cells and cell death was non-significantly enhanced by 
introducing rapamycin to the mefloquine/nelfinavir combination. As a result, further 
investigations into the use of a mefloquine/nelfinavir combination (with and without 
rapamycin) as a treatment for breast cancer should be undertaken in the future. 
The next logical step for this research would be to test the mefloquine/nelfinavir 
combination in in vivo cancer models. Murine models with xenographs of several 
different Tsc2-/- tumour types such as AML, LAM or SEGA would be suitable 
candidates. Murine models with patient-derived SEGA xenographs would also be 
extremely useful, allowing exploration of the previously mentioned risk of seizures 
and psychosis during mefloquine treatment.  
In conclusion, the data from this chapter showed that an optimised concentration 
of mefloquine and nelfinavir selectively targets mTORC1 hyperactive cells in a TSC-
based or sporadic tumour-based setting. Experimental evidence presented here 
shows that cytotoxicity caused by the mefloquine/nelfinavir combination is likely due 
to an increase in energy stress possibly in combination with an enhanced ER stress 
96 
 
burden. This energy stress cannot be optimally restored in cells without Tsc2 and 
as a result, triggers cell death.
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Chapter 4: A combination of Bortezomib and Nelfinavir 
caused selectively cell death in mTORC1 hyperactive cells 
 
4.1 Introduction:  
 
4.1.1 The proteasome 
The proteasome is a highly conserved and essential protein complex necessary for 
degrading the majority (80-90 %) of intracellular proteins in eukaryotic cells 
(Papandreou and Logothetis 2004; Dou and Zonder 2014). Because of this, the 
proteasome can make up to 1 % of the cellular protein content of eukaryotic cells 
(Buac et al. 2013). Several proteins degraded by this pathway include cell cyclins 
(that regulate the progression of cells through the cycle), several transcription 
factors (such as c-myc and  n-myc), NF-kB inhibitors (IkB), and enzymes 
(phosphatase cdc-25, tyrosine-amino transferase, topoisomerase I, topoisomerase 
IIα) (Roccaro et al. 2011).  
 The 26S proteasome was first described as a giant protease with multiple 
subunits with a combined molecular weight of 2400 kDa. The 26S proteasome is 
composed of a 700 kDa 20S core particle which consists of four subunits, two α- 
and two β-rings.  The β-rings contain multiple enzymatic sites with chymotrypsin-
like (β5), trypsin-like (β2), and post-glutamyl peptide hydrolase-like (caspase-like, 
β1) activities. The core particle is then flanked at each end by 19S regulatory 
complexes. These regulatory complexes contain a “lid” of nine or more non-
ATPases which recognise polyubiquitinated proteins and a base of 6 ATPases and 
4 non-ATPases. The base ATPases and non-ATPases are responsible for 
denaturing target proteins and deliver them to the proteolytic core (Buac et al. 2013; 
Dick & Fleming, 2010; Dou & Zonder, 2014; Papandreou & Logothetis, 2004; 
Roccaro et al. 2006).  
Because of this essential role in the cell, the proteasome and protein 
degradation has been considered as a drug target for treating cancer cells. For 
instance, inhibition of the proteasome can overwhelm the response of tumour cells 
to effectively recover from a variety of stress conditions, such as lactic acidosis, 
chromosome instability, DNA damage, ROS and heat shock, which can trigger cell 
death (Bose et al. 2014). Proteasome inhibition in mTORC1 hyperactive tumour 
98 
 
cells was shown to cause selective toxicity (Babcock et al. 2013; Siroky et al. 2017). 
It is also been shown that inhibiting just the chymotrypsin-like activity of the 20S 
core particle was able to significantly block proteasomal protein degradation 
(Nussbaum et al. 1998). 
 
4.1.2 Bortezomib 
Bortezomib is a dipeptide boronic acid derivative containing pyrazinoic acid, 
phenylalanine and leucine with boronic acid in its structure and was originally 
synthesised by Myogenics in 1995 (Dou and Zonder 2014). It became the first 
proteasome inhibitor used in humans after being fast-track approved by the FDA in 
2003 for the treatment of multiple myeloma (newly diagnosed and 
relapsed/refractory) and of relapsed/refractory mantle cell lymphoma. This was 
based on the results from a large phase II clinical trial and received full approval 
after the 2005 APEX (Assessment of Proteasome Inhibition for Extending 
Remission) phase III trial (1.3 mg/m2 for eight 21-day cycles and then three 35-d 
cycles) (Chen et al. 2011; Kapoor et al. 2012). Bortezomib (1.3 mg/m2) can be 
administered either intravenously or subcutaneously. In a phase III clinical trial in 
adults with refractory multiple myeloma, there was no significant difference 
observed between either method of administration (intravenously or 
subcutaneously) in terms of median time to first response, median progression-free 
survival median time to progression and 1-year overall survival. Subcutaneous 
administration , however, was shown to have a significant reduction in the 
incidences of peripheral neuropathy (Hoy 2013).  
Bortezomib can reversibly bind to the 20S core particle of the proteasome. 
Bortezomib has the highest affinity for the β5 subunit and has lesser affinity for the 
β1 and β2 subunits as well (Wallington-Beddoe et al. 2018). Originally, Bortezomib 
was designated as a NF-κB inhibitor, as it is able to prevent the degradation of IκB 
(a NF-κB inhibitor) (Brüning and Jückstock 2015). Another anti-cancer property of 
Bortezomib is via upregulation of the expression of NOXA (a pro-apoptotic member 
of the Bcl-2 family). Upregulation of NOXA has been shown to cause apoptosis via 
two possible methods; selective interaction with anti-apoptotic proteins of the Bcl-2 
family (Bcl-XL and Bcl-2) or by stimulating other pro-apoptotic factors (D. Chen et 
al. 2011). Bortezomib has also been shown to inhibit angiogenesis in a dose 
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dependent manner, to inhibit c-Jun and to downregulate growth factor expression 
(Roccaro et al. 2011).  
 
4.1.3 Bortezomib and blood cancers 
Bortezomib is primarily used for the treatment of blood cancers, having originally 
been approved for the treatment of multiple myeloma. In vitro studies showed that 
Bortezomib could inhibit proliferation in different myeloma cell lines including 
doxorubicin, mitoxantrone, and melphalan sensitive and resistant RPMI-8226 cell 
lines (Dou and Li 1999).  
A large phase II clinical trial (SUMMIT – Study of Uncontrolled Multiple 
Myeloma Managed with Proteasome Inhibition Therapy) showed that there was a 
35% overall (complete + partial + minimal) response rate with Bortezomib (1.3 
mg/m2 on days 1, 4, 8, and 11 of a 3-week cycle for up to eight cycles) in 202 patients 
with relapsed and refractory multiple myeloma (Richardson et al. 2003). Phase II 
clinical trials with Bortezomib have also shown promising results in the treatment of 
mantle-cell lymphoma and non-Hodgkin’s lymphoma. In patients with mantle cell 
lymphoma, there was a 46.2% response rate with Bortezomib (1.3 mg/m2 given on 
days 1, 4, 8 and 11 every 21 days) (Sehn et al. 2006). A 58% response rate to 
Bortezomib (1.5 mg/m2 on days 1, 4, 8, and 11) was observed in patients with 
indolent non-Hodgkin’s lymphoma and mantle cell lymphoma (Adams et al. 2004).  
The previously mentioned APEX phase III trial, showed that there was a 6 
month survival advantage in patients (who received at least one prior treatment) 
when compared to patients treated with dexamethasone (Richardson et al. 2007). 
In a clinical setting, Bortezomib has been shown to restore abnormal bone 
remodelling caused by myeloma by normalizing the level of bone turnover markers. 
In addition, a bone anabolic effect was described in responding myeloma patients 
treated with Bortezomib, as seen by the increase in osteoblast numbers (Aversa et 
al. 2015). Bortezomib was shown to cause induction of the lytic cycle of Epstein-
Barr virus (EBV) and Kaposi sarcoma herpes virus (KSHV). Bortezomib has also 
been shown to be able to induce the lytic cycle in human Burkitt’s lymphoma, EBV+ 
Akata cells and EBV-T lymphoma and natural killer cells at 0.5 μM (Kaluza et al. 
2006; Iwata et al. 2011). Bortezomib was also shown to have promising activity in 
Waldenström’s macroglobulinemia as a single agent (1.3 mg/m2 intravenously days 
1, 4, 8, and 11 on a 21-day cycle until two cycles past complete response (CR), 
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stable disease (SD) attained, progression (PD), or unacceptable toxicity) (Chen et 
al. 2007; Treon et al. 2007). 
 
4.1.4 Bortezomib and solid cancers  
Bortezomib has shown less clinical promise in solid cancers. For instance, 
Bortezomib failed to show efficiency compared to previously established treatments 
when tested against breast cancer, hormone-resistant prostate cancer, 
chemotherapy-naïve advanced stage non-small cell lung cancer, 
unresectable/metastatic gastric and gastroesophageal junction adenocarcinoma, 
metastatic neuroendocrine tumours, and advanced renal cell carcinoma (Dou and 
Zonder 2014). However, Bortezomib affected the growth of thyroid cancer ATC cell 
lines as a single agent or in combination with other drugs ranging from 4.5 nM up to 
10 mM (Mitsiades et al. 2006). 
 
4.1.5 Bortezomib combinations  
Combining Bortezomib with other drugs has shown degrees of clinical success. 
When Bortezomib is combined with other chemotherapies or with corticosteroids, 
response rates go from approximately 30% to between 60% and 90% (Murray et al. 
2014). In the VERTICAL phase II trial, a combination of Bortezomib (1.6 mg/m2 on 
days 1, 8, 15, and 22, cycles one to five), Bendamustine and Rituximab showed an 
overall response rate of 88% (53% complete response) in patients with relapsed 
and refractory follicular lymphoma (Shi et al. 2011). Ruan et al. (2011) carried out a 
phase I/II trial using Bortezomib (0.7 mg/m2, 1.0 mg/m2, or 1.3 mg/m2 on days 1 and 
4 for six cycles), Cyclophosphamide, doxorubicin, Vincristine, Prednisone and 
Rituximab and showed this combination had an evaluable overall response rate of 
100% with 86% complete response/unconfirmed complete response and 91% and 
72%, respectively, in refractory/relapsed mantle cell lymphoma patients. Using 
Bortezomib with lenalidomide and dexamethasone in a phase I/II trial showed a 
100% response rate in myeloma patients (75% showing a very good partial 
response or higher – although 25% of all patients did relapse after cessation of 
treatment (Dimopoulos et al. 2010)).  
 A combination of Bortezomib (1.2 mg/m2 on days 1, 4, and 8) with paclitaxel 
(175 mg/m2 on day 2) and carboplatin was tested for the treatment of solid tumours 
(Dakhil et al. 2010). However, this drug combination failed as a first-line therapy for 
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patients with metastatic oesophageal, gastric and gastroesophageal cancers. A 
combination of Bortezomib (1.3 mg/m2 on days 1, 4, 8, and 11 of an every-21-day 
cycle) and pegylated liposomal doxorubicin (30 mg/m2 on day 4) on patients with 
pre-treated metastatic breast cancer was shown to be well tolerated, however, it 
only had a minimal effect on the tumour (Irvin et al. 2010). A phase II clinical study 
of Bortezomib (1 mg/m2) and gemcitabine (1,000 mg/m2) in patients with metastatic 
pancreatic cancer showed that patients had a median survival time of 4.8 months, 
a 6-month survival rate of 41% and a 10% response rate (Alberts gills 2005). A 
positive and synergistic response was demonstrated when Bortezomib and 
irradiation (IR) were combined for the treatment of oral cancer cells (Wu et al. 2018). 
This Bortezomib (25 nM) and IR combination induced autophagic cell death via 
inhibition of IR-induced TRAF6 ubiquitination and TRAF6-mediated Akt activation. 
Bortezomib reduced TRAF6 protein expression through autophagy-mediated 
lysosomal degradation. 
 
4.1.6 Bortezomib limitations  
As with most chemotherapeutics, Bortezomib usage has been reported to have 
adverse effects on patients. The most common side effect of Bortezomib is 
peripheral neurotoxicity that occurs in 37-44% of patients. This neurotoxicity can be 
sensory, distal, symmetric and usually affects the feet more than the arms and the 
effects are usually reversible when treatment has ceased (Bose et al. 2014). Other 
common side effects include fatigue, nausea, diarrhoea, vomiting, low platelet and 
erythrocytes counts and a high rate of shingles. Less common side effects include 
headache, insomnia, joint pain, arthralgia, myalgias, oedema (of the face, hands, 
feet or legs), and low white blood cell count (Chen et al. 2011). 
 Another problem associated with Bortezomib usage is the risk of acquiring 
resistance to the drug. Bortezomib resistance can occur by several means. 
Mutations in the β5-subunit, especially substitution of Ala49, can cause resistance 
with the most common substitute being threonine as seen in myelomonocyte THP1 
cells, Jurkat cells and myeloma cell lines KMS-11 and OPM-2 (Lü et al. 2008; 
Oerlemans et al. 2008; Ri et al. 2010). Aberrant expression of the ubiquitin-
proteasome pathway components such as β5, β1 and β2 was found in Bortezomib-
resistant THP1 cells, although this was reversible after cells were placed in drug-
free media (Oerlemans et al. 2008). Bortezomib usage can cause activation of the 
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aggresome-autophagy pathway to compensate for the loss in the activity of the 
proteasome, leading to resistance (Catley et al. 2006). Another mechanism of 
resistance is that inhibition of proteasomal protein degradation with Bortezomib 
could also lead to the induction of heat shock proteins, which has been shown to 
confer resistance (Mitsiades et al. 2002). 
Interference to Bortezomib activity can also occur from external causes. The 
consumption of green tea can block the anticancer drug effects of Bortezomib. This 
occurs due to the presence of polyphenols especially (-)-epigallocatechin gallate 
(EGCG) that bind directly to boronic acid-based proteasome inhibitors, such as 
Bortezomib. Consequently, EGCG prevents the binding of Bortezomib to the 
proteasome, which was shown to prevent the triggering of ER stress and caspase-
7 activation, meaning no induction of cell death (Golden et al. 2009). 
 
4.1.7 Bortezomib and ER stress 
ER stress is caused by the accumulation of unfolded/misfolded proteins. Bortezomib 
(5-25 nM) has been shown to induce ER stress, which eventually leads to 
mitochondrial-mediated Ca2+-dependent apoptosis (Escalante et al. 2013). 
Decreased dephosphorylation of eIF2α has been shown to enhance cell death of 
Bortezomib, as cells with deregulated eIF2α have resistance to Bortezomib. When 
a non-toxic dose of salubrinal (an inhibitor of GADD34-PP1c complex) or a 
phosphorylated mimetic eIF2αS51D was used in combination with Bortezomib (4 
nmol/L), both Bortezomib-sensitive and -resistant myeloma RPMI 8226 and U266B1 
cells were nearly entirely eradicated. However, this appears to be the case only in 
blood cancers as results have been shown to be opposite in solid tumours (Schewe 
and Aguirre-Ghiso 2009). Bortezomib (10 nM) was tested against a panel of 10 
pancreatic cancer cell lines and found that cell lines with defective induction of eIF2α 
phosphorylation had a higher level of drug sensitivity. Bortezomib-sensitive cell lines 
showed impaired translation attenuation which led to a toxic accumulation of protein 
aggregates and ROS. On the other hand, Bortezomib-resistant cell lines displayed 
increased levels of eIF2α phosphorylation, had decreased translation, few protein 
aggregates, and minimal ROS production (White et al. 2018). 
Heat shock protein 90 (HSP90) is a chaperone protein that assists in the 
folding and function of proteins, stabilises proteins from heat stress and aids protein 
degradation. The use of HSP90 inhibitors and Bortezomib in combination have 
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shown varying degrees of success. A combination of 17AAG (150mg/m2) with 
Bortezomib (0.7mg/m2) in a clinical trial for patients with acute myeloid leukaemia, 
showed no clinical response but reported severe adverse effects (Walker et al. 
2013). On the other hand, tanespimycin (another HSP90 inhibitor) had a better 
response when combined with Bortezomib. This tanespimycin (100-340 mg/m2) and 
Bortezomib (0.7-1.3 mg/m2 given on days 1, 4, 8 and 11 in each 21 day cycle 
combination) showed a 27 % objective response rate in refractory and relapsed 
multiple myeloma and was well tolerated (Richardson et al. 2011). However, this 
combination failed to have any effect on solid tumours (Schenk et al. 2013). 
Inhibiting Ca2+-dependent enzyme, calpain has been shown to enhance cell death 
in myeloma cells via inhibiting autophagic survival response (which can cause 
Bortezomib resistance). A combination therapy with Bortezomib and Nelfinavir was 
shown to inhibit calpain, reversed Bortezomib resistance and induced near-
complete tumour regressions in a SCID mouse xenograft model of myeloma 
(Escalante et al. 2013).  
 
4.1.8 Bortezomib and nelfinavir  
As mentioned in the last section, a Bortezomib and nelfinavir combination was able 
to cause a regression of tumour xenograft in myeloma mouse models. However, 
this is not the only time this combination has been tested. A combination of 
Bortezomib and Nelfinavir was shown to target cisplatin-resistant cervical cancer 
cell line (SiHa) via caspase-like proteasome activity which in turn triggered 
apoptosis. The Bortezomib (20 ng/ml)/nelfinavir (20 μg/ml) combination was able to 
enhance an apoptosis-inducing TRAIL receptor antibody against SiHa cells 
(Bruning et al. 2011). The Bortezomib (15 ng/mL) and nelfinavir (15 μg/ml) 
combination was also shown to inhibit mTOR activity via ATF4-mediated SESN2 
upregulation in several cancer cell lines including breast (MDA-MB-453), ovarian 
(OVCAR3) and cervical adenocarcinoma (HeLa) (Brüning et al. 2013).  
Combinations of nelfinavir and Bortezomib were shown to synergistically kill 
NSCLC (H157 and A549) and multiple myeloma (RPMI 8226 and L363) cell lines 
via the induction of ER stress markers and apoptosis (Kawabata et al. 2012). It was 
also found that nelfinavir (20 μM) augments proteasome inhibition by Bortezomib 
(20 nM) in myeloma cells (Kraus, Bader, Overkleeft, & Driessen 2013). Combined 
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nelfinavir and Bortezomib therapies have also been trialled in several clinical trials 
(ClinicalTrials.gov: NCT01164709, NCT02188537, NCT01555281). 
 
4.1.9 Hypothesis 
In non-cancerous cells, autophagy and the proteasome work together to breakdown 
old or damaged proteins to recycle amino acids back into protein synthesis. 
However, in mTORC1 hyperactive cancer cells, autophagy is suppressed due to 
persistent inhibitory phosphorylation of ULK1 by mTORC1. At the same time, 
mTORC1 activation mediates increased expression of proteasome genes through 
the induction of NRF1 (Zhang et al .2014). As a result of hyperactive mTORC1, 
protein degradation and recycling of amino acids solely relies on the proteasome, 
making targeting the proteasome a potential vulnerability. To determine if inhibiting 
the proteasome would cause selective cell death in Tsc2-/- MEFs, while being 
tolerated by Tsc2+/+ MEFs, a combination of Bortezomib and Nelfinavir (both ER 
stress inducers which inhibit the proteasome) were used on these cell lines. The 
results from this chapter were published in (Johnson et al. 2018).       
 
4.2 Results: 
 
4.2.1 A combination of Bortezomib and nelfinavir selectively targeted Tsc2-/- 
cells in a caspase-dependent manner.  
To determine if a combination of Nelfinavir and Bortezomib selectively induced cell 
death in Tsc2-/- MEFs compared to Tsc2+/+ MEFs. Cell death was quantified by 
flow cytometry after 24 h treatment with DRAQ7 labelling using MG132 (another 
proteasome inhibitor), as a single agent and in combination with 20 μM Nelfinavir 
as a control. Both MG132 and Bortezomib as single agents caused selective cell 
death in the Tsc2-/- MEFs but not in Tsc2+/+ MEFs, indicating that Tsc2-/- MEFs 
are dependent on the proteasome for their survival (17.89% +/- 0.732 SD in Tsc2+/+ 
MEFs vs approximately 63.89% +/- 8.16 SD in Tsc2-/- MEFs when treated with 
MG132 and approximately 11.28% +/- 6.10 SD in Tsc2+/+ MEFs vs approximately 
41.42% +/- 9.09 SD in Tsc2-/- MEFs when treated with Bortezomib). Treatment with 
Bortezomib/Nelfinavir combination enhanced cell death in the Tsc2-/- MEFs (83.2% 
+/- 9.2 SD cell death), with minimal toxicity observed in the Tsc2+/+ MEFs (17.5% 
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+/- 7.7 SD). The low level of cell death in the Tsc2+/+ MEFs was not significantly 
different to the DMSO vehicle control. A similar pattern was observed for the 
MG132/Nelfinavir combination (24.70% +/- 7.07 SD in Tsc2+/+ MEFs and 89.00% 
+/- 7.39 SD in Tsc2-/- MEFs) (Figure 4.1A).  
  To further examine cell death in Tsc2-/- MEFs, several apoptosis markers 
were analysed by western blot after both Tsc2+/+ and Tsc2-/- MEFs were treated in 
an identical manner as the flow cytometry. We observed cleavage of caspase 8, 
caspase 3 and PARP in Tsc2-/- MEFs upon treatment with Bortezomib alone or co-
treatment with nelfinavir and proteasome inhibitors, whilst no cleavage was 
apparent in wild-type cells (Figure 4.1B).  
 
 
Figure 4.1: The combinations of Bortezomib/nelfinavir and MG132/nelfinavir selectively 
targeted Tsc2-/- MEFs in a caspase-dependent manner. (A) Flow cytometry carried out to 
determine cell death in Tsc2-/- and Tsc2+/+ MEFs treated with DMSO, 1 μM MG132, 50 nM 
Bortezomib (BTZ), 20 μM nelfinavir (NFV) or in combination for 24 h. Cell death was determined via 
DRAQ7 staining (n=3; mean +/- SD). (B) To determine if caspase activity was affected by 
combinations, Tsc2-/- and Tsc2+/+ MEFs were treated in an identical manner as seen in (A) (with 
the addition of 100 μM etoposide was also used as a control) for 24 h. Total protein levels of Caspase-
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8 (CASP8), Caspase-3 (CASP3), PARP, phospho-rpS6 and β-actin were measured by western blot 
analysis. Flow cytometry was carried out by Dr. Charlotte Johnson and western blotting was carried 
out by Dr. Sara Seifan. All Blots in figure 4.1 are representative of n=3 runs 
 
4.2.2 Bortezomib/nelfinavir combination killed tumour spheroids and 
prevented outgrowth. 
To determine the effects of Bortezomib/nelfinavir on established tumours in a 3D 
environment, Tsc2-/- MEFs were incubated for 72 h on an agarose layer to form 
spheroids and photographed before being treated with drugs for 96 h (the last 48 h 
including DRAQ7) before being photographed again. Treated spheroids were then 
placed in fresh non-drug media for 72 h (photographed every 24 h) to determine the 
amount of outgrowth from spheroids (i.e., indicate whether tumours were still viable). 
Because of the prolonged exposure to the drug (as opposed to 2D models) the 
concentration of Bortezomib was reduced from 50 nM to 20 nM and 10 nM 
Rapamycin was used as a control. Results showed that there was no change in size 
between treatment conditions after 96 h of treatment, except rapamycin-treated 
samples as a size reduction was observed (as expected). Treated groups were also 
tested for the amount DRAQ7 fluorescence (as an indicator of the extent of cell 
death). Results showed that while there were no major differences between DMSO 
and rapamycin treated spheroids, there was a 2-fold increase in DRAQ7 staining in 
spheroids treated with Bortezomib/nelfinavir combination (Figure 4.2A). Once 
placed back into clean media, spheroids incubated in Bortezomib/nelfinavir 
combination failed to regrow after 72 h. All other spheroids did eventually grow back, 
although rapamycin treated spheroids grew at a much slower rate compared to 
DMSO treated spheroids (Figure 4.2B).    
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Figure 4.2: Bortezomib caused cell death in established tumour spheroids and prevented 
outgrowth. (A) Tsc2-/- MEF spheroids were treated with DMSO vehicle control, 20 μM nelfinavir 
combined with 20 nM Bortezomib (NFV BTZ), or 25 nM rapamycin (RAP), for 96 h. DRAQ7 was 
added for the final 48 h to monitor cell death before images were taken and quantified. Spheroid 
diameter was determined from phase contrast images after 96 h drug treatment and plotted against 
DRAQ7 staining intensity. Statistical significance (calculated by one-way ANOVA) shows 
significance between DMSO and BTZ/NFV treated spheroids in terms of fluorescence (n=3; mean 
+/- SEM).  (B) Spheroids were re-plated onto standard tissue culture plates and grown under drug-
free conditions. Images were taken every 24 h and the area of outgrowth calculated using Image J 
(n=3). Scale bar is 200 μm and outgrowth areas are graphed. Work done in this figure was in 
collaboration with Dr. Elaine Dunlop (generated graphs) and Dr. Sara Seifan (assisted in taking 
images for outgrowth assay). Henry McCann generated images for (A) and (B). Statistical 
significance (calculated by one-way ANOVA) shows significance in outgrowth rate between DMSO 
and BTZ/NFV treated spheroids and between DMSO and RAP treated spheroids.  
 
4.2.3 Bortezomib/nelfinavir combination induced enhanced and prolonged ER 
stress in Tsc2-/- cells via the PERK pathway. 
To determine the effects the combined Bortezomib/nelfinavir treatment would have 
on the ER stress pathway, western blots were performed on Tsc2+/+ and Tsc2-/- 
MEFs treated for 6 h with drug treatment. Thapsigargin was used as positive control. 
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In the Tsc2-/- samples, there were high levels of expression for several components 
of the PERK pathway such as GADD34, CHOP and ATF4 when cells where treated 
with single agents; nelfinavir, Bortezomib and MG132 and with thapsigargin. 
Expression levels were also shown to be higher in the presence of either 
Bortezomib/nelfinavir or MG132/nelfinavir combination when compared to single 
agents or control.  Results showed that there was an increased expression of ATF4 
in MG132/nelfinavir treated Tsc2+/+ MEFs compared to Bortezomib/nelfinavir 
treatment while Bortezomib/nelfinavir treated cells had higher expression of CHOP 
compared to MG132/nelfinavir treatment in both cell lines. Ubiquitin blots show 
accumulation of ubiquitin in any cells treated with Bortezomib, MG132 or their 
respective combination showing an inhibition of the proteasome. Blots show that 
accumulation of ubiquitin is higher in single agent treated cells compared to 
combination treated cells.  Results also confirmed that Tsc2-/- MEFs had no TSC2 
expression (Figure 4.3A).  
 To determine how long this enhanced ER stress persisted, western blots 
were carried out on Tsc2+/+ and Tsc2-/- MEFs treated for either 6, 16 or 24 h with 
Bortezomib/nelfinavir combination or DMSO. In Tsc2+/+ MEFs treated with the 
combination, there was an increased expression of CHOP and ATF4 at the 6 h time 
point, but this steadily decreased at 18 and 24 h (although there a tiny increase in 
CHOP at the 24 h time point). However, Tsc2-/- MEFs showed high expression 
levels of ATF4 and CHOP (higher than those observed in the wildtype samples) at 
the 6 h time point. At the 16 h time point, expression of both proteins plummeted 
before rebounding at the 24 h time point (compared to the Tsc2+/+ MEFs) (Figure 
4.3B).  
 To confirm that ER stress was occurring, an investigation into XBP1 splicing 
(an event which only occurs in an ER stress environment due to activation of IRE1α) 
was carried out. Cells were treated for 6 h with drug, using thapsigargin as a positive 
control, before mRNA was extracted and converted to cDNA. Results were then 
processed by PCR and analysed on an agarose gel. Results showed that splicing 
occurs at a higher level in Tsc2-/- MEFs compared to Tsc2+/+ MEFs. With Tsc2-/- 
cells, splicing occurred in samples treated with the combined Bortezomib/nelfinavir 
treatment at a much higher rate compared to Bortezomib and DMSO although 
splicing levels were almost identical to those seen in thapsigargin and nelfinavir 
treated cells (Figure 4.3C). 
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 To determine the effect of inhibiting the PERK pathway would have on the 
Bortezomib and nelfinavir treated cells, Tsc2-/- MEFs were pre-treated for 30 min 
with 2 μM GSK2606414 (a PERK inhibitor), before being treated with 
Bortezomib/nelfinavir for 24 h. Flow cytometry was then carried out on samples. 
Results showed that not only did GSK2606414 fail to rescue cells, but instead 
enhanced cell death, 55.43% +/- 4.30 SD when treated with just combination vs 82.4 
3% +/- 6.00 SD when GSK2606414 was included (Figure 4.3E).  
 Elevation of protein synthesis by mTORC1 hyper-activation is likely to drive 
ER stress in TSC2 deficient cells but has not been examined to date. To determine 
the effects of the Bortezomib/nelfinavir combination on de novo protein synthesis, 
cells were treated in methionine-free media with treatment for 6 h before being 
labelled with 12.5 mCi/ml 35S-methionine for 20 min prior to harvesting in extraction 
buffer. Samples were then quantified using Bradford assay and results were 
reported in terms % positive control. Results showed the Tsc2-/- MEFs naturally 
have a much higher level of protein synthesis compared to Tsc2+/+ MEFs (346.2 % 
+/- 56.78 % vs 100 % +/- 0.0007 %). In terms of combination, there was a significant 
drop in protein synthesis in both cell lines with regards to their respective controls 
(24.7% +/- 14.74% in Tsc2+/+ MEFs vs 61.8% +/- 28.11% in Tsc2-/- MEFs) (Figure 
4.3D). 
110 
 
 
Figure 4.3: Bortezomib/nelfinavir combination affected ER stress and protein synthesis. (A) 
Tsc2+/+ and Tsc2-/- MEFs were treated with either DMSO, 1 µM thapsigargin (TPG), 50 nM 
Bortezomib (BTZ), 1 μM MG132, 20 µM nelfinavir (NFV), Bortezomib and nelfinavir combination 
(BTZ/NFV) or MG132 and nelfinavir combination (MG132/NFV) for 6 h, where indicated. Total protein 
levels of TSC2, IRE1α, ATF4, CHOP, GADD34, Ubiquitin and β-actin were detected by Western blot. 
Work was carried out by Dr. Charlotte Johnson. (B) Tsc2+/+ and Tsc2-/- MEFs were treated with 
DMSO or BTZ/NFV combination for 6 h, 16 h and 24 h. Total protein levels of ATF4, CHOP and β-
actin were determined by Western blot (C) XBP1 mRNA splicing was determined from the same 
treatments as described in (A) (except for MG132 and MG132/NFV). PCR products were resolved 
on agarose gels (unspliced = 480 bp upper band, spliced = 454 bp lower band). Work was done with 
the assistance of Dr. Elaine Dunlop. (D) Levels of protein synthesis were determined for both DMSO 
control cells and BTZ/NFV treated cells after 6 h treatment using 12.5 mCi/ml 35S-methionine and 
quantified using Bradford assay. Work was done with the assistance of Dr. Andrew Tee (E) Effects 
of inhibiting ER stress while cells were treated with BTZ/NFV combination were determined by 
treating Tsc2-/- MEFs with DMSO, BTZ/NFV combination or BTZ/NFV combination with 2 μM 
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GSK2606414 (PERK inhibitor) (BNP) (n=3; mean +/- SD). Cell death determined by flow cytometry 
and DRAQ7 staining. Statistical significance (calculated one-way ANOVA) was shown between 
Tsc2+/+ and Tsc2-/- MEFs in terms of protein synthesis and between MEFs treated with DMSO and 
BTZ/NFV (n=3; mean +/- SD). Statistical significance was also shown (by one-way ANOVA) between 
Tsc2-/- MEFs treated with BTZ/NFV and BNP. All Blots in figure 4.3 are representative of n=3 runs 
 
4.2.4 Bortezomib/nelfinavir combination did not affect energy stress levels  
To determine if the Bortezomib/nelfinavir combination affected energy levels within 
treated cells, Tsc2-/- MEFs were treated with DMSO, combination or combination 
with methyl pyruvate for 24 h. Cells were then tested for cell death using flow 
cytometry and DRAQ7 staining. Results showed that the introduction of methyl 
pyruvate was not able to rescue the treated cells from death, but instead caused a 
slight increase in the amount of cell death (73.77% +/- 18.16 SD in combination 
treated MEFs vs 78.13% +/- 9.35 SD in combination plus methyl pyruvate treated 
MEFs). Western blot was carried out to show that methyl pyruvate was effectively 
restoring energy stress (e.g., was sufficient to reduce phosphorylation of AMPK and 
ACC). Blots confirmed that methyl pyruvate was functioning accordingly (Figure 
4.4A). 
 
4.2.5 Nelfinavir and Bortezomib/nelfinavir combination blocked P-
glycoprotein activity in Tsc2+/+ and Tsc2-/- MEFS. 
Bortezomib is a substrate of P-glycoprotein and it has been shown that P-
glycoprotein expression causes resistance in cells treated with Bortezomib 
(O’Connor et al. 2013). To determine the effects that the Bortezomib/nelfinavir 
combination could have on P-glycoprotein activity, both Tsc2+/+ and Tsc2-/- MEFs 
were treated with either the Bortezomib/nelfinavir combination or control, with all 
treatments containing 5.25 µM of Rhodamine 123 (which is a substrate of P-
glycoprotein) for 30 min at 37oC. Samples were then lysed in warmed deionised 
water and fluorescence reading was taken. Results were recorded as a % of DMSO 
treated control. Data confirmed that Bortezomib failed to inhibit P-glycoprotein (as 
seen in the small increase in rhodamine 123 uptake) (115.19% +/- 2.82 SEM in 
Tsc2+/+ MEFs vs 105.59% +/- 7.61 SEM in Tsc2-/- MEFs). In Tsc2-/- MEFs 
treatment with nelfinavir, there was a slight increase in Rhodamine 123 uptake 
(127.47% +/- 7.42 SEM) indicating a minor decrease in p-glycoprotein activity (as a 
higher uptake of Rhodamine 123 indicates decreased p-glycoprotein function). In 
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Tsc2+/+ MEFs, on the other hand, nelfinavir caused a large inhibition of activity (i.e., 
a large uptake of rhodamine 123) in Tsc2+/+ MEFs (166.80% +/- 7.16 SEM) The 
combination of Bortezomib and nelfinavir surprisingly caused moderately high levels 
of activity inhibition (large increase in Rhodamine 123 uptake) in both cell lines 
(153.18% +/- 14.00 SEM in Tsc2+/+ MEFs compared to 148.71% +/- 3.74 SEM in 
Tsc2-/- MEFs) (Figure 4.4B). 
 
 
Figure 4.4: The effects of Bortezomib/nelfinavir combination of energy stress and P-
glycoprotein inhibition. (A) Tsc2−/− cells were treated with DMSO, 50 nM Bortezomib and 20 μM 
nelfinavir combination (BTZ/NFV) or BTZ/NFV combination with the addition of 8 mM methyl pyruvate 
(BTZ/NFV/MP) for 24 h. Cells were then stained with DRAQ7 and % cell death determined by flow 
cytometry (n=3; mean +/- SD). Total protein levels and phosphorylation of ACC and AMPK was 
determined by western blot. (B) Tsc2+/+ and Tsc2-/- MEFs were treated with DMSO, 50 nM 
Bortezomib, 20 μM nelfinavir or a combination of BTZ/NFV (all containing 5.25 μM Rhodamine 123) 
for 30 min at 37oC before being lysed in warmed deionised water. Fluorescence was analysed via 
plate reader at excitation at 480 nm and emission at 520 nm (n=3; mean +/- SEM). Statistical 
significance is shown between Nelfinavir treated Tsc2+/+ and Tsc2-/- MEFs. All Blots in figure 4.4 
are representative of n=3 runs 
 
4.3 Discussion: 
The purpose of this chapter was to determine whether a combination of Bortezomib 
and nelfinavir could be used to selectively target Tsc2-deficient cells while being 
well tolerated by wildtype cells. Experimental data from flow cytometry showed that 
after just 24 h, the Bortezomib/nelfinavir combination caused selective cytotoxicity 
in Tsc2-/- MEFs. This contrasts with the control MEFs treated with the 
Bortezomib/nelfinavir combination that showed only a very minor increase in cell 
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death compared to cells treated with DMSO. A similar result was seen in cells 
treated with the MG132 and nelfinavir combination, however cell death was slightly 
higher in both cell lines after 24 h. As single agents, Bortezomib and MG132 were 
both able to cause selectivity in cell death in the Tsc2-deficent cells, although at a 
lower level compared to when both were combined with nelfinavir. This gives 
evidence that cells which are Tsc2-deficient cells are highly sensitive to inhibition of 
proteasome inhibition. The reason for this is likely due to hyperactivity of mTORC1, 
which suppresses autophagy and makes these cells more dependent on 
proteasomal activity (which mTORC1 hyperactivity enhances). The combinations of 
either Bortezomib or MG132 with nelfinavir were observed to trigger caspase and 
PARP cleavage, which is indicative that both Bortezomib/nelfinavir and 
MG132/nelfinavir combinations induced apoptosis. To confirm if caspase 8 
cleavage is triggering cell death, further testing into caspase 8 activity should be 
done. An easy method of testing activity would be to treat cells with Z-IETD-FMK (a 
caspase 8 inhibitor) and investigate whether the introduction of Z-IETD-FMK is able 
to rescue cells treated with the bortezomib/nelfinavir combination. 
 During the tumour outgrowth experiment (i.e., 3D modelling), it was decided 
that Bortezomib should be reduced to 20 nM Bortezomib compared to the rest of 
this chapter. This was because when spheroids treated with 50 nM Bortezomib as 
a single agent failed to grow back after replating into fresh media (data not shown). 
This showed that established spheroids are incredible sensitive to Bortezomib as a 
single agent at 50 nM. It is worth mentioning that the reduction in the concentration 
of Bortezomib to 20 nM still killed the spheroids when combined with nelfinavir. This 
indicates that in the Bortezomib and nelfinavir combination, the concentration of 
Bortezomib used can be reduced without affecting the cytotoxic ability of the 
Bortezomib/nelfinavir combination. This evidence could be useful in future 
experiments as it could reduce the risk of adverse effects in in the clinic through 
using a reduced concentration of Bortezomib.  
 As seen with all the nelfinavir-based combinations used in this thesis, 
Bortezomib/nelfinavir and MG132/nelfinavir combinations showed high levels of 
expression of ER stress biomarkers such as ATF4, CHOP and GADD34 in the Tsc2-
deficient cell lines. The time course experiments analysing ER stress components 
showed differences of ER stress induction and recovery between MEF cell lines. In 
the Tsc2+/+ MEFs, there was a high level of expression of ATF4 and CHOP at the 
expected 6 h time point after treatment with Bortezomib and nelfinavir before 
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steadily declining to normal levels at 16 and 24 h time points (although there was a 
tiny increase in CHOP expression at 24 h). On the other hand, in the treated Tsc2-
/- MEFs, the expected expression levels of ATF4 and CHOP were observed at 6 h 
before declining at 16 h. However, expression levels rebound at 24 h, although at a 
lower level than at 6 h. The re-expression of ER stress markers, ATF4/CHOP, 
indicates that expression of these ER stress markers is biphasic, and that cell death 
in Tsc2-deficient cells can be influenced by the second spike of CHOP expression 
during the later time points. There appears to be no real difference in the level of 
XBP1 splicing between the Tsc2-/- MEFs treated with either nelfinavir or nelfinavir 
in combination with Bortezomib. This indicates that nelfinavir is solely responsible 
for inducing XBP-1 splicing.  
 In non-tumourgenic cells, down-regulated protein synthesis in an ER 
stressed environment is an efficient strategy that prevents the further build-up of 
unfolded protein within the ER. In Tsc2-deficient MEFS, there was elevated protein 
synthesis despite higher background levels of ER stress, with a 4-fold increase in 
protein synthesis in Tsc2-/- MEFs compared to wild-type controls. These elevated 
levels of protein synthesis would likely further promote ER stress within the Tsc2-
deficient cells. As well as promoting translation, mTORC1 hyperactivation increased 
the activity of the proteasome while reducing autophagy. As discussed above, 
downregulation of autophagy means the proteasome becomes the principal 
mechanism to reduce ER stress via protein degradation in mTORC1-driven cells.  
The introduction of the combined treatment of Bortezomib with nelfinavir to 
Tsc2+/+ and Tsc2-/- MEFs caused a dramatic reduction in the levels of protein 
synthesis. For instance, protein synthesis was nearly non-existent after 6 h of 
Bortezomib/nelfinavir treatment in both the Tsc2-/- and Tsc2+/+ MEFs. The 
introduction of the PERK inhibitor, GSK2606414 was shown to cause a large 
increase in cell death in the Tsc2-/- MEFs after 24 h of treatment with both nelfinavir 
and Bortezomib. This gives evidence that the induction of ER stress via PERK was 
required for cell survival during treatment with ER stress inducers. By blocking 
PERK pathway activation, it is possible that Tsc2-/- MEFs were unable to tolerate 
higher levels of ER stress. This piece of evidence could be useful for the 
development of future combinations for mTORC1 hyperactive cells.  
 The work in this chapter demonstrated for the first time that functional loss of 
TSC2 and subsequent mTORC1 hyperactivation sensitised cells to combined 
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proteasomal inhibition and ER stress induction. These findings have clinical 
relevance in stratified medicine, where cancers with a compromised signal 
transduction through the PI3K-AKT-mTORC1 pathway may be sensitised to 
nelfinavir and Bortezomib. This data implies that high ER stress burden along with 
hyperactive mTORC1 signalling could function as predictive biomarkers of drug 
efficacy when considering combined nelfinavir and Bortezomib treatment.  
In conclusion, the combination of Bortezomib and nelfinavir was successfully 
able to selectively kill Tsc2-/- cells while being well tolerated by wildtype controls in 
an apoptotic manner caused by prolonged ER stress and proteasome inhibition.
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Chapter 5: Drug screen identified a combination of 
cepharanthine and nelfinavir that selectively targeted 
Tsc2-/- cells. 
 
5.1 Introduction:  
 
5.1.1 Piperlongumine 
Piperlongumine (also called piplartine) is an amide alkaloid which is a biologically 
and pharmacologically active constituent of the plant Piper longum (Long pepper) 
from South East Asia (Farooqi et al. 2018; Piska et al. 2018). Piperlongumine has 
become a compound of interest in the field of cancer research due to its ability to 
selectively kill a variety of cancer cell types via targeting the JAK-STAT, NF-κB and 
PI3K/AKT/mTOR pathways (Farooqi et al. 2018).  
A combination of piperlongumine (5 mg/kg) and approved chemotherapeutic 
agent gemcitabine (25 mg/kg) was shown to cause cell death in pancreatic ductal 
adenocarcinoma (PDAC) cell lines, MIA PaCa-2 and PANC-1. Cell death was 
caused through a caspase-dependent mechanism via increased ROS levels and 
caused cell cycle arrest in the G0/G1 phase of the cell cycle (Mohammad et al. 
2018). A similar result was demonstrated when piperlongumine (up to 8 μM) was 
combined with cotylenin A (a plant growth regulator – 15 μg/ml) although in this 
combination, elevated levels of ROS production caused cell death via ferroptosis 
(programmed cell death dependent on iron and characterized by the accumulation 
of lipid peroxides) (Yamaguchi et al. 2018).  
 Piperlongumine (up to 5 μM) has also been proven to cause cell death in 
several other cancer cell lines. For instance, piperlongumine was shown to be able 
to target the cancer stem cell population in oral cancer cell line models (SAS and 
CGHNC8) via gene-expression of stemness-related transcription factors, SRY-Box 
2, POU class 5 homeobox 1, and Nanog homeobox (Chen et al. 2018).  A 
combination of piperlongumine (10 μM), and the p53-reactivator, APR246 (25 μM), 
demonstrated selective induction of apoptosis and autophagic cell death in a  head 
and neck squamous cell carcinoma (HNSCC) cell line (UMSCC10A) via ROS 
production and suppression of glutathione (GSH) S-transferase pi 1 (GSTP1, a GST 
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family member that catalyses the conjugation of GSH with electrophilic compounds 
to fulfil its detoxification function) (Li et al. 2018a).  
 Piperlongumine has also been shown to have antiproliferative properties in 
the lung cancer cell line A549 via increased ROS production, decreased expression 
of cyclin D1, CDK4, CDK6 and p-Rb (retinoblastoma), suppressed phosphorylation 
of AKT (but increased ERK1/2 phosphorylation) and significantly decreased nuclear 
translocation of NF-κB p65 in cells when treated with 40 μM of piperlongumine (Seok 
et al. 2018). It was observed that  piperlongumine inhibited cell growth and induced 
apoptosis via ROS mediated mitochondrial disruption and interference of the JNK 
pathway in the melanoma cell line A375 (Xiong et al. 2018). Furthermore, a study 
showed that piperlongumine nanoparticles had anticancer activity in vitro against 
colorectal cancer cell lines, A549 and CT26 cells, and anti-metastatic activity in an 
in vivo CT26 cell pulmonary metastasis mouse model (Cha et al. 2018). 
 
5.1.2 Chelerythrine Chloride  
Chelerythrine is a natural benzo[c]phenanthridine alkaloid and is extracted from 
plant species, such as Chelidonium majus, Macleaya cordata, and Sanguinaria 
Canadensis. Chelerythrine was originally identified as an inhibitor of protein kinase 
C (PKC) 9 and the Bcl-2 family proteins (Wu et al. 2018a). However, it is now known 
that chelerythrine has multiple drug targets/mechanisms depending on the cancer 
cell line being used. In NSCLC cell lines, chelerythrine (up to 20 μM) was shown to 
cause a decrease in cell viability and colony formation, and induced apoptosis in a 
concentration-dependent manner in A549 and NCI-H1299 cells via increased ROS 
production (Tang et al. 2018). Chelerythrine was observed to induce distinctive 
autophagy in both cell lines (accompanied autophagy in the A549 cells and pro-
death autophagy in the NCI-H1299 cells). Another study demonstrated that a 
combination of chelerythrine with Erlotinib (an EGFR tyrosine kinase inhibitor) in SK-
MES-1, A549, HCC827, SK-MES-1 and A549 cells had additive effects (He et al. 
2017).This combination of chelerythrine (5 μM) with Erlotinib (5 μM) was able to 
decrease cell viability, clonogenicity, migratory and invasive capabilities and induce 
apoptosis via effectively blocking EGFR signalling through decreased protein 
phosphorylation of downstream targets such as STAT3, ERK1/2, p38 MAPK and 
Bad. 
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More recently it was showed that chelerythrine (5 μM) selectively inhibited 
the growth of triple-negative breast cancer (TNBC) cell lines compared to non-TNBC 
cell lines and was able to induce apoptosis in these cell lines via inhibition of Protein 
Kinase N2 (PKN2 – a PKC subtype). It was also shown that chelerythrine 
synergistically targeted TNBC cell lines when combined with the chemotherapy 
reagent, taxol (Lin et al. 2017). In MCF7 cells, chelerythrine (10 μM) was found to 
down regulate the gene-expression of VEGFA, BCL2 and KRAS (genes involved in 
evasion, angiogenesis and self-sufficiency of cancer cells) via binding to in cellulo 
quadruplex motifs found at the promoter regions of these oncogenes (Kundu et al. 
2017). 
Chelerythrine has also been able to target several other cancer cell lines. For 
instance, it was demonstrated that chelerythrine (up to 10 μM) suppressed the 
growth of renal cancer cell lines, HEK-293 and SW-839, in a time- and dose-
dependent manner and was able to induce apoptosis in these cell lines via 
significantly decreasing phosphorylation of extracellular signal-regulated kinase 
(ERK) and AKT, upregulation of p53, B-cell lymphoma 2 (Bcl-2)-associated X 
protein (Bax), cleaved caspase-3 and cleaved poly (adenosine diphosphate-ribose) 
polymerase (PARP), and downregulation of Bcl-2, caspase-3 and PARP (Chen et 
al. 2016). A recent study described that chelerythrine could change the cell 
cytoskeletal structure of hepatocellular carcinoma cancer (HCC) cell line Hep3B, by 
reducing the expression of p-FAK (focal adhesion kinase), as well as inhibiting 
metastasis by downregulating the expression of MMP-2/9 (matrix 
metalloproteinase) mainly through the PI3K/AKT/mTOR signalling pathway (Zhu et 
al. 2017b). It was found in prostate cancer that chelerythrine (10 μM) caused an 
increased accumulation of ROS, leading to a rise in ER stress and apoptosis (Wu 
et al. 2018a).  An unbiased drug screen in TSC2-null patient-derived cells that 
examined the loss of cell viability was carried out and identified chelerythrine 
(Medvetz et al. 2015). In this study, chelerythrine (2 μM) was found to induce ROS 
and to deplete GSH selectively in TSC2-null cells, resulting in selectively induced 
necroptosis. 
 
5.1.3 BPTES 
Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulphide (BPTES) is an 
allosteric glutaminase (GLS) inhibitor (Xiang et al. 2015) which binds to the loop 
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segment of the protein that regulates access of glutamine to the active site and to 
the dimer:dimer interface that participates in the phosphate-dependent 
oligomerization and activation of the enzyme (McDonald et al. 2014). BPTES has 
been used to target several cancer cell types. BPTES was able to induce cell cycle 
arrest by reducing glutamate leading to a significant reduction in ATP levels 
(although levels of ROS or GSH were not affected by the treatment) in NSCLC cell 
lines (Lee et al. 2016). It was also showed that when BPTES (10 μM) is combined 
with 5-fluorouracil (5-FU – a thymidylate synthase inhibitor) (5-10 μM), it caused 
synergistic cell death via cell cycle arrest in NSCLC cell lines. BPTES was also used 
by Ulanet et al. (2014) to identify NSCLC cell lines which are GLS dependent and 
had express markers characteristic of a mesenchymal phenotype (low E-cadherin 
and high vimentin expression). They are also showed that if lung cancer cells were 
induced (using TGF-β) to undergo epithelial to mesenchymal transition (EMT), it 
would cause cells to become more sensitive to BPTES and was associated with 
impaired mitochondrial respiratory capacity and increased sensitivity to oxidative 
stress.  
 Encapsulated BPTES in nanoparticles with dense poly (ethylene glycol) 
(PEG) surface coatings provided an effective method of delivering BPTES to 
pancreatic tumours while minimizing toxicity to cycling pancreatic cells 
(Zimmermann et al. 2016). However, this failed to target noncycling hypoxic 
pancreatic cells. To counter this, the encapsulated BPTES was combined with 
metformin. GLS inhibition in PDAC MiaPaCa2 cells induced by BPTES (500 nM) 
sensitized the cells to ß-lapachone (an NADPH:quinone oxidoreductase). This 
results in NADPH depletion via high levels of ROS production and caused 
nicotinamide adenine dinucleotide (NAD)+ depletion through PARP hyperactivation. 
This completely overwhelmed the ability of the DNA repair machinery to repair ß-
lap-induced DNA lesions (Luo et al. 2015).  
 BPTES induced metabolism changes in the breast cancer cell lines MCF7 
(an oestrogen receptor dependent cell line) and MDA-MB231 (a triple negative cell 
line) compared to non-cancerous MCF10A cells in glutamine metabolism, 
glycolysis, TCA cycle and amino acids pathways. The metabolic response, however, 
was distinctly different in both cancer cell types (Nagana Gowda et al. 2018). This 
is probably due to different genetic regulations such as preferences to estrogen 
receptor and dependence of glucose or glutamine for proliferation. A combination of 
BPTES with etoposide and cisplatin was tested on TNBC cell lines HCC1937 and 
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BT-549. Results showed that in HCC1937 cells, pre-treatment with BPTES (10 μM) 
caused an increase in the toxic effects of cisplatin and etoposide, as demonstrated 
by reduced proliferation, increased expression of apoptosis-related proteins 
(cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and a decreased ratio 
of Bcl-2/BAX. However, in BT-529 cells, enhanced cell death was only seen when 
cells were treated with a combination of BPTES and etoposide (Chen et al. 2016).  
  
5.1.4 Paroxetine Hydrochloride Hemihydrate 
Paroxetine (also known as Paxil and Seroxat) is an antidepressant that belongs to 
the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major 
depressive disorder, obsessive-compulsive disorder, social anxiety disorder, panic 
disorder, posttraumatic stress disorder, generalized anxiety disorder and 
premenstrual dysphoric disorder. It has been used in the treatment of menopausal 
hot flashes and night sweats. Paroxetine is also used for the treatment of depression 
and hot flashes in breast cancer patients and survivors (although it did not influence 
fatigue levels in patients/survivors) (Stearns et al. 2000; Pezzella et al. 2001; 
Morrow et al. 2003; Roscoe et al. 2005). It has also been shown to have cytotoxicity 
in several cancer cell lines.  
 Paroxetine (up to 50 μM) was able to induce apoptosis in oral cancer cell 
lines (OC2) in a Ca2+-independent manner. Paroxetine was shown to induce an 
increase in cytosolic free Ca2+ concentrations by causing phospholipase C-
independent Ca2+ release from the ER and Ca2+ influx via store operated Ca2+ 
channels in a manner regulated by protein kinase C and phospholipase A2 (Fang 
et al. 2011). In cultured human osteosarcoma cells (MG63), paroxetine was shown 
to reduce cell viability in a concentration- and time-dependent manner and was able 
to induce apoptosis via inducing p38 MAPK-associated caspase-3 activation (Chou 
et al. 2007). As seen by Fang et al. (2011), cell death was Ca2+-independent but 
also induced an increase in cytosolic free Ca2+ concentrations via mobilization of 
intracellular Ca2+ stored in the ER and Ca2+ influx from an extracellular medium. 
Paroxetine also caused an increase in cytosolic free Ca2+ concentrations in treated 
PC3 human prostate cancer cells (Pan et al. 2009).  
 Paroxetine has been shown to reduce cell viability in colon carcinoma cells 
HT29 and has been shown to arrest HT29 and LS1034 cells at the G0/G1 stage of 
the cell cycle and stimulate DNA fragmentation in a dose-dependent manner. Cells 
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appear to die in an apoptotic manner as there is evidence of increased caspase-3 
activation, increased c-Jun and decreased Bcl-2 expression (Arimochi and Morita 
2006; Gil-Ad et al. 2008).  
 
5.1.5 Trifluoperazine 
Trifluoperazine (sold as Eskazinyl, Eskazine, and Jatroneura, etc.) is a calmodulin 
inhibitor and an antipsychotic drug used for the treatment of schizophrenia (Wang 
et al. 2018). Trifluoperazine has good bioavailability in brain and has shown an 
anticancer effect in several types of cancer (Feng et al. 2018). A library of 80 
dopaminergic ligands were screened and it was demonstrated that trifluoperazine 
inhibited the growth and proliferation of glioblastoma cancer cells in a dose 
dependent manner (Pinheiro et al. 2018). Treatment with trifluoperazine (up to 10 
μM) caused an increased accumulation of LC3B-II and p62, indicating a disruption 
of autophagy flux and impaired acidification of the lysosomes in glioblastoma cancer 
cells U251, U87 and P3 (Zhang et al. 2017). It was also shown that trifluoperazine 
had an additive effect when combined with radiation via down-regulation of 
cathepsin L. Trifluoperazine potently suppressed proliferation, motility, and invasion 
of glioblastoma cells in vitro, and tumour growth in in vivo xenograft mouse model 
(Kang et al. 2016). It was demonstrated that this was caused by massive and 
irreversible release of Ca2+ from intracellular stores by inositol 1,4,5-trisphosphate 
receptor (IP3R) subtypes 1 and 2 by directly interacting at the TFP-binding site of a 
Ca2+-binding protein, calmodulin subtype 2 (CaM2). However, it was also showed 
that trifluoperazine failed to improve the survival time in mice models of 
glioblastoma. However, analogs of trifluoperazine were able to reduce tumour size 
and increased the survival time in brain xenograft mouse model of glioblastoma via 
increased Ca2+ like trifluoperazine (Kang et al. 2018). In doxorubicin (DOX) resistant 
SHG44/DOX glioma cells, doxorubicin resistance was reduced by using 
trifluoperazine via inhibition of the nuclear exclusion of Forkhead box O1 (FOXO1) 
(a tumour suppressor) leading to a downregulation of MDR genes. This resulted in 
an increase in the intracellular concentration of doxorubicin which resulted in 
cytotoxicity, cell cycle arrest and early apoptosis (Chen et al. 2018).  
 Trifluoperazine caused an increase in the nuclear localization of FOXO1 in 
HCC lines SMMC-7721 and Bel-7402. Trifluoperazine was shown  to inhibit the 
vitality of both cell lines and induce cell cycle arrest at G0/G1, while in vivo restricted 
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angiogenesis and tumour growth with a reduced expression of VEGF, Bcl-2, and 
PCNA (Cai et al. 2017). In TNBC cell lines, MDA-MB-468, MDA-MB-231, and 4T1, 
trifluoperazine (up to 20 μM) induced G0/G1 cell cycle arrest via decreasing the 
expression of both cyclin D1/CDK4 and cyclin E/CDK2, and stimulated 
mitochondria-mediated apoptosis. Trifluoperazine suppressed the growth of 
subcutaneous xenograft tumour and brain metastasis in vivo and prolonged the 
survival of mice bearing brain metastasis (Feng et al. 2018). A combination of 
trifluoperazine (TFP) with gemcitabine (GEM), and paclitaxel (PTX) was tested for 
the treatment of pancreatic cancer cells. The TFP-GEM-PTX combination was 
shown to be slightly synergistic and when each drug was used at it IC60, it was 
shown to be optimal in inhibiting PDAC PANC-1 cells (Molins and Jusko 2018). 
Trifluoperazine was able to inhibit the formation of cancer stem cells (CSC) and 
down regulated the expression of CSC markers, CD44/CD133. It was also shown 
that trifluoperazine inhibited Wnt/β-catenin signalling in gefitinib-resistant lung 
cancer spheroids. When trifluoperazine (0.5-5 μM) and gefitinib (2.5-10 μM) were 
combined, they were able to overcome drug resistance in lung CSCs and enhanced 
the inhibitory activity of gefitinib in lung cancer metastatic and orthotopic CSC animal 
models (Yeh et al. 2012).  
  
5.1.6 17-AAG 
17-allylamino,17-demethoxygeldanamycin (17AAG) was the first inhibitor of heat 
shock protein 90 (Hsp90) to enter a phase I clinical trial in cancer. Colorectal (CRC) 
carcinoma cell lines HT29, HCT116, HCT15 and KM12 treated with 17AAG had 
depletion of c-raf-1 and AKT and inhibition of signal transduction and caused down 
regulation of hsp70, hsp90β, keratin 8, keratin 18 and caveolin-1 although 
expression of Hsp90 client protein genes was not affected (Workman et al. 2002). 
17AAG was demonstrated to synergise well in a combination with either 
capecitabine and Irinotecan to cause cytotoxicity in HT29 cells. The combination of 
all three drugs was shown to down-regulate matrix metalloproteinase-9 (MMP-9) 
and vascular endothelial growth factor (VEGF) mRNA levels, have anti-metastatic 
properties, and caused elevated lipid peroxidation and reduced total antioxidant 
capacity in HT-29 cells (Zeynali-Moghaddam et al. 2019). A triple combination of 
17AAG (IC50 = 62 nM in HT29 cells and 14.4 nM in HCT116 cells), capecitabine 
(IC50 = 3.27 μM in HT29 cells and 1.63 μM in HCT116 cells) and oxaliplatin (IC50 = 
4.60 μM in HT29 cells and 1.74 μM in HCT116 cells) showed that while a double 
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combination of 17AAG with either capecitabine or oxaliplatin showed synergy in 
HT29 and HCT116 cells, but when all three drugs were used in combination, 
synergy only occurred in HCT116 cells (Mohammadian et al. 2017).  
 17AAG sensitizes NSCLC cells expressing high levels of p185 to paclitaxel-
mediated growth arrest and apoptosis via depletion of p185. In cells with low levels 
of p185, the combination had only an additive effect (Nguyen et al. 1999). 17-AAG 
enhanced cytotoxicity and cell growth inhibition of etoposide in NSCLC cell lines 
H1703 and H520, which were associated with the downregulation of XPC 
expression and inactivation of AKT (Chen et al. 2018). 
 17AAG was shown to be able to inhibit the hypoxic induction of the HIF-1 
target genes in malignant plasma cells (Kocemba-Pilarczyk et al. 2018). Using solid 
lipid nanoparticles to carry a combination of 17AAG and paclitaxel to target gastric 
cancer cells, the encapsulated combination was shown to reduce cell viability and 
colony formation in cell line MKN45 and induced apoptosis, inhibited growth of 
xenograft and influenced the protein levels of Hsp90, MnSOD, Cleaved caspase 3 
and Cleaved PARP (Ma et al. 2018). In HNCC lines, HN30 and HN6, the expression 
of PTEN and p53 proteins were suppressed and AKT and Mdm2 expression was 
reduced by the presence of 17AAG (2 μmol/L) (Pontes et al. 2018). 
 
5.1.7 Etoposide 
Etoposide (VP-16–213, epipodophyllotoxin, 4′-demethyl-9-[4,6–0-ethylidene-D-
glucopyranoside]) is a topoisomerase II inhibitor, which was approved by the FDA 
in 1983 after demonstrating antineoplastic activity in AML, Hodgkin’s lymphoma, 
non-Hodgkin’s lymphoma, lung cancer (both small cell and non-small cell), gastric 
cancer, breast cancer and ovarian cancer (Hande 1998). Kaufmann (1989) showed 
that exposing human HL-60 or KG1A leukaemia cells to 17 μM etoposide for 45 min 
was able to cause DNA degradation 4 h later. Etoposide (up to 3 μM) was also 
shown to be able to inhibit MYB – a transcription factor which plays key roles in 
hematopoietic cells and has been implicated in the development of leukemic HL60 
cells, although it did require a 10x fold higher concentration to achieve this 
compared to teniposide usage (Yusenko et al. 2018). A combination of azacytidine, 
etoposide, and cytarabine was shown to generate an increased response and 
prolonged survival rates in patients with poorly prognosed AML (Onec et al. 2018). 
A combination of lomustine, cytarabine, cyclophosphamide and etoposide was 
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shown to be an effective and well-tolerated conditioning regimen prior to 
hematopoietic stem cell transplant (HSCT) in patients with primary refractory or 
relapsed lymphoma (Gokarn et al. 2018). A combination of bendamustine, 
etoposide, and dexamethasone was shown to be able to mobilize peripheral blood 
hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma 
(Press et al. 2018). 
Etoposide has become one of the most commonly used cancer drugs. Using 
6 cycles of cisplatin combined with etoposide (60 mg/m2 etoposide on days 1–3 and 
50 mg/m2 cisplatin on day 1 at 21-day intervals), a complete response was achieved 
in a patient with small cell neuroendocrine carcinoma at the primary lesion and at 
the cervical lymph node metastases (Wang et al. 2018). A patient with large cell 
neuroendocrine carcinoma was successfully treated with a cisplatin/etoposide 
combination (four cycles of cisplatin (80 mg/m2, on day 1) and etoposide (100 
mg/m2, on days 1, 2, and 3)) as well (Hidaka et al. 2018). 
Gestational trophoblastic neoplasia (GTN) is a highly chemosensitive and 
curable gynaecologic malignancy. Aminimoghaddam et al. (2018) used a 
combination regimen of etoposide, methotrexate, actinomycin-D/etoposide, and 
cisplatin (EMA/EP) to cause a complete remission in 88% of patients treated for high 
risk GTN. In low-risk GTN, Kanno et al. (2018) showed that primary remission rates 
and drug resistant rates of 5-day etoposide treatment (drip infusion) were 
significantly higher and significantly lower than those of 5-day intramuscular 
methotrexate treatment. 
 A complete response was achieved in a patient with metastatic oesophageal 
carcinosarcoma comprising of neuroendocrine carcinoma, squamous cell 
carcinoma, and sarcoma after 4 cycles of a etoposide/cisplatin combination 
(cisplatin at 60 mg/m2 on day 1 and etoposide at 100 mg/m2 on days 1–3) 
(Tsuchihashi et al. 2018). Unfortunately, in this case, the patient’s tumour 
reoccurred 5.5 months after the final course of treatment. The addition of 
atezolizumab (a humanized monoclonal anti–programmed death ligand 1 (PD-L1) 
antibody) to a chemotherapeutic combination of carboplatin and etoposide as a first-
line treatment for extensive-stage small-cell lung cancer was shown to induce 
significantly longer overall survival and progression-free survival than treatment with 
carboplatin/etoposide combination alone (Lin et al. 2018). An elderly patient with 
Langerhans’s cell sarcoma was successfully treated using a combination of 
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etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (Matsukawa 
et al. 2018). 
 
5.1.8 Doxorubicin  
Doxorubicin (also called Adriamycin) is a cytotoxic anthracycline antibiotic obtained 
from Streptomyces peucetius var caesius used for the treatment of several forms of 
cancer. It is believed to act as a topoisomerase I inhibitor and intercalates between 
adjacent base pairs of the double helix of DNA thus impairing the synthesis of DNA, 
RNA, and proteins. In fourteen randomised trials that used pegylated liposomal 
doxorubicin (PLD – a liposome-encapsulated formulation of doxorubicin) on ovarian 
cancer cell lines, it was shown that there were no overall survival rate differences 
between PLD-based treatment and other regimens. However, there was a 
significant progression free survival benefit of a PLD-based schedule observed, 
particularly in second-line and in platinum-sensitive subgroups (Staropoli et al. 
2014). Similar results were observed when PLD was combined with carboplatin and 
compared to the combination of carboplatin and paclitaxel (La-Beck et al. 2013). 
However, both combinations have different side effect profiles as PLD/carboplatin 
had more gastrointestinal toxicity, anaemia, thrombocytopenia, cutaneous toxicity, 
and mucositis/stomatitis, but less neutropenia, neuropathy, and alopecia when the 
combination was compared to carboplatin and paclitaxel. A phase II trial which 
involved a combination of PLD (30 mg/m2 on day 3) and irinotecan (80 mg/m2 on 
days 1 and 15) for the treatment of recurrent ovarian cancer was carried out by Shoji 
et al. (2014). Results showed that the combination was a useful treatment method 
with a high response rate and manageable adverse reactions. The use of pegylated 
liposomal doxorubicin hydrochloride (PLDH), topotecan, paclitaxel, trabectedin and 
gemcitabine in the treatment of advanced recurrent or refractory ovarian cancer was 
reviewed (Edwards et al. 2015). It was shown that there were significant benefits for 
PLDH plus platinum in terms of overall survival (OS) compared to platinum 
monotherapy. PLDH plus platinum significantly prolonged progression-free survival 
(PFS) compared to paclitaxel plus platinum. In terms of non-platinum-based 
treatments, PLDH monotherapy and trabectedin plus PLDH were found to 
significantly increase OS, but not PFS, compared to topotecan monotherapy. With 
regards to platinum-resistant/-refractory (PRR) disease, there was no significant 
differences for any treatment compared with alternative regimens in OS and PFS. 
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 Doxorubicin is one of the most effective agents for both early and advanced 
breast cancer. A meta-analysis of ten randomised controlled trials for the use of 
liposomal doxorubicin in advanced breast cancer found that liposomal doxorubicin 
had a significant reduction in the risk of cardiotoxicity and significant improvement 
in the overall response rate compared with conventional doxorubicin (Xing et al. 
2015). No significant difference between the two forms of doxorubicin was reported 
in terms of overall survival. Resveratrol was shown to reduce hypoxia-induced 
resistance to doxorubicin in MCF7 breast cancer cells via decreased CBR1 
expression by decreasing HIF-1α protein expression (Mitani et al. 2014). In MCF7 
cells with multidrug resistance, using mesoporous silica nanoparticles to 
encapsulated doxorubicin, it was able to overcome drug resistance and improve 
doxorubicin cytotoxicity in these cells (Wang et al. 2014). Combining short-time 
focused ultrasound (FUS) hyperthermia with PLD was shown to be able to 
significantly enhance the PLD delivery into brain metastases of breast cancer and 
effectively inhibit tumour growth compared with mono-treatments of either PLD or 
short-time FUS hyperthermia (Wu et al. 2014). 
 Loading doxorubicin into composite (polyethylene glycol-
polycaprolactone/Pluronic P105) micelles (an aggregate of surfactant molecules 
dispersed in a liquid colloid) was shown to significantly enhance cellular doxorubicin 
accumulation and inhibit doxorubicin release (Xu et al. 2012). It was also showed 
that the micelles were able to radiosensitise lung cancer A549 multicellular 
spheroids and cause significantly reduced survival of cells treated by radiation and 
composite micelles compared with those treated with radiation and free doxorubicin 
or radiation alone. Introduction of 1-guanyl-1,7-diaminoheptane (GC7) sensitizes 
bladder cancer (BIU-87, J82, and UM-UC-3) cells to doxorubicin (up to 1 μg/ml) by 
preventing epithelial–mesenchymal transition through inhibition of eukaryotic 
translation initiation factor 5A2 activation (Liu et al. 2015d). Human atherosclerotic 
plaque-specific peptide-1 (AP1) conjugated to liposomal doxorubicin was observed 
to cause selective cell death in IL-4Rα-overexpressing murine CRC CT26 cells. It 
was also showed that there was significant inhibition of tumour growth and 
decreased cardiotoxicity of doxorubicin in mouse models treated with the conjugate 
when it is administered intravenously (Yang et al. 2015). 
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5.1.9 Luteolin 
Luteolin (3′,4′,5,7-tetrahydroxyflavone) is a flavonoid identified in a variety of 
vegetables, including broccoli, green peppers and celery and has been shown to 
have in vitro and in vivo anti-cancer activity against various cancer cells (Feng et al. 
2018; Han et al. 2018). Luteolin was observed to be able to selectively target 
hepatocellular carcinoma cell (HCC) line SK-Hep-1 cells compared to normal cells. 
Cell death was apoptotic with activation of caspase 8, −9 and −3 and cleavage of 
PARP was caused by inhibiting AKT phosphorylation (and disrupting the 
PI3K/AKT/mTOR pathway) (Im et al. 2018). A combination of luteolin (10 μM) with 
sorafenib (3 μM) (a small-molecule multi-kinase inhibitor) synergistically killed HCC 
cell lines Hep3B and SMMC-7721 via JNK-mediated apoptosis (Feng et al. 2018).  
 ProFine is a combination of luteolin, quercetin, and kaempferol formed into a 
composition (Mamouni et al. 2018). This combination was shown to synergistically 
cause cell death in prostate cancer cell line C4-2 in an apoptotic manner and cause 
suppression of androgen receptor expression and inhibit transcription of androgen-
regulated genes. Luteolin was shown to be able to suppress the stemness of 
prostate cancer cells by Wnt singling pathway inhibition via upregulation of FZD6 
(frizzled class receptor 6 - a negative regulator of β-catenin transcriptional activity) 
(Zhou et al. 2018). 
 Luteolin was observed to be able to obstruct metastasis through both direct 
and indirect mechanisms (Cook 2018). Luteolin can suppress breast cancer 
invasion by inhibiting VEGF production and its receptor’s activity and can decrease 
epithelial–mesenchymal transition markers and metastatic proclivity. Luteolin was 
observed to be antiproliferative via suppressing receptor tyrosine-kinase (RTK) 
activity. In CRC cells, luteolin (up to 80 μM) suppressed cell proliferation and cellular 
transformation of HCT116 and HT29 cells in a dose-dependent manner via 
epigenetic modifications of the nrf2 gene with subsequent induction of its 
downstream antioxidative stress pathway (Zuo et al. 2018). Luteolin (up to 100 μM) 
showed proapoptotic activity in pancreatic cancer cell line SW1990 by targeting the 
BCL-2. Luteolin was shown to displace BAX from the hydrophobic cleft of BCL-2, 
allowing mitochondrial permeabilization (Li et al. 2018b).  
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5.1.10 Trequinsin 
Trequinsin is a phosphodiesterase III inhibitor which is used as a strong 
antihypertensive agent. A combination of trequinsin with epigallocatechin-3-O-
gallate (EGCG - green tea polyphenol which is a substrate of 67-kDa laminin 
receptor (67LR)) was shown to be able to suppress cancer stem cell properties in 
PDACs via suppression of the FOXO3 and CD44 axis. In vivo, this combination 
suppressed PDAC tumour growth and metastasis (Kumazoe et al. 2017).  
 
5.1.11 FLLL31 
FLLL31 is a small molecule derived from curcumin (Holmer et al. 2015). This 
compound was designed to bind selectively to Janus kinase 2 (JAK2) and to the Src 
homology-2 domain of Signal Transducer and Activator of Transcription 3 (STAT3) 
(which serve crucial roles in STAT3 dimerization and signal transduction). FLLL31 
(up to 10 μM) was shown to be able to inhibit STAT3 phosphorylation, DNA-binding 
activity, and transactivation in vitro which could impede multiple oncogenic 
processes and induced apoptosis in pancreatic and breast cancer cell lines (PANC-
1 and MDA-MB-231 respectively) (Lin et al .2010). It was also shown that FLLL31 
inhibited colony formation in soft agar and cell invasion. It was also shown to 
synergise well with doxorubicin against breast cancer cells. A combination of 
FLLL31 (5 μM) with Tumour Necrosis Factor-Related Apoptosis Inducing Ligand 
(TRAIL) (20ng/ml) synergised to cause apoptosis in pancreatic cancer cell lines 
(S2013 and S2VP10) by preventing down-regulation of DR5 (Majumder et al. 2016). 
 
5.1.12 Hypothesis 
This lab group has seen several successful combinations containing nelfinavir such 
as mefloquine (McCann et al. 2018), chloroquine (Johnson et al. 2015), bortezomib 
(Johnson et al. 2018) and salinomycin (Dunlop et al. 2017), which can selectively 
target mTORC1 hyperactive cell lines. The purpose of this chapter was to identify 
any potential combination with nelfinavir from the above drugs which can selectively 
target mTORC1 hyperactive cell lines. To do this, the drugs in question were tested 
through several layers on screening in order and the combinations with the strongest 
selectivity for Tsc2-/- MEFs underwent further testing.   
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5.2 Results: 
 
5.2.1 Drug combinations tested showed selective inhibition of Tsc2-/- cells. 
To determine if the drugs chosen for the screen can inhibit cell growth, drugs were 
divided into two panels with drugs at varying concentrations in combination with 20 
µM nelfinavir and cells and treated for 48 h. Concentrations for the chosen drugs 
were selected based on a literature search of concentrations used for the treatment 
of cancer cell lines. To determine inhibition of cell proliferation, a CyQUANT assay 
was carried out. Results were calculated as a % of cell number which was 
normalised to 100% for DMSO treated cells.  
The first panel consisted of piperlongumine, chelerythrine chloride, BPTES, 
paroxetine hydrochloride hemihydrate, cepharanthine and trifluoperazine (Figure 
5.1A). Results from the panel are summarised in Table 5.1.  
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Table 3.1: Results from CyQUANT panel screen 1. Results for the first CyQUANT Panel which 
featured rapamycin (RAP) as a control, chelerythrine chloride (CC), piperlongumine (Pip), BPTES, 
paroxetine hydrochloride hemihydrate (Paro), and cepharanthine (Cep) in combination with nelfinavir 
(NFV) 
 % of Control Cell Number 
 Tsc2+/+ Tsc2-/- 
Drug Average SEM Average SEM 
DMSO 100.00 0.00 100.00 0.00 
Rap 100nM 64.95 5.52 63.57 5.86 
NFV 20µM 50.32 3.22 51.78 4.20 
Pip 5µM/NFV 20µM 43.21 1.77 37.79 3.54 
Pip 10µM/NFV 20µM 35.20 8.05 25.09 6.71 
Pip 20µM/NFV 20µM 38.45 8.25 23.08 5.40 
CC 5µM/NFV 20µM 17.77 5.66 8.74 2.45 
CC 7.5µM/NFV 20µM 9.31 2.93 6.66 2.53 
CC 10µM/NFV 20µM 12.86 4.31 11.27 1.93 
BPTES 5µM/NFV 20µM 44.73 4.50 49.96 1.76 
BPTES 10µM/NFV 20µM 41.22 6.04 48.09 3.58 
BPTES 20µM/NFV 20µM 39.85 3.76 26.50 6.04 
Paro 1.25µM/NFV 20µM 48.57 1.16 38.85 6.85 
Paro 2.5µM/NFV 20µM 44.41 6.72 31.69 6.66 
Paro 5µM/NFV 20µM 38.49 5.63 24.99 5.49 
Tri 1.25µM/NFV 20µM 49.89 1.55 37.05 8.55 
Tri 2.5µM/NFV 20µM 43.67 2.22 34.93 7.53 
Tri 5µM/NFV 20µM 44.33 1.87 26.54 6.22 
Cep 1.25µM/NFV 20µM 40.46 5.86 25.68 4.90 
Cep 2.5µM/NFV 20µM 40.02 5.24 25.70 4.79 
Cep 5µM/NFV 20µM 39.86 6.04 24.87 4.17 
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The second drug panel was made up of 17-AAG, etoposide, doxorubicin 
hydrochloride, luteolin, trequinsin and FLLL31 (Figure 5.1B). Results from this 
second panel are summarised in Table 5.2.  
 
Table 5.2: Results from CyQUANT panel screen 2. Results for the first CyQUANT Panel which 
featured rapamycin (RAP) as a control, etoposide (ETO), doxorubicin hydrochloride (Dox), 17AAG, 
luteolin (Lut), trequinsin (Tre), and FLLL31 in combination with nelfinavir (NFV) 
 % of Control Cell Number 
 Tsc2+/+ Tsc2-/- 
Drug  Average SEM Average SEM 
DMSO 100.00 0.00 100.00 0.00 
Rap 100nM 81.67 3.02 73.42 3.87 
NFV 20µM 64.19 8.56 62.06 2.42 
Eto 25µM/NFV 20µM 47.96 5.61 52.26 2.71 
Eto 50µM/NFV 20µM 55.16 7.50 46.23 1.86 
Eto 100µM/NFV 20µM 59.00 2.74 54.93 4.45 
Dox 12.5nM/NFV 20µM 62.78 5.56 54.99 2.23 
Dox 25nM/NFV 20µM 54.16 3.74 53.67 3.42 
Dox 50nM/NFV 20µM 48.61 5.47 48.53 5.99 
17-AAG .5µM/NFV 20µM 57.39 7.48 48.34 3.88 
17-AAG 1µM/NFV 20µM 54.57 8.05 48.17 2.71 
17-AAG 2µM/NFV 20µM 52.81 8.48 45.04 2.65 
Lut 5µM/NFV 20µM 33.36 2.80 49.36 2.56 
Lut 10µM/NFV 20µM 27.92 4.92 46.86 0.43 
Lut 20µM/NFV 20µM 41.41 5.49 43.74 2.13 
Tre 10uM/NFV 20µM 44.42 5.02 51.98 3.81 
Tre 20uM/NFV 20µM 38.60 3.15 46.34 5.01 
Tre 40uM/NFV 20µM 34.79 3.47 29.68 7.91 
FLLL31 1.25µM/NFV 20µM 33.16 2.25 35.38 6.76 
FLLL31 2.5µM/NFV 20µM 27.54 2.15 24.91 3.39 
FLLL31 5µM/NFV 20µM 25.45 6.45 15.05 0.53 
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Figure 5.1: Drug screen to see the effects of drug combinations on cell proliferation. Tsc2+/+ 
and Tsc2-/- MEFs were treated with (A) 100 nM rapamycin (RAP), piperlongumine, chelerythrine 
chloride (CC), BPTES, paroxetine hydrochloride hemihydrate (Paro), cepharanthine (Cep) and 
trifluoperazine (Tri) (n=3; mean +/- SEM)  (B) 17-AAG, etoposide (ETO), and doxorubicin 
hydrochloride (Dox), luteolin (Lut), trequinsin (Tre), and FLLL31 at various concentration combined 
with 20 μM nelfinavir (NFV) for 48 hours. Fluorescence was read on a plate reader with excitation at 
480 nm and emission at 520 nm (n=3; mean +/- SEM). Results written as mean +/- SEM. Statistical 
significance is shown between treated Tsc2+/+ MEFs and Tsc2-/- MEFs. 
 
5.2.2 A combination of cepharanthine and nelfinavir selectively killed Tsc2-/- 
cells. 
To determine if the drug combinations tested have cytotoxicity capabilities, several 
drug combinations were selected from the CyQUANT screening carried out and 
tested at two concentrations representing the higher and lower ranges of therapeutic 
concentrations in combination with 20 µM nelfinavir (Figure 5.2). Reasons for the 
drugs and concentrations used will be discussed in the discussion section of this 
chapter.    
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 Chelerythrine combinations showed slight cytotoxic selectivity for Tsc2-/- 
cells when compared to results seen in wildtype cells. However, at the higher 
concentration (5 µM) combination, both cell types suffered high toxicity; 74.36% +/- 
16.08 SD vs 80.24% +/- 15.23 SD while at the 2.5 µM combination both cell types 
suffered minimal cell death compared to the control cells (8.07% +/- 0.81 SD in 
Tsc2+/+ MEFs vs 20.28% +/- 4.38 SD in Tsc2-/- MEFs) in combination treated cells 
compared to 4.94% +/- 2.02 (in Tsc2+/+ MEFs) vs 4.83% +/- 3.08 (in Tsc2-/- MEFs) 
in control cells.   
 Trifluoperazine combinations showed selective cytotoxicity for Tsc2-/- cells. 
However, the 10 µM trifluoperazine combination (representing the higher 
concentration range) wiped out both the Tsc2+/+ and Tsc2-/- MEFs (95.80% +/- 
3.13 SD vs 96.92% +/- 2.31 SD). In the lower concentration range combination (2.5 
µM trifluoperazine), selective cytotoxicity occurred in Tsc2-/- cells, however, cell 
death in both cell lines was quite poor (12.89% +/- 7.55 SD in Tsc2+/+ MEFs vs 
20.37% +/- 7.07 SD in Tsc2-/- MEFs). 
 Combinations containing paroxetine showed higher cell death in Tsc2-/- cells 
compared to wildtype cells. The 5µM paroxetine combination showed much higher 
selective cell death compared to other high range concentrations used for other 
drugs tested; 21.70% +/- 1.85 SD in Tsc2+/+ MEFs vs 65.42% +/- 6.40 SD in Tsc2-
/- MEFs. The 2.5 µM paroxetine combination showed similar results to other drug 
combinations used in a similar concentration and failed to show much cell death in 
either cell line; 13.43% +/- 1.77 SD in Tsc2+/+ MEFs vs 26.90% +/- 12.38 SD in 
Tsc2-/- MEFs.  
 Trequinsin-based combinations failed to show significant cell death at either 
range of concentrations used for this assay. The 10 µM trequinsin combination failed 
to cause high levels of cell death compared to the other drug combinations used at 
this range; 7.55% +/- 2.96 SD in Tsc2+/+ MEFs vs 19.20% +/- 5.08 SD in Tsc2-/- 
MEFs. The 2.5 µM combination showed similar results as seen with the lower range 
concentration of all previous drugs tested; 7.37% +/- 3.07 SD in Tsc2+/+ MEFs vs 
15.78% +/- 3.56 SD in Tsc2-/- MEFs. 
 Cepharanthine containing combinations showed higher levels of selectivity 
compared to all other drug combinations tested for cytotoxicity. The higher range of 
10 µM cepharanthine, showed similar levels of cell death as seen in the two cell 
lines; 84.28% +/- 2.28 SD in Tsc2+/+ MEFs vs 96.88% +/- 2.97 SD in Tsc2-/- MEFs. 
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However, in the 2.5 µM cepharanthine combination, results show the highest level 
of selectivity seen in this assay with 16.85% +/- 7.54 SD cell death reported in in 
Tsc2+/+ MEFs compared to 87.66% +/- 11.65 SD cell death seen in in Tsc2-/- 
MEFs.   
       
 
Figure 5.2: Drug screen to determine the effects of drug combinations on cell death. Tsc2+/+ 
and Tsc2-/- MEFs were treated with chelerythrine chloride (CC), paroxetine hydrochloride 
hemihydrate (Paro), cepharanthine (Cep) and trifluoperazine (Tri) and trequinsin at various 
concentration combined with 20 μM nelfinavir (NFV) for 48 h. % Cell death was measured via flow 
cytometry and DRAQ 7 Staining. Statistical significance is shown between treated Tsc2+/+ MEFs 
and Tsc2-/- MEFs (n=3; mean +/- SD). 
 
5.3 Discussion: 
The purpose of this chapter was to identify any potential nelfinavir-based 
combinations from a drug screen of the above chosen drugs. which could be further 
investigated. The drugs chosen for this screen were selected either for their 
selectivity for TSC2-deficient cells (chelerythrine, paroxetine, trifluoperazine – drug 
screen carried out by (Medvetz et al. 2015)) or for their potential role in the 
combination such as DNA damage (doxorubicin), oxidative stress (luteolin, 
piperlongumine, FLLL31 and cepharanthine) or ER stress (17AAG).   
 The range of concentrations, used in the CyQUANT assay, were selected 
based on literature searches of each drug in relation to treatments of cancer cell 
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lines and then decreased by 2-fold each time, to prevent non-specific cytotoxicity in 
Tsc2+/+ control MEFs due to synergy with nelfinavir. The fixed 20 μM nelfinavir was 
chosen as this standard nelfinavir concentration was used by the lab group in 
relation to combinations unless results showed different nelfinavir concentration 
improved optimisation (see (Johnson et al. 2014), (Johnson et al. 2018) and 
(McCann et al. 2018) for details). Data obtained from the CyQUANT assay showed 
that all combinations tested were able to inhibit cell proliferation although only four 
combinations demonstrated a significant difference in inhibition between the 
Tsc2+/+ and Tsc2-/- MEFs when tested at two different concentrations (paroxetine, 
trifluoperazine, piperlongumine and luteolin) and only one at three different 
concentrations (cepharanthine). Luteolin, trequinsin, BPTES were shown to favour 
Tsc2-/- MEFs proliferation compared to control MEFs (although significance was 
only seen in luteolin treated samples). As a result, these drugs were initially 
eliminated from further testing. However, seeing the problems of trying to convert 
results from the CyQUANT to data for cell death concentrations in Chapter 3, all the 
drugs were allowed to proceed to the cell death stage of drug screen.  
 For the first part of the cell death drug screen, all drug combinations tested 
in the CyQUANT stage were investigated via observation assay (observing both 
Tsc2+/+ and Tsc2-/- MEFs under light phase microscopy to check for cell coverage, 
changes in cell morphology and signs of cell death when compared to cells treated 
with DMSO after 48 h of treatment. The data for this observation assay was not 
included in this result chapter. After this assay, an initial flow cytometry was 
performed to confirm observed results (Data not shown) at two different 
concentrations, one representing high concentration and one representing a low 
concentration. It was from this initial flow cytometry that several drugs 
(Piperlongumine, BPTES and Luteolin) were eliminated due to either lack of 
selectivity or due to lack of cytotoxicity in the Tsc2-/- cells. For etoposide, 
doxorubicin, 17AAG and FLLL31, these drugs were eliminated for different reasons. 
FLLL31 was redirected towards projects which were purely focused on inhibiting the 
STAT3 pathway in TSC2-deficient cell models. 17AAG was eliminated as results 
from Chapter 3 (Figure 3.8) showed that 17AAG was more than capable of 
selectively targeting Tsc2-/- MEFs as a single agent. In terms of doxorubicin and 
etoposide, doxorubicin and nelfinavir combinations have previously been tested 
(Srinivas et al. 1998; Lucia et al. 2011) and both combinations are currently being 
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tested with nelfinavir in several clinical trials (NCT01555281 for doxorubicin; 
NCT00589056 and NCT01108666 for etoposide). 
 Within the drug screens, only two drugs showed promise as potential 
selective combinations: paroxetine and cepharanthine. Both drugs appeared to be 
well tolerated at lower concentrations by Tsc2+/+ MEFs and to target Tsc2-/- MEFs, 
selectively. Of the two drugs, cepharanthine showed the highest level of cytotoxicity 
compared to the paroxetine which had nearly 90 % cell death compared to 
approximately 65 %. As a result, it was decided that the primary focus was to further 
optimise the cepharanthine/nelfinavir combination to maximise cell death in 
mTORC1-hyperactivity cells, while being well tolerated by control cells and 
identifying the mode of action (see Chapter 6). 
 In conclusion, this drug screen identified that a combination of nelfinavir and 
cepharanthine was well-tolerated by Tsc2+/+ MEFs while causing maximum cell 
death in Tsc2-/- MEF.
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Chapter 6: Cepharanthine and nelfinavir combination 
selectively targeted Tsc2-/- cells. 
 
6.1 Introduction:  
 
6.1.1 Cepharanthine 
Cepharanthine is a cationic and amphipathic bisbenzylisoquinoline alkaloid derived 
from the plant Stephania cepharantha Hayata (a member of the Menispermaceae 
family, indigenous to Japan and China). It makes up 19.5 to 33.5 % of the extract 
from the plant (Furusawa & Wu, 2007; Paudel, Karki, & Kim, 2016). Cepharanthine 
has been used in Japan for over 40 years to treat a variety of diseases including 
snakebites, bronchial asthma, alopecia areata, leukopenia, allergies and HIV 
without any serious side effects reported (Edashige et al. 1991; Harada et al. 2001; 
Kawahara et al. 2005; Seubwai et al. 2010; Rogosnitzky and Danks 2011).  
Cepharanthine has also been shown to cause perturbation of plasma 
membrane function, lipid peroxidation, inhibition of histamine release, anti-
inflammatory effects such as TNFα-mediated NFκB activation, suppression of 
cytokines and inhibition of platelet aggregation (Ita et al. 2008; Kikukawa et al. 
2008). Cepharanthine was also demonstrated to have an anti-atherosclerotic effect 
through attenuation of inflammation, lipid peroxidation and vascular smooth muscle 
cell migration and proliferation (Paudel et al. 2016). Cepharanthine has also been 
known for its antitumor properties seen over a variety of different cancer types.   
 
6.1.2. Cepharanthine and blood cancers 
Cepharanthine was shown to be able to inhibit the growth of primary effusion 
lymphoma (a rare form of non-Hodgkin’s lymphoma) cell lines (BCBL-1, TY-1 and 
RM-P1) in both an in-vitro and in-vivo setting. It was shown that cepharanthine was 
able to cause apoptosis in these cells via inhibition of NF-κB that is hyperactivated 
in these cells (Takahashi-Makise et al. 2009). In human leukaemia cell lines, Jurkat 
and K562, cepharanthine was able to induce apoptosis via selective activation of 
mitogen-activated protein kinases (MAPKs) – cepharanthine activated extracellular 
signal-regulated kinases (ERKs) and p38 MAPK but did not activate JNKs (Wu et 
al. 2002). Cepharanthine was shown to halt the progression of thrombocytopenic 
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purpura with low doses (Tabata et al. 2012). Cepharanthine also demonstrated an 
anti-myeloma effect. Myeloma cells exposed to cepharanthine had an increased 
production of ROS and triggered capase-3 activation (Kikukawa et al. 2008).  
 
6.1.3 Cepharanthine and solid cancers 
Cepharanthine was shown to have a cytotoxic effect in several different cell lines; 
CRC cell lines HT29, LS174T and SW620 and HCC cell line HepG2 with an IC50 of 
between 2.4 and 5.3 μM (Bun et al. 2008). Cepharanthine stimulated AMPK-mTOR 
dependent induction of autophagy and autophagic cell death in a panel of apoptosis-
resistant cells (Law et al. 2015). 
Cepharanthine was shown to inhibit tumour growth and angiogenesis in oral 
squamous cell carcinoma cells (OSCC), both in vitro and in vivo. Growth and 
angiogenesis were prevented via inhibiting expression of pro-angiogenic interleukin 
8 (IL8), vascular endothelial growth factor (VEGF) and NF-κB activity (Harada et al. 
2009). Treatment of Cepharanthine on cholangiocarcinoma cell lines caused a 
significant inhibition of growth in a dose- and time-dependent manner. It was found 
that Cepharanthine caused NF-κB inactivation by inhibiting nuclear translocation, 
which led to caspase 3 and 9 activated apoptosis in these cell lines (Seubwai et al. 
2010).  
 Cepharanthine was shown to be able to inhibit 12-0-tetradecanoyl phorbol-
13-acetate (TPA) mediated tumour promotion in two stage mouse skin 
carcinogenesis initiated 7,12-dimethylbenz[α]anthracene (DMBA). Cepharanthine 
was able to inhibit the phosphorylation of Hl histone by Ca2+-phospholipid-
dependent protein kinase (PKC) in a concentration dependent manner. 
Cepharanthine also inhibited the association of Hl histone with phospholipid 
vesicles, but it did not inhibit autophosphorylation of PKC. Cepharanthine also 
inhibited TPA-stimulated phosphorylation of some cytoplasmic proteins of mouse 
skin epidermis (Edashige et al. 1991; Yasukawa et al. 1991).  
 The treatment of cepharanthine against human adenosquamous carcinoma 
cells caused G1 arrest via expression of p21WAF1 that led to caspase 3 mediated 
apoptosis (Harada et al. 2001). Cepharanthine was found to inhibit angiogenesis 
and tumour growth in vivo in a cholesterol-dependent manner. Cepharanthine 
inhibited the endolysosomal trafficking of free-cholesterol and low-density 
lipoprotein in human umbilical vein endothelial cells (HUVEC) by binding to 
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Niemann-Pick disease, type C1 (NPC1) protein and increasing the lysosomal pH 
(Lyu et al. 2017).    
  Cepharanthine inhibited cell growth and tumourgenesis in nasopharyngeal 
carcinoma cell lines in vitro by modifying the regulation of genes involved in several 
roles including cell cycle, DNA repair, apoptosis and NF-κB pathway (Liu et al. 
2015b). There was a direct antitumour effect in ICR mice exhibiting Ehlrich ascites 
tumour treated with cepharanthine (Asaumi et al. 1995). 
 
6.1.4 Cepharanthine combinations 
Cepharanthine has shown success in both blood and solid tumours when used in 
combination with other drugs. When combined with vincristine and Adriamycin, 
cepharanthine enhanced cytotoxicity in leukaemia cell lines L1210 and p388 (Kato 
and Suzumura 2017) and in HNCC cell lines HC-2, HC-3, HC-4, HC-7 and HC-9 
(Komiyama et al. 1989). The combination of cepharanthine and Adriamycin was also 
shown to be further enhanced by the introduction of hyperthermia (Nagaoka et al. 
1987). Combining vincristine, epirubicine and cepharanthine was shown to have a 
beneficial effect on bone metastasis which arise from renal cell carcinoma (Shichiri 
et al. 1994).   
 Combining cepharanthine to radiotherapy has been shown to improve 
treatment. In human cervical adenocarcinoma (HeLa) cell line, 
cepharanthine/radiotherapy combination therapy caused radiation sensitivity via 
inhibition of the STAT3 pathway and COX2 (Fang et al. 2013). Cepharanthine 
induced radio-sensitivity in OSCC cell lines (Tamatani et al. 2007). Cepharanthine 
was shown to be able to suppress γ-irradiation induced inflammatory response (NF-
κB activity and the production of IL-6 and IL-8) while at the same time enhancing 
PARP cleavage. In OSCC cells, the combination was also able to inhibit double 
stranded DNA repair after exposure to radiation (Harada et al. 2012). A combination 
of cepharanthine with an oral antineoplastic agent, S-1 was also shown to have a 
very good effect on human OSCC xenografts and significantly induced apoptosis 
(Harada et al. 2009).   
 The introduction of cepharanthine to interferon-β/-γ was shown to have a 
synergistic effect in terms of anti-proliferative properties in a dose-dependent 
manner on several cancer cell lines including: CRC (RPMI 4788), human lung 
carcinoma (PC 10), human uterine cervical cancer (HeLa) and human breast cancer 
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(ZR-75-1). A combination of cepharanthine and interferon-γ was shown to suppress 
metastatic development (Ono et al. 1994). A combination of cepharanthine and 
dacomitinib was able to enhance dacomitinib’s anti-cancer properties in NSCLC cell 
lines as cepharanthine was able to inhibit autophagic survival response which is 
induced due to dacomitinib usage (Tang et al. 2018).  
 A combination of cepharanthine and nimustine hydrochloride was seen to 
enhance cell death in malignant glioma cell lines: U87MG, U251MG and T98G via 
apoptosis in both p53 wildtype cells and p53 mutant cells (Kono et al. 2002). In 
NSCLC A549 cells that are resistant to gemcitabine, cepharanthine was able to 
inhibit multidrug resistance protein 7 (MRP7) and reverse gemcitabine resistance. 
A combination of cepharanthine with onconase (a ribonuclease from oocytes or 
early embryos of Northern Leopard frog) was able to completely abolish cell growth 
in several cancer cell lines including human promyelocytic leukaemia (HL-60), 
histiomonocytic lymphoma (U937), multiple myeloma (RPMI-8228), prostate 
carcinoma (DU145) and prostate adenocarcinoma (LNCaP) (Ita et al. 2008). 
Cepharanthine was shown to enhance the toxicity of conjugates of epidermal growth 
factor with Pseudomonas exotoxin when used against HeLa cells (Shiraishi et al. 
1988). In terms of lung metastasis induced by Lewis lung carcinoma, metastasis 
was greatly inhibited by a combination of cepharanthine and 5-fluorouracil (5-FU) 
(Ito et al. 2008).  
   
6.1.5 Hypothesis 
In the drug screen within Chapter 5, cepharanthine was demonstrated to selectively 
induce cell death in Tsc2-/- MEFs and was well tolerated by wildtype control cells 
when combined with the HIV inhibitor, nelfinavir. The purpose of this chapter was to 
expand on this initial finding, to further optimise this drug combination and to explore 
whether both drugs were synergistic. Once an optimised drug combination was 
determined, this chapter investigated the mechanism(s) of drug action that induced 
selective cytotoxicity in the Tsc2-/- MEFs.   
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6.2 Results: 
 
6.2.1 An optimized combination of cepharanthine and nelfinavir synergised to 
selectively target mTORC1 hyperactive cells. 
Having determined that a combination of cepharanthine and nelfinavir was a 
suitable candidate for selective cytotoxicity of Tsc2-/- cells (see Chapter 5), the next 
step was to determine an optimised combination of both drugs. To optimise this 
cepharanthine and nelfinavir drug combination, each drug was tested either as a 
single agent or in a combination of varying concentrations. Cells were incubated for 
48 h and results from flow cytometry were written as % cell death (Figure 6.1A). 
Results are summarised in Table 6.1. 
 
Table 6.1 Results from cell death flow cytometry. Results of flow cytometry to determine how 
cytotoxic cepharanthine (Ceph) and nelfinavir (NFV) are to Tsc2+/+ and Tsc2-/- MEFs as single 
agents or in combination over a range of concentrations 
 % Cell Death 
 Tsc2+/+ Tsc2-/- 
Drug Average SD Average SD 
DMSO 2.43 0.33 3.31 0.56 
NFV 20 µM 9.31 7.30 15.80 1.77 
NFV 10 µM 4.72 6.92 9.54 2.01 
Ceph 5 µM 5.20 1.80 5.25 1.33 
Ceph 2.5 µM 1.44 0.34 4.84 2.69 
Ceph 1.25 µM 1.35 0.21 4.23 1.06 
Ceph 5/NFV 20 µM 19.83 6.65 93.90 1.92 
Ceph 2.5/NFV 20 µM 8.93 6.21 92.60 2.69 
Ceph 1.25/NFV 20 µM 4.49 1.28 85.73 4.88 
Ceph 5/NFV 10 µM 4.73 1.97 19.53 1.67 
Ceph 2.5/NFV 10 µM 2.83 0.04 12.44 6.73 
Ceph 1.25/NFV 10 µM 2.86 0.36 11.56 5.42 
 
To figure out how synergistic this drug combination was, various 
concentration of cepharanthine, nelfinavir and several combinations of 
cepharanthine and nelfinavir using 20 µM nelfinavir as a base were tested via flow 
cytometry. Results were then processed in CompuSyn and a CI value was 
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generated. Results showed that combinations containing ≥ 2.5 µM cepharanthine 
showed high levels of synergy in wildtype cells while all combinations tested showed 
good synergy in Tsc2-/- MEFs (CI value = 0.05 in Tsc2+/+ MEFs vs 0.11 in Tsc2-/- 
MEFs when treated with 10 µM cepharanthine/20µM nelfinavir, 0.15 vs 0.13 with 5 
µM cepharanthine/20µM nelfinavir, and 0.52 vs 0.16 with 2.5 µM 
cepharanthine/20µM nelfinavir respectively). In combinations where the 
cepharanthine was less than 2.5 µM, results in wildtype MEFs were only minorly 
synergistic when compared to Tsc2-/- MEFs treated with identical treatments (CI 
value = 0.90 in Tsc2+/+ MEFs vs 0.31 in Tsc2-/- MEFs with 1.25 µM 
cepharanthine/20µM nelfinavir and 0.91 vs 0.61 with 0.625 µM cepharanthine/20µM 
nelfinavir) (Figure 6.1B (i-iv)). 
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Figure 6.1: Optimization and synergy of cepharanthine and nelfinavir. (A) Flow cytometry (with 
scatter blots) performed to measure cell death in Tsc2+/+ and Tsc2-/- MEFs treated with dimethyl 
sulfoxide (DMSO), cepharanthine (Ceph) or nelfinavir (NFV) as single agents at various 
concentrations or in combination (Ceph/NFV) at various concentrations after 48 h treatment (n=3; 
mean +/- SD). (B)  Dose response curves were performed in Tsc2+/+ and Tsc2-/- MEFs using flow 
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cytometry to measure cell death following treatment with (i) nelfinavir (NFV); (ii) cepharanthine 
(Ceph) and (iii) combined cepharanthine with a fixed concentration of 20 µM nelfinavir (Ceph/NFV) 
(n=3; mean +/- SD). Synergy was then calculated using CompuSyn and graphed (iv) as F(a) value 
vs CI value. Statistical significance is shown with combination or single agent treated Tsc2-/- MEFs 
compared to their wild-type controls. 
 
To confirm that Tsc2 loss was responsible for the induction of cell death, the 
concentration was tested using ELT3 cell lines (both null type (V3) and Tsc2 re-
expressed (T3)) via flow cytometry. Results were recorded as % cell death and 
etoposide was used as a positive control. Results showed that in both cell lines, the 
combination of cepharanthine and nelfinavir were extremely cytotoxic (80.93% +/- 
20.37 SD in ELT-T3 cells vs 92.55% +/- 8.99 SD in ELT-V3 cells). Both 
cepharanthine and nelfinavir used as single agents were also shown to be more 
cytotoxic in ELT3 cell lines when compared to MEFs (9.3 % +/- 7.30 SD in Tsc2+/+ 
MEFs vs 15.80% +/- 1.77 SD in Tsc2-/- MEFs compared to 14.09% +/- 5.39 SD in 
ELT-T3s vs 34.90% +/- 9.38 SD in ELT-V3s when treated with nelfinavir and 5.20% 
+/- 1.80 SD in Tsc2+/+ MEFs vs 5.25% +/- 1.33 SD in Tsc2-/- MEFs compared to 
25.83% +/- 8.13 SD in ELT-T3s vs 55.70% +/- 5.98 SD in ELT3-V3s when treated 
with cepharanthine) (Figure 6.2A).  
To determine if the combination could be used to target sporadic cancers, 
the combination was tested against three different types of mTORC1 hyperactive 
cancer cell lines (breast, colorectal and lung). Results were recorded as % cell death 
and etoposide was used as a positive control. Results from the flow cytometry 
showed that the combination caused high levels of cell death in all sporadic cancer 
lines tested (96.95% +/- 1.86 SD in HCT116, 90.13% +/- 7.48 SD in NCI-H460 and 
66.13% +/- 14.91 SD in MCF7 cells). HCT116 cells appeared to be sensitive to 20 
μM nelfinavir as a single agent as results showed a high level of cell death (67.53% 
+/- 4.65 SD) (Figure 6.2B). 
 
145 
 
 
Figure 6.2: Combination of cepharanthine and nelfinavir caused cytotoxicity in mTORC1 
hyperactive tumour cells. (A) ELT3-T3 and ELT3-V3; (B) MCF7, HCT116 and NCI-H460 were 
treated with either DMSO, 100 μM etoposide (ETO), 5 µM cepharanthine (Ceph), 20 µM nelfinavir 
(NFV) or cepharanthine and nelfinavir combination (Ceph/NFV) for 48 h. Cells were then tested by 
flow cytometry and cells were separated into viable and non-viable cell populations via DRAQ7 
staining(n=3; mean +/- SD).  Statistical significance is shown with combination treated ELT3-V3 cells 
to their wild-type controls and comparing single drug treatment of nelfinavir and combination in 
HCT116. 
 
6.2.2 Cepharanthine/nelfinavir combination prevented tumour colony 
formation and prevented tumour regrowth from treated spheroids. 
To determine the effects of cepharanthine/nelfinavir in a 3D environment, Tsc2-/- 
MEFs were either plated in either agar (for tumour colony formation assay) or 
agarose (for tumour outgrowth assay).  
To determine if the combined cepharanthine/nelfinavir treatment could 
prevent the formation of tumours, Tsc2-/- MEFs were treated with drugs for 14 days 
before being photographed, using rapamycin as a positive control. Results for the 
colony assay showed that the cepharanthine/nelfinavir combination significantly 
reduced the size of tumour colonies compared to single agents or in the presence 
of DMSO. Colonies treated with 5 µM Cepharanthine/ 20 µM Nelfinavir showed a 
similar size when compared to colonies treated with rapamycin (62.24 μm +/- 20.88 
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SD in combination treated colonies vs 63.39 μm +/- 19.58 SD in rapamycin treated 
colonies). Colonies treated with cepharanthine and nelfinavir as single agents also 
showed a reduction in colony size compared to the DMSO-treated spheroids 
(231.99 μm +/- 90.98 SD in DMSO-treated colonies compared to 126.29 μm +/- 
53.27 SD in cepharanthine treated colonies and 108.26 μm +/- 32.20 SD in nelfinavir 
treated colonies) (Figure 6.3A).  
 To determine the effects of the combination on established tumour spheroids, 
Tsc2-/- MEFs were incubated for 72 h to form spheroids on agarose and 
photographed before being treated and after being treated with drugs for 96 h (the 
last 48 h including DRAQ7). Spheroids were then place in fresh non-drug media for 
72 h (photographed every 24 h). Results showed that there was no change in size 
between any of the treatment conditions after 96 h of treatment. The morphologies 
of DMSO cepharanthine and nelfinavir treated cells remained the same, however, 
samples treated with the cepharanthine/nelfinavir combination changed to an 
increased “fluffy” appearance (Figure 6.3B). Once placed back into clean drug-free 
media, spheroids previously incubated in the combined cepharanthine/nelfinavir 
treatment failed to regrow after 72 h. All other spheroids did eventually grow back, 
although while cepharanthine and nelfinavir treated spheroids grew at similar rates, 
these were slower compared to DMSO treated spheroids (Figure 6.3C). 
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Figure 6.3: Mefloquine/nelfinavir combination prevented tumour formation and tumour 
spheroid growth. Colony formation was tested in Tsc2-/- MEFs seeded on soft agar that were 
treated for 14 days with Dimethyl Sulfoxide (DMSO), 5 µM cepharanthine (Ceph), 20 µM nelfinavir 
(NFV) or in combination Ceph/NFV (n=3; mean +/- SD). Tumour diameters were measured using 
Image J. Significance was observed when comparing combined nelfinavir and cepharanthine 
treatment to DMSO vehicle control. Work done was assisted by Lauren McEneaney (B) Tsc2-/- MEF 
spheroids were grown for 72 h before being treated under the same conditions as (A) for 96 h. 
DRAQ7 was supplemented for the final 48 h to monitor cell death before images were taken. (C) 
Spheroids treated in (B) were re-plated onto standard tissue culture plates and grown in drug-free 
media. Images were taken every 24 h and the area of outgrowth was calculated using Image J, scale 
bar is 200 μm and outgrowth area is graphed. Statistical significance is shown with combination 
treated tumour colony size compared to their wild-type controls and comparing outgrowth of 
combination treated spheroids to single agent and DMSO treated spheroids (n=3; mean +/- SD). 
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6.2.3 Cepharanthine/nelfinavir combination targeted Tsc2-/- cells in an mTOR 
and autophagy/lysosomal-independent manner. 
To determine if the autophagy flux was altered by the combination, western blots 
were carried out on Tsc2+/+ or Tsc2-/- MEFs treated for 3 h with bafilomycin A1 as 
a positive control. Results showed that cepharanthine was able to cause 
accumulation of LC3-II in both cell lines. The combination was also able to cause 
LC3-II accumulation in both cell lines. Accumulation levels were slightly higher in 
Tsc2+/+ MEFs compared to Tsc2-/- MEFs. p62 was basally elevated in Tsc2-/- 
MEFs compared to Tsc2+/+ MEFs and did not appear to be greatly affected by the 
treatment of bafilomycin A1, single agents or combination (Figure 6.4A). 
Cepharanthine has been shown to accumulate in the lysosome and cause 
inhibition of lysosomal cathepsin B and cathepsin D maturation (Shiraishi et al. 
1988b; Tang et al. 2018). To determine how the cepharanthine/nelfinavir 
combination would affect the lysosome, Tsc2-/- MEFs were treated for 48 h with 
either DMSO, cepharanthine/nelfinavir combination, cepharanthine/nelfinavir 
combination with 100 nM bafilomycin A1 (a v-ATPase inhibitor), or bafilomycin A1 
before being analysed via flow cytometry. Results showed that bafilomycin A1 as a 
single agent was able to cause a considerable amount of cell death in Tsc2-/- MEFs 
(76.93% +/- 8.12 SD). Results also showed that bafilomycin A1 failed to rescue cells 
from death in Tsc2-/- MEFs treated with the cepharanthine/nelfinavir combination 
(86.63% +/- 9.05 SD in cells treated with just cepharanthine/nelfinavir vs 87.87% +/- 
5.35 SD in cells treated with cepharanthine and bafilomycin A1). To confirm that 
bafilomycin A1 was working correctly, western blots were carried out with both 
Tsc2+/+ and Tsc2-/- MEFs, treated for either 3 h or 24 h in combination or 
combination with bafilomycin A1. Western blots showed that in combination plus 
bafilomycin A1 treated samples showed the accumulation of LC3-II in both cell lines 
increasing from 3 h to 24 h. Accumulation of p62 (also referred to as SQSTM1) was 
seen in both cell lines as well (at 24 h in Tsc2+/+ MEFs and at both 3 h and 24 h in 
Tsc2-/- MEFs). In Tsc2-/- MEFs treated with just combination, results showed that 
while accumulation of both LC3-II and p62 was observed at the 3 h time point, cells 
appeared to recover as no accumulation was detected at the 24 h time point (Figure 
6.4B (i-ii)). 
To determine if mTORC1-hyperactivity was important for the induction of cell 
death, flow cytometry was carried out on Tsc2-/- MEFs treated with DMSO, 
rapamycin,  cepharanthine/nelfinavir, with rapamycin (along with a 1 h rapamycin 
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pre-treatment) for 48 h. Results showed that the introduction of rapamycin failed to 
rescue cell death in Tsc2-/- MEFs (86.63% +/- 9.05 SD in combination-treated cells 
vs 88.93% +/- 4.01 SD in combination plus rapamycin treated cells). Rapamycin 
also showed very little cell death when used as a single agent (6.36% +/- 3.55 SD). 
To confirm if rapamycin was inhibiting mTORC1 activity, western blots were carried 
on the previously mentioned cell lines treated in the same conditions as the flow 
cytometry. Results showed that samples treated with combination and rapamycin 
showed a complete or near complete inhibition of RSP6 phosphorylation, confirming 
rapamycin was successfully inhibiting the mTORC1 pathway (Figure 6.4C (i-ii)). 
 
 
Figure 6.4: Inhibition of mTORC1 was not associated with combination-induced cell death 
and the combination caused minimal inhibition of autophagy which was not associated with 
cell death. (A) Tsc2-/- and Tsc2+/+ MEFs were treated with 20 μM nelfinavir (NFV) and 5 µM 
cepharanthine (Ceph), 100 nM bafilomycin A1 or cepharanthine and nelfinavir (Ceph/NFV) for 3 h. 
Accumulation of lipidated LC3-II and p62 were analysed by western blot. (B(i)) Tsc2-/- were treated 
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with 20 μM nelfinavir (NFV) and 5 µM cepharanthine (Ceph) or Ceph/NFV with 100 nM Bafilomycin 
A1 (BAF) for 48 h. Cell death was determined using flow cytometry (n=3; mean +/- SD). Statistical 
significance (calculated by one-way ANOVA) shown between DMSO-treated and Ceph/NFV treated 
cells and between DMSO-treated cells and Ceph/NFV/BAF treated cells. (B(ii)) To determine if BAF 
was functioning as expected, western blotting was carried out to determine the accumulation of 
lipidated LC3-II and p62 in the cells treated in (B(i)) after 3 h and 24 h of treatment. Total protein 
levels of β-actin were used as a loading control. (C(i)) Tsc2-/- MEFs were pre-treated with 50 nM 
rapamycin (RAP) for 1 h, where indicated, before being treated with either 20 μM nelfinavir (NFV) 
and 5 µM cepharanthine (Ceph) or MQ/NFV with RAP for 48 h. Cell death was determined using 
flow cytometry (n=3; mean +/- SD). (C(ii)) To determine if RAP was functioning as expected, western 
blotting was carried out to determine rp-S6 phosphorylation at Ser235/236 in the cells treated in (A) 
after 48 h of treatment. Statistical significance (calculated by one-way ANOVA) shown between 
DMSO-treated and Ceph/NFV treated cells and between DMSO-treated cells and Ceph/NFV/RAP 
treated cells. All Blots in figure 6.4 are representative of n=2 runs 
 
6.2.4 Cepharanthine/nelfinavir combination did not affect the production of 
reactive oxygen species (ROS). 
To confirm if the combination was causing an effect on the production of ROS, both 
Tsc2+/+ and Tsc2-/- MEFs were stained with DCFDA before being treated with 
several different treatments; DMSO, TBHP (positive controls), 
cepharanthine/nelfinavir and cepharanthine/nelfinavir with either methyl pyruvate or 
NAC (negative controls). Results written as ROS Generation fluorescence (RGF). 
Results showed that the cepharanthine/nelfinavir combination caused a decrease 
in ROS production compared to cells treated with just DMSO (862.54 RGF +/- 
481.48  SEM in Tsc2+/+ MEFs vs 993.04 RGF +/- 492.61 SEM in Tsc2-/- MEFs). 
The introduction of the ROS scavengers also caused a reduction in ROS production 
(304.04 RGF +/- 201.78 SEM in Tsc2+/+ MEFs vs 447.91 RGF +/- 244.06 SEM in 
Tsc2-/- MEFs in the presence of NAC and 121.54 RGF +/- 45.26 SEM in Tsc2+/+ 
MEFs vs 208.92 RGF +/- 79.57 SEM in Tsc2-/- MEFs in the presence of methyl 
pyruvate) (Figure 6.5A). 
To determine if ROS production played a role in cell death, flow cytometry 
was carried out in Tsc2-/- MEFs treated with either DMSO, drug combination or drug 
combination with NAC for 24 h (as NAC is a short-lived inhibitor). Results showed 
that the presence of NAC failed to rescue cells from death (41.20% +/- 6.90 SD 
when treated with mefloquine/nelfinavir combination and NAC compared to 44.82% 
+/- 3.60 SD when treated with just the combination) (Figure 6.5B). 
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Figure 6.5: Cepharanthine/nelfinavir combination caused minimal effect on ROS production. 
(A) Tsc2+/+ and Tsc2-/- MEFs were stained in 25 μM 2’, 7’ –dichlorofluorescin diacetate (DCFDA) 
for 45 min at 37oC. Cells were washed and treated with DMSO, Tert-Butyl Hydroperoxide (TBHP), 
cepharanthine and nelfinavir combination (Ceph/NFV), combination plus N-acetyl-L-cysteine 
(Ceph/NFV + NAC) or combination plus methyl pyruvate (Ceph/NFV + MP) for 4 h. Fluorescence 
was read on plate reader at excitation at 485 nm and emission at 535 nm (n=3; mean +/- SEM). (B) 
Tsc2-/- MEFs treated with DMSO, cepharanthine and nelfinavir combination (CN) or combination 
plus N-acetyl-L-cysteine (CN + NAC) for 24 h. Cell death was measured via flow cytometry using 
DRAQ7 staining (n=3; mean +/- SD). Statistical significance (calculated by one-way ANOVA) shown 
between DMSO-treated and Ceph/NFV treated cells, between NAC-treated cells and Ceph/NFV 
cells, between DMSO-treated cells and Ceph/NFV/NAC treated cell and between NAC-treated cells 
and Ceph/NFV/NAC treated cells. 
 
6.2.5 Cepharanthine and nelfinavir as single agents, as well as in combination 
blocked P-glycoprotein activity in Tsc2+/+ and Tsc2-/- MEFS. 
Cepharanthine has been shown to be a substrate of P-glycoprotein and binding 
causes inhibition of activity and transport of cytotoxic drugs out of cells (Mizobata et 
al. 2002). To determine if cepharanthine/nelfinavir combination could inhibit P-
glycoprotein activity, both Tsc2+/+ and Tsc2-/- MEFs were treated with either 
combined cepharanthine/nelfinavir treatment or control, with all treatments 
containing 5.25 µM of Rhodamine123 (which is a substrate of P-glycoprotein) for 30 
min at 37oC. Samples were then lysed in warmed deionised water and a 
fluorescence reading was taken. Results were recorded as a % of DMSO treated 
control. Results confirmed that cepharanthine inhibited P-glycoprotein activity (as 
seen in the increased Rhodamine 123 uptake compared to DMSO) in Tsc2-/- but 
not in Tsc2+/+ MEFs (103.70% +/- 10.70 SEM in Tsc2+/+ MEFs and 147.16% +/- 
15.56 SEM in Tsc2-/- MEFs compared to 100 % in DMSO treated cells respectively). 
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Nelfinavir (as seen in Chapter 4) also caused P-glycoprotein inhibition (large 
observable increase in rhodamine 123 uptake) in Tsc2+/+ cells but caused minor 
inhibition (slight observable uptake) in Tsc2-/- cells (166.80% +/- 7.16 SEM in 
Tsc2+/+ MEFs compared to 127.47% +/- 7.42 SEM in Tsc2-/- MEFs). The 
combination of cepharanthine and nelfinavir showed poor activity inhibition (as seen 
in a slight increase in rhodamine 123 uptake) in Tsc2-/- MEFs. It did however cause 
a greater level of inhibition (a larger uptake) in Tsc2+/+ MEFs (135.07% +/- 19.15 
SEM in Tsc2+/+ MEFs compared to 117.25% +/- 8.62 SEM in Tsc2-/- MEFs) (Figure 
6.6). 
 
 
Figure 6.6: Mefloquine/nelfinavir combination affected rhodamine 123 uptake. Tsc2+/+ and 
Tsc2-/- MEFs were treated with DMSO, 5 μM cepharanthine, 20 μM nelfinavir or a combination of 
cepharanthine and nelfinavir (all containing 5.25 μM rhodamine 123) for 30 min at 37 oC before being 
lysed in warmed deionised water. Fluorescence was analysed via plate reader at excitation at 480 
nm and emission at 520 nm (n=3; mean +/- SEM). Statistical significance is shown between 
combination treated Tsc2+/+ and Tsc2-/- MEFs 
. 
6.2.6 Cepharanthine/nelfinavir combination induced enhanced and prolonged 
ER stress in Tsc2-/- cells via the PERK pathway. 
To determine the effects the combination would have on ER stress pathways in both 
Tsc2+/+ and Tsc2-/- MEFs, western blots were performed on Tsc2+/+ and Tsc2-/- 
MEFs treated for 6 h with drugs using tharsigargin was a positive control. Results 
showed that there was a large difference in expression of ER stress makers 
between Tsc2+/+ and Tsc2-/- MEFs as can be seen in IRE1α (although expression 
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levels showed a decrease in expression of the protein in Tsc2-/- MEFs and an 
increase in expression in Tsc2+/+ MEFS when both cell types are treated with the 
combination) and in SESN2 (in which expression appeared to be too greatly affect 
the presence of drugs, either control, single agent or combination). In the Tsc2-/- 
MEFs, there were high levels of expression for several components of the PERK 
pathway such as GADD34, CHOP and ATF4 when cells where treated with drugs, 
and levels were higher in the presence of the cepharanthine/nelfinavir combination 
when compared to single agents especially in CHOP although differences in 
GADD34 and ATF4 were less pronounced. At the same time point, components of 
the mTOR pathway were also tested to determine the effects on the pathway. 
Results showed a higher basal level of phosphorylation of S6K in Tsc2-/- MEFs 
compared to Tsc2+/+ MEFs although expression levels did decline in cells treated 
with single agent or combination. In terms of RPS6 phosphorylation, the presence 
of either nelfinavir or the combination caused a decreased phosphorylation in 
Tsc2+/+ MEFs compared to Tsc2-/- MEFs. Results also confirmed that Tsc2-/- 
MEFs had no Tsc2 expression. (Figure 6.7A). 
 To confirm that ER stress was occurring, an investigation into XBP1 splicing 
was carried out. Both Tsc2+/+ and Tsc2-/- MEFs were treated for 6 h with treatments 
used in Figure 6.7A, using tharsigargin as a positive control, before mRNA was 
extracted and converted to cDNA. Results were then processed by PCR and 
analysed on an agarose gel. Results showed that splicing occurs at a higher level 
in Tsc2-/- MEFs compared to Tsc2+/+ MEFs. With Tsc2-/- cells, splicing occurred 
in samples treated with the cepharanthine/nelfinavir combination at a much higher 
rate compared to single agents or DMSO (Figure 6.7B). 
 
6.2.7 Cepharanthine/nelfinavir combination affected energy stress levels in 
Tsc2-/- cells. 
To determine if the combined cepharanthine/nelfinavir treatment influenced energy 
stress, flow cytometry was carried out in Tsc2-/- MEFs treated for 48 h with either 
DMSO, cepharanthine/nelfinavir combination or combination with methyl pyruvate. 
Results showed that the presence of methyl pyruvate was able to rescue Tsc2-/- 
cells from death (86.63% +/- 9.05 SD when treated with just cepharanthine/nelfinavir 
compared to 38.95% +/- 6.91 SD when cells were treated with both 
cepharanthine/nelfinavir and methyl pyruvate) (Figure 6.7C). 
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Figure 6.7: The effects of cepharanthine/nelfinavir combination on ER stress and energy 
stress. (A) Tsc2+/+ and Tsc2-/- MEFs were treated with either DMSO, 1 µM thapsigargin (TPG), 5 
µM cepharanthine (Ceph), 20 µM nelfinavir (NFV), or cepharanthine and nelfinavir combination 
(Ceph/NFV) for 6 h, where indicated. Total protein levels of TSC2, IRE1α, ATF4, CHOP, GADD34, 
S6K1, SESN2 and β-actin and S6K1 phosphorylated at Thr389 and RPS6 phosphorylated at 
Ser235/236 were detected by Western blot. (B) Xbp1 mRNA splicing was determined from the same 
treatments as described in (A). PCR products were resolved on agarose gels (unspliced = 480 bp 
upper band, spliced = 454 bp lower band). (C) Tsc2-/- cells were treated with DMSO, 5 μM 
cepharanthine and 20 μM nelfinavir combination (Ceph/NFV) or cepharanthine/nelfinavir 
combination with the addition of 8 mM methyl pyruvate (MQ/NFV/MP) for 48 h. Cells were then 
stained with DRAQ7 and % cell death determined by flow cytometry (n=3; mean +/- SD). Statistical 
significance is shown comparing combination treated Tsc2-/- and combination plus methyl pyruvate 
treated Tsc2-/- MEFs and DMSO. All Blots in figure 6.7 are representative of n=2 runs 
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6.3 Discussion: 
In Chapter 5, a combination of cepharanthine and nelfinavir was shown to be highly 
selective for targeting Tsc2-/- MEFs while being well tolerated by wildtype controls. 
The purpose of this chapter was to further investigate this novel combination, to 
optimise it and identify potential modes of action against not only mutant MEFs, but 
against other sporadic mTORC1 hyperactive cells. To date, it appears that this is 
the first time that a combination of cepharanthine and nelfinavir has been used for 
the treatment of mTORC1 hyperactive tumour cells.  
In terms of the concentration of cepharanthine used in this chapter, the 5 μM 
used falls in the same range as several other cancer cell lines including HeLa cells, 
cepharanthine (IC50 of 8.9 μM), multiple myeloma cells (IC50 between 2 and 8 μM 
and CRC cell lines (IC50 of between 2.4 μM and 5.3 μM) (Bun et al. 2008; Kikukawa 
et al. 2008; Law et al.  2015). Cepharanthine can also be used at a much higher 
concentration which can affect the mechanisms of action which will be discussed 
later in this section. With regards to nelfinavir, the concentration used was above 
the range discussed in chapter 3 (4.96 µM (Zhang et al. 2001) to 18 µM (Marzolini 
et al. 2001)). However, several combinations developed by the lab group have used 
this nelfinavir concentration and showed positive results (Johnson et al. 2015; 
Dunlop et al. 2017a; Johnson et al. 2018).  
 Cepharanthine combined with nelfinavir was able to cause high levels of 
cytotoxicity in Tsc2-/- MEFs when 20 μM of nelfinavir was used as the base. It is 
interesting to note that at this concentration of nelfinavir, all concentrations (1.25-5 
μM) of cepharanthine used showed high levels of cell death in Tsc2-/- MEFs while 
being well tolerated in Tsc2+/+ MEFs (although the level of cell death did increase 
in a dose-dependent manner). On the other hand, using 10 μM Nelfinavir based 
combinations showed a dramatic decrease in cell death at all cepharanthine 
concentrations used (although there was still significant difference in cell death 
observed between both cell types). Initially a combination consisting of 2.5 μM 
cepharanthine and 20 μM nelfinavir was chosen as the optimised concentration for 
future testing as it had the same level of cell death as the 5 μM cepharanthine and 
20 μM nelfinavir but had less cell death in the control cells. However, during 
experimentations in this chapter, it was observed that this combination started to fail 
in inducing cell death in Tsc2-/- MEFs as the cells became older and the cells 
reached passage numbers higher than p35. Because of this reduction in 
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performance, it was decided that a combination of 5 μM cepharanthine and 20 μM 
nelfinavir would be used for all future testing.  
 When testing against mTORC1 hyperactive sporadic cancer cell lines, two 
unusual results were observed. ELT3 cell lines were used to show that Tsc2-
deficiency plays a role in selectivity in a cell line which is considered “hardier” than 
Tsc2-/- MEFs. ELT3 cells with the re-expression of TSC2 (ELT-T3) were used as a 
control to represent Tsc2+/+ MEFs. In the normal scenario, as seen in (Johnson et 
al. 2015; Johnson et al. 2018; McCann et al. 2018), the results from ELT3 cell lines 
are expected to be similar to those found in MEFs. In the case of 
cepharanthine/nelfinavir combination however, both ELT3 cell lines tested showed 
high cytotoxicity levels. High levels of toxicity were expected in wildtype ELT3 cells 
as seen in Tsc2-/- MEFs. However, in the ELT3-T3 cells, this level of cytotoxicity 
was not expected and significantly higher than compared to Tsc2+/+ MEFs. One 
reason for these high levels of cytotoxicity is possibly due to ELT3 cells having more 
mutations compared to MEFs (which only have mutations in p53 and Tsc2 as 
previously mentioned in Chapter 2). Getting a full detailed list of all the mutations in 
ELT3 cell lines used may allow for further investigations into possible modes of 
action based on the mutations present in the cells. Combining these results with the 
results of the rapamycin rescue assay carried out almost certainly confirms that lack 
of TSC2 or any activity of the mTOR pathway does not play a role in mechanism in 
which the cepharanthine/nelfinavir combination kills cells. Cepharanthine as a single 
agent also showed high levels of selectivity for wildtype ELT3 cells but at a lower 
rate compared to the cepharanthine/nelfinavir combination. 
 In HCT116 cells tested, the presence of 20 μM nelfinavir seemed to cause 
high levels of cell death. This is an unusual result as in Chapter 3, the presence of 
10 μM nelfinavir caused minimal cell death to HCT116. It is an interesting 
observation that doubling the nelfinavir can cause such an increase in cell death as 
it could mean that using higher concentrations (such as 20 μM) of nelfinavir could 
be used as a monotherapy for this cell type of colorectal cancer. There are still plenty 
of opportunities for this combination with regards to sporadic tumours. Results from 
this chapter showed that against sporadic cell lines such as HCT116 and NCI-H460, 
the cepharanthine/nelfinavir combination worked exceptionally well against these 
tumour types and could be a viable treatment option in the future should the 
combination pass pre-clinical and clinical trials. Results also showed that the 
presence of the combination was able to cause high levels of cell death in the drug-
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resistant cell line MCF7 compared to when these cells were treated with single 
agents or even the etoposide control.  Because of this, further investigations into 
combination therapy as a treatment for forms of drug resistant breast cancer may 
be a viable option to undertake in the future. This is especially true with regards to 
identifying the mechanism of triggering cell death in this cell line which may be useful 
for treating other drug-resistant cell lines. 
 As described in this chapter’s introduction, cepharanthine can be used as an 
autophagy inhibitor (Tang et al. 2018). Results showed that the combination was 
able to halt autophagy in both MEF cell lines after 3 h of treatment. However as 
seen in the autophagy time course, the evidence points to MEFs (both wildtype and 
mutant) being able to restore autophagic activity by the 24 h time point, indicating 
that while the combination disrupted autophagic activity, the effects were only short 
lived and more than likely does not play a role in cell death. The results of the 
bafilomycin A1 rescue assay, which was carried out to determine if bafilomycin A1 
could prevent cell death, in a manner similar to that seen in chloroquine/nelfinavir 
combination (lysosomal accumulation of drug combination) (Johnson et al. 2015) 
also showed that lysosomal accumulation of cepharanthine/nelfinavir did not play a 
role in cell death.   
 Cepharanthine/nelfinavir combination was shown to cause a reduction in 
ROS production. This result is different from results seen in other treatments against 
other cancer cells. In both NSCLC cell lines H1299 and A549 and choroidal 
melanoma cells, the presence of cepharanthine caused an increase in ROS 
production which lead to cell death (Hua et al. 2015; Zhu et al. 2017a). However, 
one important fact to note is that the concentrations of cepharanthine used to cause 
cytotoxicity in the targeted cell lines were multiple fold higher compared to the 5 μM 
cepharanthine used in this chapter as Hua et al. (2015) used up to 120 μM and Zhu 
et al. (2017) used as high as 60 μM and even 80 μM in several experiments. In TK6 
lymphoblastoid cells, a similar range of cepharanthine concentrations as to those in 
this chapter (up to 8.3 μM) were tested and similar results to the results in this 
chapter was observed in the form of ROS scavenging and protection of DNA (Sierra 
et al. 2015). The results of this chapter combined with the results observed in 
literature showed that cepharanthine can act as either a ROS scavenger or a ROS 
producer in a concentration-dependent. This knowledge could be useful for future 
cepharanthine-based combinations as it means the role of the cepharanthine can 
be changed based on the concentrations used if it does not induce high levels of 
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cytotoxicity in wild type normal cells. The NAC rescue assay also showed that ROS 
production did not play a role in cell death as the addition of NAC failed to rescue 
Tsc2-/- MEFs after 24 h treatment.   
 As with all combinations tested in this thesis, one of first ideas to what may 
be triggering cell death, was elevated levels of ER stress. When cells were treated 
with cepharanthine/nelfinavir combination, there were elevated expressions of the 
main components of the PERK pathway. Data from the XBP-1 splicing assay 
showed that the cepharanthine and nelfinavir combination was able to trigger near 
complete splicing of XBP-1. High levels of splicing were seen in cells treated with 
nelfinavir as a single agent although this was most likely due to the concentration of 
nelfinavir used (20 μM). 
 The cepharanthine/nelfinavir combination was tested in combination with 
methyl pyruvate to determine if energy stress was one of the principle causes of cell 
death. Results showed that the combination of cepharanthine and nelfinavir was 
causing cell death via energy stress death.  
 An unusual observation about cepharanthine is that there have been no 
major reports of significant safety issues or adverse effects (Masuda et al. 1993; 
Kakehi et al. 1994; Morita et al. 2002). As previously stated in Chapter 3, the original 
target population of this thesis were patients with TSC-associated tumours. Because 
of the many complications associated with TSC which were discussed in Chapter 1, 
it would be important to use drugs which would not worsen the effects associated 
with this disease. As a result, cepharanthine due to its low risk of adverse effects, 
would be a suitable candidate for future development of treatments and 
combinations for use in TSC patients and associated tumours.  
In conclusion, the data showed that an optimised concentration of 
cepharanthine and nelfinavir synergised to selectively target mTORC1 hyperactive 
cells in a TSC-based or sporadic tumour-based setting. The data presented showed 
that cytotoxicity of the combined cepharanthine/nelfinavir treatment was likely due 
to an increase in energy stress, that was not optimally restored in cells without TSC2 
and as a result, triggers cell death. 
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Chapter 7: General Discussion 
 
7.1 Discussion introduction 
The purpose of this thesis was to identify novel nelfinavir-based drug combinations 
that could be used to selectively kill mTORC1 hyperactive cells while being tolerated 
by wildtype cells. In this thesis, three nelfinavir-based combinations identified: 
mefloquine, Bortezomib and cepharanthine. The mefloquine/nelfinavir, 
Bortezomib/nelfinavir and cepharanthine/nelfinavir combinations were also 
investigated in depth to determine the mode of drug action to induce cytotoxicity in 
mTORC1 hyperactive cells. The data obtained from experimental work suggests 
that mefloquine/nelfinavir and cepharanthine/nelfinavir combinations caused cell 
death by induced energy stress possibly in combination with prolonged ER stress, 
while the Bortezomib/nelfinavir combination caused cytotoxicity via enhanced ER 
stress and proteasomal inhibition.  
  
7.2 Optimisation and Synergy 
 
7.2.1 Optimisation 
A challenge associated with testing the cytotoxicity of drugs was choosing a suitable 
method to optimise the range of drug concentrations. Cell viability dyes such as 
resazurin and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
could be used, as they are suitable when screening cells in a 96 well plate format 
and would allow for a much wider spectrum of concentrations to be tested compared 
to using flow cytometry from cells grown on a 24-well plate. However, the main 
problem with these dyes is that they function via cell metabolism (converted from 
substrate to product via metabolic action of the tested cell). While this may be 
suitable in wildtype cells, Tsc2-/- MEFs are metabolically dysfunctional due to higher 
level of mTORC1 activation (as confirmed in the RNA sequencing in Chapter 3) 
meaning that there is a higher risk of false positives being generated.  
The initial idea was to use the CyQUANT assay as it binds to DNA and not 
involved in metabolism and as a result avoids the above-mentioned concerns of 
false positivity. The CyQUANT is also a quick assay. Cells treated with the drugs 
can also be frozen (allowing for a flexible schedule of analysis) and was able to be 
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used in a 96-well plate format. However, the main problem with using the CyQUANT 
assay was that the assay was designed to show effects on cell number, which is 
dependent on both cell proliferation and loss of cell viability. As we see in Chapter 
3 and Chapter 5, all drug combinations tested were able to affect cell number. This 
is likely due to reduced cell proliferation, to varying degrees. However, when the 
same conditions were tested via flow cytometry, there was no detectable cell death. 
Therefore, the CyQUANT experimental procedure was not sufficient to determine 
loss of cell viability due to the effects of the drugs. While the CyQUANT could show 
selectivity for reducing cell number between Tsc2+/+ and Tsc2-/- MEFs to a degree, 
it could not determine if inhibition of Tsc2+/+ cell numbers was due to cell death or 
simply the drug’s effect to inhibit proliferation. For future projects, it is strongly 
recommended that CyQUANT assays should not be used exclusively as a technique 
to determine cell death. Rather, flow cytometry (using DRAQ7 or other cell death 
specific dye like propidium iodide) should be used as the principle measure of cell 
death for metabolically active Tsc2-/- MEFs. 
There was a noticeable difference between the optimisation of 
mefloquine/nelfinavir and cepharanthine/nelfinavir. Mefloquine/nelfinavir 
optimisation was seen at only two sets of drug concentrations (as previously 
mentioned in Chapter 3); 5 μM mefloquine and 20 μM nelfinavir and 10 μM 
mefloquine and 10 μM nelfinavir.  There was a narrow range of drug concentration 
where selectivity to cell death was observed in the Tsc2-/- MEFs. While the 
optimisation range for mefloquine/nelfinavir was incredible narrow, optimisation 
between cepharanthine and nelfinavir occurred over a wider range of cepharanthine 
concentration (when nelfinavir was set at 20 μM). At least three concentrations of 
cepharanthine showed high selectively for Tsc2-/- MEFs and were well tolerated by 
wildtype cells (which improved as cepharanthine concentration was reduced). 
However, a 10 μM nelfinavir base caused cepharanthine/nelfinavir combinations to 
become ineffective. It was also worth noting that the age of cells did not affect the 
cytotoxicity of the mefloquine/nelfinavir combination but did affect the 
cepharanthine/nelfinavir combination (initially a 2.5 μM cepharanthine/ 20 μM 
nelfinavir combination was chosen for further testing however, as discussed in 
Chapter 6; this concentration failed to kill Tsc2-/- MEFs after a passage number 
greater than 30). No optimisation was carried out on the Bortezomib/nelfinavir 
combination during this thesis as the chosen concentration of both drugs were 
determined previously (Johnson et al. 2018).   
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The drug concentrations used in chapter appear to fall into acceptable levels 
of testing. As discussed in chapter 3, the concentrations used for the 
mefloquine/nelfinavir combination (10 μM mefloquine and 10 μM nelfinavir) been 
shown to be viable in patients (nelfinavir 4.96-18 µM and mefloquine 2.1‐23 μM 
(Marzolini et al. 2001; Zhang et al. 2001; Dow et al. 2005)). While the 20 μM 
nelfinavir used in the cepharanthine and bortezomib combinations falls slightly 
beyond the 18 μM range seen in Marzolini et al. (2001), nelfinavir at 20 μM has been 
used in several combinations for in vitro testing such as salinomycin and chloroquine 
(Johnson et al. 2015; Dunlop et al. 2017) and was lower than the nelfinavir 
concentration used with bortezomib in the treatment of cervical cancer cell lines 
(ranging from 26-35 μM (Bruning et al. 2011; Brüning et al. 2013)). The bortezomib 
concentration used in chapter 4 was similar to bortezomib/nelfinavir combinations 
against cervical cancer cell lines (39-50 nM).The 5 μM cepharanthine used in 
chapter 6 falls well with the concentration range used by in vitro studies; HeLa cells 
(IC50 of 8.9 μM), multiple myeloma cells (IC50 between 2 and 8 μM) and CRC cell 
lines (IC50 of between 2.4 μM and 5.3 μM) (Bun et al. 2008; Kikukawa et al. 2008; 
Law et al.  2015) while Hua et al. (2015) used up to 120 μM cepharanthine and Zhu 
et al. (2017) used as high as 60 μM and even 80 μM in several experiments.  
  
7.2.2 Synergy 
Both mefloquine/nelfinavir and cepharanthine/nelfinavir combinations had varying 
degrees on synergy. For the mefloquine/nelfinavir combinations, synergy for drug 
cytotoxicity was achieved only at 10 μM mefloquine and 10 μM nelfinavir and at 100 
μM mefloquine and 10 μM nelfinavir in Tsc2-/- MEFs while in 
cepharanthine/nelfinavir combinations, all combinations tested in Tsc2-/- MEFs 
where shown to be synergistic (ranging from extremely synergistic to mildly 
synergistic). As shown in Chapter 3, mefloquine/nelfinavir combinations containing 
less than 10 μM mefloquine were extremely antagonistic compared to low 
concentration of cepharanthine/nelfinavir combinations (which were shown to be 
synergistic).  
 In Tsc2+/+ MEFs, mefloquine/nelfinavir was only synergistic at high 
concentrations (100 μM mefloquine/10 μM nelfinavir). At 10 μM mefloquine or lower, 
all the combinations were antagonistic (as seen and discussed in Chapter 3). 
Mefloquine/nelfinavir was well tolerated in the wildtype cells until the introduction of 
162 
 
higher concentration of mefloquine (>10 μM) which was shown to be cytotoxic. All 
cepharanthine/nelfinavir combinations were shown to be synergistic in the Tsc2-/- 
MEFs with combinations only showing reduced synergy (almost becoming additive) 
when the cepharanthine concentration in these combinations was reduced. 
 Synergy analysis was not carried out in this thesis for the nelfinavir and 
Bortezomib. However, synergy was undertaken by Johnson et al. (2018). They 
showed that like cepharanthine/nelfinavir combinations, combinations of 
Bortezomib and nelfinavir across a wide range of concentrations was synergistic in 
the Tsc2-/- MEFs. In Tsc2+/+ MEFs, the lowest concentration of 
Bortezomib/nelfinavir combination tested was shown to be antagonistic, while all 
other Bortezomib/nelfinavir combinations were shown to be synergistic. 
 
7.3 Other cell lines 
In this thesis, having shown that the mefloquine/nelfinavir and 
cepharanthine/nelfinavir combinations were able to selectively target mutated cells 
in a TSC-associated environment (i.e., Tsc2-/- MEFs), the next logical step was to 
determine cytotoxicity of these drug combinations on other TSC-associated (ELT3 
cell lines) and sporadic cancer cell lines.  
 In ELT3 cell lines (which are Tsc2-null), results differed greatly when 
comparing the mefloquine/nelfinavir combination to the cepharanthine/nelfinavir 
combination. When treated with mefloquine/nelfinavir, both ELT3 cell lines (ELT3-
V3 and the control ELT3-T3) showed similar results compared to those seen in the 
MEFs. On the other hand, the cepharanthine/nelfinavir combination was shown to 
cause non-selective cell death in both cell lines. The reason for this discrepancy 
between the two different drug combinations was already suggested in Chapter 6, 
as it may be possible that other mutations found in the ELT3 cells (they are cancer 
cells) may be sensitive to the cepharanthine/nelfinavir combination but not to 
mefloquine/nelfinavir combination. As mentioned in Chapter 6, an in-depth look at 
the mutations in the ELT3 cells may give clues into new possible targets to exploit.  
As single drug agents, both cepharanthine and mefloquine were able to 
cause roughly the same amount of cell death in ELT3-V3 cells. In ELT3-T3 cells, 
mefloquine caused more cell death when compared to cepharanthine, however the 
introduction of nelfinavir did not affect the level of cell death caused by mefloquine, 
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while nelfinavir greatly enhanced cell death in these cells caused by cepharanthine. 
With regards, to nelfinavir, cell death in both cell lines were relatively similar when 
either 10 μM or 20 μM nelfinavir were used.  
In this thesis, three mTORC1 hyperactive sporadic cancer cell lines 
representing three different cancer types were used; NCI-H460 (lung), HCT116 
(CRC) and MCF7 (breast). When these three cancer types were treated with either 
mefloquine/nelfinavir combination or cepharanthine/nelfinavir combination, near 
complete eradication was seen in the NCI-H460 and HCT116 cells.  
In MCF7 cells, both mefloquine/nelfinavir and cepharanthine/nelfinavir drug 
combinations were shown to induce a respectable level of cell death with over 60% 
cell death occurring in both treatments. Because of this result, a second breast 
cancer line (MBA-M40, which is tamoxifen resistant) was treated with both drug 
combinations. The observations made from the experiments with this cell line were 
positive as both combinations (as well as 10 μM mefloquine as a single agent) 
caused near-complete eradication of the cells. However, results from this analysis 
were limited as the high levels of cell death observed in the control cells (nearly 40 
%). As a result, the data from MBA-M40 cells were not included in this thesis.  
As a single drug agent, mefloquine could cause moderate levels of cell death 
in NCI-H460 and HCT116 cells when compared to cepharanthine-treated cells, 
although neither drug was able to kill the MCF7 cells without the addition of 
nelfinavir. As expected 20 μM nelfinavir caused a higher level of cell death 
compared to 10 μM nelfinavir in the NCI-H460 and HCT116 cells. An unusual 
observation was made when 20 μM nelfinavir was added to the HCT116 cells. It 
was found that 20 μM nelfinavir by itself caused over 60% cell death in the HCT116 
cells. This high level of cell death in the HCT116 cells was not observed by Johnson 
et al. (2018) who found that nelfinavir only induced 20% cell death. The reason for 
this sizeable variance of cell death has not been determined but might be due to 
differences in passage number or the density of cells upon addition of nelfinavir. 
While no work in this thesis was done with nelfinavir and Bortezomib in 
sporadic cell lines, Johnson et al. (2018) showed that this drug combination was 
able to cause significant cell death in HCT116 and NCI-H460 cell lines after just 24 
h (at nearly 60%). Longer duration of treatment would be worthwhile for future 
studies, which might raise the percentage of cell death and drug effectiveness in 
MCF-7 cells. 
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7.4 Tumour spheroids  
 In a 2D tissue culture environment, mefloquine/nelfinavir, Bortezomib/nelfinavir and 
cepharanthine/nelfinavir combinations caused selective cytotoxicity to Tsc2-null and 
sporadic cancer cells. To progress our understanding of the combinations, the next 
step was to see whether they would also be effective in 3D tumour models, such as 
tumour spheroids. Tumours spheroids are thought to be the most suitable in vitro 
model for drug testing in oncology (Costa et al. 2016). This is due to their ability to 
reproduce common features found in solid tumours in vivo. These features include 
cellular heterogeneity (as spheroids could be generated from cancer cells cultured 
with other cell types (Costa et al. 2014)), cell-cell signalling, internal structure 
(different layers of cells which are affected by factors such as nutrients, oxygen, 
proliferation and pH (Koppenol et al. 2011)), cell-cell physical interactions (which 
can affect a drug’s ability to penetrate a tumour spheroid (Ricci et al. 2013)), growth 
kinetics, gene expression and drug resistance.  
The tumour colony formation assay is a tumourgenic assay that was originally 
used to identify and to help define tumour suppressor genes (Karuppusamy 
Rathinam et al. 2014). Tumour colony formation assays can also be used to 
determine if drugs (or drug combinations) have anti-tumourgenic properties (i.e., 
could be used as a preventative treatment as well as a curative treatment). Both 
mefloquine/nelfinavir and cepharanthine/nelfinavir combinations were shown to 
prevent the growth of soft agar-embedded tumour colonies over a 14-day period. 
As single agents, both mefloquine and 10 μM nelfinavir failed to inhibit the formation 
of tumour colonies while on the other hand, cepharanthine and 20 μM nelfinavir 
caused a moderate reduction in tumour colony formation. Bortezomib, as a single 
drug agent, was able to cause a 36% reduction to the formation of tumour colonies, 
while the combination of Bortezomib and nelfinavir was able to completely inhibit 
tumour colony formation similar to the results seen with both mefloquine and 
cepharanthine combinatory treatments with nelfinavir (Johnson et al. 2018).  
While these results showed that all three nelfinavir drug combinations 
showed promise as preventative treatments for TSC patients who are prone to 
tumour development, it would be strongly recommended not to use the 
mefloquine/nelfinavir or the bortezomib/nelfinavir combinations for this purpose. 
This is due to the known side effects and weaknesses of both mefloquine and 
bortezomib (as discussed previously in Chapters 3 and 4). There is an argument to 
be made that rapamycin and (especially) everolimus could be used as a 
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preventative treatment, as supported by the results from the EXIST-1 trial. However, 
usage of rapalogs also carry complications of long-term usage such as pneumonitis 
(Atkins et al. 2004), immunosuppression (resulting in localized and systemic 
infections, including potentially life-threatening pneumonia and infections from 
bacteria, invasive fungi viral infections such as hepatitis B virus reactivation 
(Trelinska et al. 2015; Sadowski et al. 2016) and metabolic disorders 
(hyperglycaemia and diabetes (Vergès and Cariou 2015). Of all the drug 
combinations tested, the most promising for use as a preventative therapy would 
likely be cepharanthine/nelfinavir combination due to the lack of severe side effects 
associated with cepharanthine (although there are no studies into long-term usage 
of cepharanthine reported).   
 The tumour outgrowth carried out in this thesis was designed to examine the 
long-term effects of the drug combinations on established tumour spheroids and to 
investigate their penetration ability (i.e., whether the drug combination completely 
kill the bulk of tumour spheroids or only cause partial killing of the spheroid, allowing 
recovery of cells to grow back when the spheroid was replated into drug-free media). 
All three drug combinations were shown to cause complete penetration of tumour 
spheroid and could kill the spheroid, as shown by the failure of combination treated 
tumour spheroids to grow back once the spheroids were replated in fresh drug-free 
media. When the tumour spheroids were treated with any of the three drug 
combinations, all spheroids developed the same “fluffy” appearance (which may be 
due to cells on the outer rim dying and detaching from the spheroid). To determine 
if the drug combinations were effectively penetrating the spheroids, the spheroids 
were incubated with DRAQ7 (as a marker of cell death) for the last 48 h of drug 
treatment. Both mefloquine/nelfinavir and Bortezomib/nelfinavir treated tumour 
spheroids had incredibly high levels of DRAQ7 fluorescence when compared to the 
DMSO controls. This indicates that both drug combinations had the ability to fully 
penetrate tumour spheroids and cause cytotoxicity to all layers of the tumour 
spheroid.  
Unusually, as discussed in Chapter 3, mefloquine (as a single drug agent)-
treated spheroid also developed this “fluffy” appearance after 4 days of treatment 
and showed similar DRAQ7 fluorescence when compared to either 
mefloquine/nelfinavir or Bortezomib/nelfinavir combinations. However, this change 
in appearance and level of DRAQ7 fluorescence appeared to be superficial as 
mefloquine-treated spheroids grew out once replated in drug-free media. This 
166 
 
indicates that only the outer layers (and possibly not the core) of the spheroids were 
killed by mefloquine and that some cells survived this mono-drug therapy.  
In DMSO solvent only, nelfinavir (at 20 μM and 10 μM) and cepharanthine 
(as a single agent) treated tumour spheroids: all treated tumour spheroids shared 
similar morphological appearance as round spheroids with low DRAQ7 
fluorescence (indicating a higher proportion of cell survival) and grew back once 
they were re-plated in drug-free media (at varying rates). Cepharanthine-treated 
tumour spheroids rebounded a lot quicker compared to mefloquine-treated 
spheroids while 20 μM nelfinavir-treated spheroids were slower to grow out in 
comparison to the 10 μM nelfinavir-treated spheroids.  
 
7.5 mTOR pathway 
As the main aim of this thesis was to develop treatments which are selective for 
mTORC1 hyperactive cells, it was important to determine the potential effects of 
each drug combination on the mTORC1 pathway. In this thesis, the effects of 
mefloquine/nelfinavir and cepharanthine/nelfinavir combinations were examined. 
From data obtained from 6 h western blots both cepharanthine/nelfinavir and 
mefloquine/nelfinavir combination caused dephosphorylation of S6K1 and 
dephosphorylation of RSP6 (cepharanthine/nelfinavir treatment only) in the wildtype 
Tsc2+/+ MEFs. In Tsc2-/- MEFs, the cepharanthine/nelfinavir combination caused 
dephosphorylation of both S6K1 and RPS6, while treatment with 
mefloquine/nelfinavir caused no change in phosphorylation of S6K1 when 
compared to the DMSO control. To determine if mTORC1 signal transduction played 
a role in cell death, rapamycin was introduced to both nelfinavir drug combinations 
(to inhibit mTORC1 activity). Neither mefloquine/nelfinavir nor 
cepharanthine/nelfinavir treated Tsc2-/- MEFs were able to be rescued from cell 
death when rapamycin was introduced. This data shows that the state of mTORC1 
activity in treated Tsc2-/- MEFs did not affect the mechanism of cytotoxicity triggered 
by either mefloquine/nelfinavir or cepharanthine/nelfinavir drug treatments. The 
state of mTORC1 activity also appeared not to play a role in the cytotoxicity of 
sporadic cancer cell lines (at least when treated with mefloquine/nelfinavir with or 
without rapamycin). This data strongly indicated that mefloquine/nelfinavir causes 
mTORC1-independent cell death in a variety of cell types. This could also be said 
167 
 
for the cepharanthine/nelfinavir combination, however, further testing in sporadic 
cancer cell lines would be required to validate this. 
 
7.6 Autophagy and lysosomal activity  
Mefloquine belongs to the quinine family (which contains known autophagy inhibitor 
chloroquine) and cepharanthine is also a known autophagy inhibitor (Johnson et al. 
2015; Tang et al. 2018). Therefore, it was important to determine if either 
cepharanthine/nelfinavir or mefloquine/nelfinavir combination could affect 
autophagy and autophagy flux. It is possible that cytotoxicity of these drugs could 
be because of autophagy inhibition. After 3 h of treatment, both mefloquine/nelfinavir 
and cepharanthine/nelfinavir combinations were able to cause accumulation of LC3-
II in both Tsc2+/+ and Tsc2-/- MEFs. The amount of LC3-II accumulation differed 
between the two drug combinations, as cepharanthine/nelfinavir was able to cause 
roughly the same amount of accumulation in both MEF lines (although the LC3-II 
accumulation in both cell lines were quite weak). On the other hand, accumulation 
of LC3-II was greater in the Tsc2+/+ MEFs than compared to the Tsc2-/- MEFs when 
cells were treated with the mefloquine/nelfinavir drug combination. Neither 
combination was able to cause much variation in the levels of p62 accumulation in 
either cell line.  
 As described in both Chapter 3 and Chapter 6, both mefloquine and 
cepharanthine are known to accumulate in the lysosome (Glaumann et al. 1992; 
Tang et al. 2018). Bafilomycin A1 was used to prevent H+ build-up in lysosomes 
through the inhibition of v-ATPase leading to alkylation of the lysosomes. 
Consequently, Bafilomycin A1 prevented mefloquine drug accumulation within 
lysosomes (as quinine drugs become entrapped in acidic membrane 
compartments). Bafilomycin A1 was unsuccessful in rescuing Tsc2-/- MEFs from 
cell death with treatments with mefloquine, which suggested that the cytotoxic drug 
action of mefloquine is unlikely through the effects of mefloquine at lysosomes. 
Other acid membrane compartments where mefloquine could accumulate could 
possibly include mitochondria and the Golgi apparatus. 
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7.7 ROS production 
From the observed data from Chapter 3 and Chapter 6, it is unlikely that the low 
level of ROS produced by either mefloquine/nelfinavir or cepharanthine/nelfinavir 
combinations influenced cell death in the Tsc2-/- MEFs. The low levels of ROS 
production was an unusual result for mefloquine/nelfinavir treatments, as 
mefloquine has previously been shown to enhance ROS production in prostate 
cancer cells (Yan et al. 2013), while nelfinavir has been shown to induce ROS 
production in breast cancer cells (Soprano et al. 2016). The low level of ROS 
production as a result of cepharanthine/nelfinavir treatment was expected, as the 
function of cepharanthine as a ROS producer or scavenger is determined by the 
concentration used (as discussed in detail in Chapter 6, where the concentrations 
used of cepharanthine in this thesis were unlikely to induce ROS) (Hua et al. 2015; 
Sierra et al. 2015; Zhu et al. 2017a). Interestingly, in mefloquine/nelfinavir-treated 
Tsc2-/- MEFs, NAC (non-significantly) caused a minor rescue in treated cells. 
However, no such rescue was achieved when NAC was introduced to 
cepharanthine/nelfinavir treated cells.  
Loss of TSC1 and TSC2 and subsequent activation of mTORC1 is likely to 
increase the level of mitochondrial ROS and contribute to tumour formation through 
metabolic transformation. In MEFs and rat renal proximal tubular epithelial Tsc2-
deficient cells, loss of Tsc2 was shown to cause an increased expression of NADPH 
oxidase (Nox)1, Nox2, and Nox4 (Nox isoforms), which in turn, caused increased 
generation of ROS (Habib and Abboud 2016). Oxidative stress in cells can lead to 
increased expression of catalase and superoxide dismutase (SOD), which converts 
superoxides into water and restores oxidative stress  (Wan et al. 2014). Glutathione 
synthetase (GSH) when inhibited by L-buthionine sulfoximine (BSO) was found to 
trigger cell death in Tsc2-/- MEFs (Li et al. 2016), and other antioxidant pathways 
(Lam et al. 2018). In Tsc2-/- MEFs, p62 accumulation levels remained roughly even, 
regardless of what treatment was used (as seen in Chapter 3 and Chapter 6). p62 
in Tsc2-/- MEFs was found to protect the mitochondria from ROS production-
associated damage by maintaining the levels of glutathione (an essential 
antioxidant) and possibly by promoting mitophagy (Lam et al. 2017b).  
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7.8 ER stress 
The central hypothesis of this thesis was to exploit the homeostatic vulnerabilities 
within TSC2-deficient cells. mTORC1 hyperactivity enhances the volume of 
unfolded protein within the ER, as a result of heightened levels of de novo protein 
translation and a reduced efficiency of autophagy to remove the unfolded protein. 
Consequently, cell lines lacking TSC2 become more sensitive to drug treatments 
that induce ER stress. Nelfinavir is a well-known ER stress enhancer and has been 
used as the basis for at least two other combination created by this research group 
(Johnson et al. 2015; Dunlop et al. 2017b). As a result, one of the initial ideas for 
the cytotoxic mechanism of the mefloquine, cepharanthine and/or Bortezomib 
combinations was prolonged ER stress.  
All three combinations were able to induce the expression of components of 
the PERK pathway (ATF4, CHOP and GADD34). All three combinations were also 
shown to have little to no effect on the expression of IRE1α. As expected using 20 
μM nelfinavir as a single agent increased expression of stress markers compared 
to 10 μM nelfinavir (used as a single agent).  
The induction of ER stress was examined in detail in both Chapter 3 
(mefloquine/nelfinavir) and Chapter 4 (Bortezomib/nelfinavir), with each giving an 
interesting insight into the induction of ER stress over time. At 6 h, both mefloquine 
and Bortezomib combinations resulted in the high expression of ATF4 and CHOP 
in both Tsc2+/+ and Tsc2-/- MEFs. After 16 h of treatment with 
Bortezomib/nelfinavir, ER stress recovery was observed in the Tsc2+/+ MEFs and 
unexpectedly in the Tsc2-/- MEFs. However, after 24 h of Bortezomib/nelfinavir 
treatment, expression of ER stress markers returned to similar levels seen in 
samples which were treated with mefloquine/nelfinavir combinations at 24 h and 48 
h. To determine if this unexpected dip in expression levels was unique to the 
Bortezomib/nelfinavir treatment, it would be recommended post-thesis to carry out 
a short-term time course (6, 16, 24 h) using the mefloquine/nelfinavir and 
cepharanthine/nelfinavir treatments. All three combinations were able to cause near 
complete/ total splicing of XBP-1 with Bortezomib/nelfinavir showing the lowest 
amount of splicing. Interestingly, 20 μM nelfinavir (as a single agent) is nearly able 
to cause the same amount of splicing as Bortezomib/nelfinavir treatment (as seen 
in Chapter 4). Cepharanthine/nelfinavir, on the other hand caused near complete 
splicing. This indicates that while Bortezomib did not affect splicing levels when 
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combined with 20 μM nelfinavir, cepharanthine caused enhanced splicing when 
combined with the same concentration of nelfinavir.  
While reviewing data from RNA sequencing, mefloquine/nelfinavir and 
Bortezomib/nelfinavir combinations, as carried out by (Johnson et al. 2018) were 
both shown to enhance expression of ER stress associated genes such ATF4, 
CHOP (DDIT3), DDIT4 and HSPA5 (HSP70) and ERO1L (which is involved in the 
formation of disulphide bonds in the ER lumen) in Tsc2+/+ and Tsc2-/- MEFs. Both 
drug combinations have also been shown to influence genes involved in pro-survival 
such as IMPACT and TRAF5 as well as genes involved in pro-death such as ATF3.  
 
7.9 Energy stress 
In TSC2-deficient cells, ATP-heavy cellular activities such as lipogenesis and 
protein cause cells to become hypersensitive to glucose deprivation and highly 
dependent on glutamate dehydrogenase-dependent glutamine metabolism via the 
TCA cycle for survival (as discussed in Chapter 1). In order to counter this high 
energy demand, TSC-deficient cells enhance ATP generation by increasing 
mitochondrial biogenesis. Evidence of enhanced mitochondrial biogenesis was 
observed in the RNA sequencing carried out in Chapter 3 as Tsc2-/- MEFs naturally 
have a higher expression of genes involved in this process such as PPARGC1α, 
PPARδ, and PPARγ when compared to Tsc2+/+ MEFs. As previously mentioned in 
Chapter 3, this evidence showed that Tsc2-/- MEFs are sensitive to energy stress 
and could be a viable target for treatment. 
Results from Chapters 3 and 6 showed that cell death in Tsc2-/- MEFs was 
rescued by the introduction of methyl pyruvate. Methyl pyruvate is a substrate of the 
TCA cycle which is preferentially metabolised in the mitochondria and is involved in 
stimulating ATP production and in supporting the conversion of pyruvate metabolites 
into amino acids (Jijakli et al. 2002). As methyl pyruvate rescued cell death from 
cepharanthine/nelfinavir and mefloquine/nelfinavir-based treatments, this gives 
evidence that both these drug combinations cause cell death via energy stress.  
How methyl pyruvate could rescue these cells could one of several reasons: 
1.) Methyl pyruvate replenishes the much-needed ATP for the Tsc2-/- MEFs, and 
as result, prevents energy deficiency; 2.) Methyl pyruvate is an alkalising agent 
(Jijakli et al. 2002) which could more indirectly prevent the cellular distribution of the 
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drugs to specific areas (such as mitochondria and/or lysosomes); 3.) methyl 
pyruvate is a ROS scavenger and could help in reducing the amount of ROS being 
produced by cells treated with the drug treatments (although from the data obtained 
from the ROS production assay in chapters 3 and 6 shows that ROS is unlikely to 
be involved in cytotoxicity). 
What causes this increased energy stress in cells treated with mefloquine 
and cepharanthine combination may also be due to ER stress. While ER stress is 
unlikely the main trigger of cell death, recovery from ER stress might contribute to 
energy depletion through de novo protein synthesis of chaperone and heat shock 
proteins that are required for the unfolding and refolding of protein aggregates in the 
ER, processes that heavily consume ATP. As observed in both Chapter 3 and 
Chapter 4, ER stress can last up to 24 h, and even 48 h (in the case of 
mefloquine/nelfinavir) (Figure 7.1). 
  SESN2 (which acts as a link between ER stress and energy stress) was 
shown to be naturally elevated in Tsc2-/- MEFs compared to Tsc2+/+ MEFs. Neither 
mefloquine/nelfinavir or cepharanthine/nelfinavir combinations could affect 
expression levels of SESN2 at 6 h in Tsc2-/- MEFs. However, at 24 h, there was a 
noticeable difference in SESN2 expression in mefloquine/nelfinavir treated Tsc2-/- 
MEFs compared to DMSO and mefloquine/nelfinavir/methyl pyruvate-treated Tsc2-
/- MEFs. This indicates the activation of energy stress in Tsc2-/- MEFs when treated 
with mefloquine/nelfinavir only occurred after prolonged exposure to drug therapy 
(which is corroborated by the energy stress time course carried out in Chapter 3). 
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Figure 7.1: ER stress and energy stress. The introduction of drug combination caused ER stress 
via the PERK pathway. Production of ATF4 (combined with low ATP levels) caused activation of 
SESN2 which triggered the AMPK/PGC1α pathway resulting in mitochondrial biogenesis. Energy 
stress, which may be assisted by prolonged ER stress, triggered cell death in cells treated with drug 
combination. 
 
The Bortezomib/nelfinavir combination was also tested using methyl 
pyruvate, however, the results from this assay showed that Bortezomib/nelfinavir 
did not cause energy stress. In fact, the introduction of methyl pyruvate caused a 
slight (non-significant) increase in cell death (after 24 h).  
While this work explores drug treatments that were cytotoxic, there were 
differences in how the cells died depending on the treatment, i.e., whether cell death 
was controlled (apoptosis) or was uncontrolled (necrotic). Apoptosis is an ATP-
dependent mechanism (Eguchi et al. 1997). As seen in Chapter 4, 
Bortezomib/nelfinavir treatment induced apoptosis via caspase 8 cleavage. 
Combined with the result of the methyl pyruvate assay from Chapter 4, this data 
showed that cell death by Bortezomib/nelfinavir combination is apoptotic in nature. 
On the other hand, evidence from Chapter 3 with regards to caspase cleavage and 
methyl pyruvate rescue could be seen as strong evidence that cell death caused by 
the mefloquine/nelfinavir combination is more likely to be uncontrolled. Whether or 
not this cell death is due to oncotic (impairment of ionic pumps, cell swelling, clearing 
of the cytosol, dilation of the ER and Golgi, mitochondrial condensation, chromatin 
clumping, and cytoplasmic bleb formation) or necrotic (the loss of cell membrane 
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integrity and an uncontrolled release of products of cell death into the extracellular 
space) in nature will require further examination post-thesis.  
 
 7.10 P-glycoprotein 
Permeability glycoprotein (p-glycoprotein, also known as either multidrug resistance 
protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or 
cluster of differentiation 243 (CD243)) is a 170 kDa membrane-associated 
glycoprotein and affiliated with the ABC superfamily. MDR1 is a product of the 
MDR1 gene and functions an ATP-dependent efflux pump with broad substrate 
specificity which is responsible for pumping foreign substances (such as drugs) out 
of cells (Riffkin et al. 1996; Shao et al. 1997; Zhou et al. 2017). MDR1 is responsible 
for the development of multidrug resistance in several cancer types including breast, 
ovarian, bladder and oesophageal  (Hanada et al. 2005; Zahedi et al. 2011; Rijpma 
et al. 2014; Zhou et al. 2017). 
 Through literature research, it became apparent that mefloquine, nelfinavir 
and cepharanthine are substrates of p-glycoprotein and shared the ability to inhibit 
p-glycoprotein activity. Cepharanthine-induced p-glycoprotein inhibition was shown 
to sensitize erythroleukemia cells (HEL) and gastric cancer cells (KATO-II) to 
tamoxifen (Mizobata et al. 2002), multidrug resistance (to vincristine, actinomycin 
D, daunomycin) in a KB epidermoid carcinoma cell subline (Shiraishi et al. 1987), 
oesophageal squamous cell carcinoma cells to cisplatin (Zhou et al.  2017) and 
ovarian cancer cell to docetaxel (Zahedi et al. 2011). The effects of mefloquine-
induced p-glycoprotein inhibition was shown to affect a multi-drug resistant subline 
of the human oral squamous carcinoma cell lines KB and was described in detail in 
Chapter 3.  
Nelfinavir is also a substrate of p-glycoprotein and has been shown to inhibit 
p-glycoprotein (Washington et al. 1998; Liu et al. 2018). However, as previously 
mentioned in Chapter 3, prolonged exposure to nelfinavir can cause an increase of 
P-glycoprotein expression that potentially could lead to reduced drug exposure after 
multiple doses (Faucette et al. 2004; Lucia et al. 2011). Choo et al. (2000) showed 
that inhibition of p-glycoprotein enhanced the distribution of nelfinavir, particularly to 
the brain and testes in male patients.  
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 Mefloquine and cepharanthine are p-glycoprotein inhibitors and were shown 
to inhibit p-glycoprotein in both Tsc2+/+ and Tsc2-/- MEFs (both with mefloquine, 
and only the Tsc2-/- MEFs with cepharanthine) via rhodamine 123 uptake assay. It 
was hypothesised that the combination of cepharanthine/nelfinavir and 
mefloquine/nelfinavir would cause enhanced p-glycoprotein inhibition and be a 
cause of cell death via drug accumulation. However, results for both 
mefloquine/nelfinavir and cepharanthine/nelfinavir combinations showed stronger p-
glycoprotein inhibition in Tsc2+/+ MEFs compared to Tsc2-/- MEFs.  
  One possible reason for low level of p-glycoprotein inhibition in Tsc2-/- MEFs 
may due to the type of experiment used. Rhodamine 123 is a substrate of p-
glycoprotein (which is pumped out of the cell) and is often used to determine if a 
chemical alters p-glycoprotein function (higher uptake = less p-glycoprotein activity). 
While Rhodamine 123 is suitable for testing a single agent’s effect on p-glycoprotein 
(as observed when mefloquine and cepharanthine were tested), using a 
combination of two chemicals, both of which are substrates of p-glycoprotein may 
have caused disruptions to the analysis possibly due to varying levels of selectivity 
of p-glycoprotein for each chemical. As a result, it is recommended that an 
alternative assay (possibly using labelled drugs, either radioactive or fluorescent) 
be used to determine if the results of Rhodamine 123 assay are correct or to give a 
better understanding of the relationship between the combinations and p-
glycoprotein.  
 Bortezomib was also tested, as Bortezomib is a substrate of P-glycoprotein 
and P-glycoprotein expression causes Bortezomib-resistance in cancer cells treated 
with the drug (O’Connor et al. 2013). As expected Bortezomib failed to cause any 
inhibition of p-glycoprotein but the combination induced inhibition in both control and 
Tsc2-null cells and was most likely due to the presence of nelfinavir. 
 
7.11 Comparing side effects 
Nearly all the drugs used in this thesis have been shown to have some characteristic 
side effect associated with them. Bortezomib has its peripheral neurotoxicity (Bose 
et al. 2014) and potential for the target tumour cells to develop resistance after 
prolonged use (Lü et al. 2008; Oerlemans et al. 2008; Ri et al. 2010), which were 
discussed in detail in Chapter 4. The neurotoxic effect of mefloquine, such as 
seizures and neuropsychiatric adverse effects are discussed in Chapter 3. 
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Consequently, the side-effects of mefloquine has led to its replacement as a malaria 
treatment (Tickell-Painter et al. 2017; Remington L. Nevin 2012). However, of the 
three drug tested in combination with nelfinavir, cepharanthine is the only drug that 
that has mild side effects (Masuda et al. 1993; Kakehi et al. 1994; Morita et al. 2002). 
As the main target population of this thesis are TSC patients, it is vital that all 
complications associated with the disease be accounted for when developing 
treatments for TSC-associated tumours. Because of the low risk of adverse effects 
associated with cepharanthine, it would appear that cepharanthine would be the 
most suitable of the three drug combinations with nelfinavir for future work with 
regards to TSC-associated tumours. 
 
7.12 Clinical relevance  
To date, there have no reports of using either mefloquine/nelfinavir or 
cepharanthine/nelfinavir combinations being used as treatment for either TSC-
associated tumours and/or sporadic cancers. Bortezomib/nelfinavir combination has 
been used several times before for the treatment of sporadic cancers such as 
cervical, ovarian, prostate and others as described in the introduction of Chapter 4. 
However, as mentioned in Chapter 4, this is the first time that Bortezomib and 
nelfinavir have been used in combination to target TSC-associated (or to be more 
precise, the first time that mTORC1 hyperactive cells have been shown to be 
sensitive to combined proteasomal inhibition and ER stress induction).  
 As discussed in their respective chapters, both mefloquine and 
cepharanthine (while not clinically approved for treatment at present) have been 
shown to have potent anticancer properties over a wide range of tumour types. As 
a result, combinations with nelfinavir could theoretically be used over a wide range 
of tumours (as many tumour types are also mTOR hyperactive as discussed in 
chapter 1).  
 These treatments also have clinical relevance as all drugs used in this thesis 
are clinically approved either as established anticancer treatments (as is the case 
of Bortezomib), or other medical treatment (malaria for mefloquine, HIV for nelfinavir 
and several different functions for cepharanthine in Japan as discussed in Chapter 
6). Because of this, it is accepted that these drugs are safe to use in human patients 
and have established guidelines for usage and how to handle adverse effects. As a 
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result, this could allow all three combination therapies to be fast-tracked to clinical 
trials for both TSC-associated and sporadic cancers.   
  
7.13 Future work 
For the first step into future work, testing all three combinations in heterozygous 
Tsc2+/- MEFs would be the most logical. As mentioned in chapter 1, all TSC patients 
are TSC1 or TSC2 heterozygous (+/-). It is possible that these drug concentrations 
would have a higher basal level of toxicity in TSC patients. Furthermore, exosomes 
from TSC1-null cells have been shown to cause cells with preserved TSC1 function 
to behave like TSC1-/- cells (Patel et al. 2015), so these drugs might be cytotoxic to 
normal cells within the environment of the tumour site. Considering how potently 
cytotoxic the three combinations were against Tsc2-null MEFs, it is imperative that 
heterozygous cells that could mimic the ‘normal’ TSC patients’ cells should also be 
tested. The main question involving heterozygous cells would be how well they 
would tolerate any of the three combinations (would these cells respond like the 
Tsc2 wildtype with good tolerance or a worse response because of the 
heterozygosity of Tsc2. How the drug combinations’ optimisation could be affected 
would also need to be answered as combinations may require lower concentrations 
of drugs to stabilise tolerance. While this may not be a problem for cepharanthine 
(as it works remarkably over a wide range of concentrations) and Bortezomib (as 
results were positive when cells were treated with either 50 nM or 20 nM 
Bortezomib/nelfinavir combinations). The problem arises in the case with 
mefloquine. As observed in Chapter 3 and discussed earlier in this chapter, 
mefloquine has an incredible narrow maximised therapeutic range and having to 
modify the concentration of either mefloquine or nelfinavir or both for Tsc2+/- MEFs 
could be disastrous for the combination effectiveness against Tsc2-/- MEFs and (in 
the worst-case scenario) render the combination useless for the treatment of TSC-
associated tumours.  
Should mefloquine/nelfinavir and/or cepharanthine/nelfinavir combinations 
show low cytotoxicity in Tsc2+/- MEFs, the next step would be to start testing in pre-
clinical models. Bortezomib/nelfinavir has already been tested in mice bearing Tsc2-
null ELT3 xenograft tumours (as seen in (Johnson et al. 2018)). Results showed 
combined nelfinavir and Bortezomib decreased tumour growth by approximately 
70% compared with vehicle-treated mice. While Driessen et al. (2016) showed that 
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a Bortezomib/nelfinavir combination could be tolerated by human patients, the 
particular Bortezomib/nelfinavir combination used in this thesis and by Johnson et 
al. (2018) killed nearly 80 % of mice treated when compared to only approximately 
14 % of mice in the vehicle treated group. Mefloquine/nelfinavir combinations 
(compared to cepharanthine/nelfinavir combinations) have better options with 
regards to types of tumours that can be tested. Mefloquine can pass the blood-brain 
barrier which means that mice models with SENs, SEGAs and cortical tubers can 
be used. It could also be important to use TSC mice models with epilepsy such as 
those developed by Zeng et al. (2011) to determine if the risk of mefloquine-
associated seizures could worsen the frequency and severity of TSC-associated 
seizures. With cepharanthine/nelfinavir combinations, it would be interesting to see 
what side effects are observed in animals treated compared to cepharanthine as a 
single drug agent (which has been observed in human patients to have no adverse 
effects).  
While earlier in the chapter (section 7.2.1), it was discussed how 
cepharanthine (when combined with 20 μM nelfinavir) can be used over a wider 
range of concentrations (5 μM – 1.25 μM tested) compared to mefloquine (which 
was only viable at 10 μM mefloquine and 10 μM nelfinavir and 5 μM mefloquine and 
20 μM respectively). However, when compared to other drug treatments currently 
available for the treatment of TSC-associated and sporadic tumours, both drug 
combinations could be considered having very narrow windows of usage. As the 
work done in the thesis is purely in vitro, the use of animal models could be useful 
in investigating the maximised therapeutic range of these combinations. The main 
aim for using animal models in this manner would be to determine if the maximised 
therapeutic range could be made flexible in an in vivo environment, allow for a wider 
range of drug concentrations in each combination (provide that chosen 
concentrations maintain the high levels of selective cytotoxicity while producing 
minimal side effects). 
From data obtained from the drug screen performed in Chapter 5, another 
drug combination that might be viable for the treatment of Tsc2-null tumours would 
be paroxetine and nelfinavir. Results from the drug screen showed that a 
combination of 5 μM paroxetine and 20 μM nelfinavir was well tolerated by control 
cells and caused considerable cytotoxicity to Tsc2-/- MEFs (over 60 %). The only 
reason further investigations into this combination were not pursued in this thesis 
was due to the comparatively better results obtained from the 
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cepharanthine/nelfinavir combination. From the initial data obtained in Chapter 5, 
like mefloquine/nelfinavir, paroxetine has a very narrow range as (when combined 
with 20 μM nelfinavir) a fold increase was shown to cause complete cell death in 
wildtype and mutant cells (data not shown), while a fold decrease caused a dramatic 
reduction in cytotoxicity. Further optimisation of drug (potentially by reducing the 
nelfinavir concentration allowing for wider range of paroxetine to be used) may be a 
potentially useful avenue to investigate in the future and could potentially lead to 
another successful nelfinavir-based therapeutic for the treatment of mTOR 
hyperactive tumours. It may also be important to determine if this concentration is 
biologically viable as well as patient who use paroxetine use it at a dose of 0.06 to 
0.18 μM (Tomita et al. 2014). 
 
7.14 Summary of thesis 
The aim of this thesis was to identify novel drug combinations that selectively target 
TSC2-deficient cells. Through this work, the following significant findings have been 
discovered: 
• The combination of mefloquine and nelfinavir caused selective cell death in 
mTORC1 hyperactive cells through energy stress. 
• The combination of Bortezomib and nelfinavir caused selective cell death in 
mTORC1 hyperactive cells via prolonged ER stress and proteasome 
inhibition. 
• After drug screening, a combination of cepharanthine and nelfinavir was able 
to cause cytotoxicity in mTORC1 hyperactive cells as a result of energy 
stress. 
• Energy stress was shown to be a suitable vulnerability which could be 
exploited in terms of mTORC1 hyperactive cells. 
• To date, none of the above combinations have been used in a TSC-based 
environment. Therefore, they could be of potential therapeutic use. 
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7.15 Conclusion  
In conclusion, three novel nelfinavir-based treatments were presented in this thesis 
which selectively caused cell death in mTORC1 hyperactive cells while being 
tolerated by wildtype cells. Two of these combinations (mefloquine and 
cepharanthine) caused cytotoxicity via induced energy stress and potentially 
prolonged ER stress while the third (Bortezomib) caused cell death via inhibition of 
the proteasome and prolonged ER stress.
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